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Abstract!
 
Evolution of HIV-1 Subtype C gp120 envelope Sequences in the Female Genital Tract 
and Blood Plasma during Acute and Chronic Infection 
 
K. Ramdayal 
 
PhD Thesis, South African National Bioinformatics Institute, University of the 
Western Cape, South Africa 
 
Heterosexual transmission of HIV-1 via the female genital tract is the leading route of HIV 
infection in sub-Saharan Africa. Viruses then traffic between the cervical compartment and 
blood ensuring pervasive infection. Previous studies have however reported the existence 
of genetically diverse viral populations in various tissue types, each evolving under 
separate selective pressures within a single individual, though it is still unclear how 
compartmentalization dynamics change over acute and chronic infection in the absence of 
ARVs. To better characterize intrahost evolution and the movement of viruses between 
different anatomical tissue types, statistical and phylogenetic methods were used to 
reconstruct temporal dynamics between blood plasma and cervico-vaginal lavage (CVL) 
derived HIV-1 subtype C gp120 envelope sequences. A total of 206 cervical and 253 blood 
plasma sequences obtained from four treatment naïve women enrolled in the CAPRISA 
Acute Infection study cohort in South Africa were evaluated for evidence of genotypic and 
phenotypic differences between viral populations from each tissue type up to 3.6 years 
post-infection. Evidence for tissue-specific differences in genetic diversity, V-loop length 
variation, codon-based selection, co-receptor usage, hypermutation, recombination and 
potential N-linked glycosylation (PNLG) site accumulation were investigated.  
 
Of the four participants studied, two anonymously identified as CAP270 and CAP217 
showed evidence of infection with a single HIV-1 variant, whereas CAP177 and CAP261 
showed evidence of infection by more than one variant. As a result, genetic diversity, 
PNLGs accumulation and the number of detectable recombination events along the gp120 
env region were lowest in the former patients and highest in the latter. Overall, genetic 
 
 
 
 
! vii!
diversity increased over the course of infection in all participants and correlated 
significantly with viral load measurements from the blood plasma in one of the four 
participants tested (i.e. CAP177). 
 
Employing a structured coalescent model approach, rates of viral migration between 
anatomical tissue types on time-measured genealogies were also estimated. No persistent 
evidence for the existence of separate viral populations in the cervix and blood plasma was 
found in any of the participants and instead, sequences generally clustered together by time 
point on Bayesian Maximum Clade Credibility (MCC) trees. Clades that were 
monophyletic by tissue type comprised mostly of low diversity or monotypic sequences 
from the same time point, consistent with bursts of viral replication. Tissue-specific 
monophyletic clades also generally contained few sequences and were interspersed among 
sequences from both tissue-types. Tree and distance-based statistical tests were employed 
to further evaluate the degree to which cervical and blood plasma viruses clustered 
together on Bayesian MCC trees using the Slatkin-Maddison (S-M), Simmonds 
Association index (AI), Monophyletic Clade (MC), Wright’s measure of population 
subdivision (FST) and Hudson’s Nearest Neighbour (Snn) statistics, in the presence and 
absence of monotypic and low diversity sequences. Statistical evidence for the presence of 
tissue-specific population structure disappeared or was greatly reduced after the removal of 
monotypic and low diversity sequences, except in CAP177 and CAP217, in 3/5 of 
longitudinal tree and distance-based tests.  
 
Analysis of phenotypic differences between viral populations from the blood plasma and 
cervix revealed inconsistent tissue-specific patterns in genetic diversity, codon-based 
selection, co-receptor usage, hypermutation, recombination, V-loop length variation and 
PNLG site accumulation during acute and chronic infection among all participants. There 
is therefore no evidence to support the existence of distinct viral populations within the 
blood plasma and cervical compartments longitudinally, however slightly constrained 
populations may exist within the female genital tract at isolated time points, based on the 
statistical findings presented in this study.  
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Definitions!!
!
AI  Association index is a statistic that assesses the population 
structure within a sample by weighting the contribution of 
each internal node based on how deep it is positioned on a 
phylogenetic tree (Wang et al., 2001; Gantt et al., 2010). 
 
BF 
 
Bayes factor is a theoretical Bayesian framework that is 
most often used for the comparison of multiple models, 
usually to determine which model better fits the data 
(Jeffreys, 1961; Drummond & Rambaut, 2007). 
 
FST The FST test is a distance-based statistic that assesses the 
correlation! of !randomly! chosen! alleles !within a! 
subpopulation !relative! to !the !total population (Wright, 
1943; Weir & Cockerham, 1984; Holsinger & Weir, 
2009). 
 
Likelihood The likelihood of the data is the probability of the 
observed genotypes based on the specified model 
parameters (Wilson & Rannala, 2003). 
 
Mann-Whitney U test The non-parametric Mann-Whitney U test compares the 
distributions of two unmatched populations and estimates 
if one of two populations is randomly larger than the other 
(Mann & Whitney, 1947). 
 
MC Maximum (single-state) clade size is a statistic that 
quantifies the observation that stronger phylogeny-trait 
associations should produce larger monophyletic clades 
that share a single trait (Gantt et al., 2010). 
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MCC tree A maximum clade credibility tree is the phylogenetic tree 
within a posterior distribution of trees with the highest 
product of clade posterior probabilities that is generated 
using Bayesian phylogenetic inference methods (Presti, 
2010; Dictionary 3.0, 2011).  
 
MCMC 
 
Markov chain Monte Carlo methods are a class of 
algorithms that sample from a probability distribution 
based on a Markov chain construction (Robert & Casella, 
2004).  
 
Outliers Values in a set of data that are so extreme relative to the 
other data in the sample that they appear to not form part 
of the sampled data set (Zar, 1999).  
 
PS  Parsimony score, also known as the Slatkin-Maddison 
test, reconstructs character states at ancestral nodes in a 
tree or posterior distribution of trees using a parsimony 
approach, where the significance of the observed number 
of state changes within a phylogeny or phylogenies are 
calculated and compared to a null distribution of PS 
statistics for randomized phylogenies (Slatkin & 
Maddison, 1989; Parker et al., 2008; Gantt et al., 2010).  
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Research(Motivation!
 
The overeaching goal of this study was to determine if HIV-1 evolves separately within 
different tissue types in patients that have not been exposed to antiretroviral therapy, over 
long-term HIV-1 infection. The biological and clinical implications of independently 
evolving viruses influences three important disease management issues including mother-
to-child transmission, female-to-male transmission and targeted therapeutic, prophylactic 
or eradication strategies. Therefore defining anatomical compartments, in which 
independent viral evolution may be occurring due to compartmentalization of viral 
populations, is crucial and an increasing amount of work has gone into this area of 
research.  
 
To investigate if viral compartmentalization did exist during acute and chronic infection, 
the aims of this study were as follows:  
i. Determine whether genotypic or phenotypic differences exist between viral 
populations in the cervix and blood plasma. 
ii. Statistically assess the degree of viral compartmentalization between the sampled 
tissue types. 
iii. Statistically assess the flow of viruses between the cervix and blood plasma in each 
participant.  
iv. Statistically evaluate if genotypic patterns correlate with phenotypic traits such as 
viral loads, CD4 cell counts or other clinical indicators associated with disease 
progression. 
Based on the above aims, the following objectives were undertaken: 
i. Assess if viral evolution was compartmentalized by tissue type through 
phylogenetic and statistical analyses. 
ii. Determine the amount of homologous recombination that has occurred between 
viruses sampled in the cervix and blood plasma for each participant, and 
characterize any detectable hypermutation patterns. 
iii. Estimate the most likely number of viral variants that each participant was infected 
with and the degree to which viral populations were compartmentalized by tissue 
type between participants infected by single and multiple transmitted variants. 
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iv. Estimate the direction, timing and relative rates of viral migration between the 
cervix and blood plasma. 
v. Statistically evaluate whether viral populations in the cervix and blood plasma 
demonstrated any evidence of phenotypic differences, i.e. in genetic diversity, 
variable-loop lengths, co-receptor usage, potential N-linked glycosylation sites or 
selection pressures. 
! !
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Chapter(1!
Introduction!
 
The HIV/AIDS epidemic is a crisis of enormous spiritual, social, economic and political 
proportions that may be the most devastating health disaster in human history, (UNICEF, 
2003; Lamptey et al., 2006; Afonso et al., 2012). In sub-Saharan Africa, the area most 
severely affected by the epidemic, 25 million people were reported to be living with 
HIV/AIDS from the total of 35.3 million infected globally at the end of 2012 (Rossenkhan et 
al., 2012; UNAIDS, 2013). South Africa accounts for 6.4 million of these cases where there 
is an estimated 14.4% HIV prevalence in women and 9.9% prevalence in men (Shisana et al., 
2014). Although the incidence of HIV infections have been on the decline in recent years 
(UNAIDS, 2012), young women in this region between the ages of 15 and 34 remain on 
average, approximately eight times more likely to be HIV positive than men in the same age 
group (Shisana et al., 2014). The majority of infections in this region are caused by HIV-1 
subtype C viruses that have been transmitted heterosexually through the genital mucosa 
(Karim et al., 2010; Buonaguro et al., 2007; van Harmelen et al., 1997; Kemal et al., 2003). 
Globally, approximately 90% of HIV-1 infections are transmitted this way since the genital 
mucosa is the initial point of contact for the majority of exposed individuals (Kemal et al., 
2003; Hladik & Hope, 2009).  
 
The female genital tract therefore plays a central role in both sexual and perinatal 
transmission of HIV and is generally the source of systemic infection in women, however the 
complex biological processes that influence transmission dynamics and the persistence of 
HIV infection within this anatomical compartment remain incompletely understood (Karim et 
al., 2010; Kaushic, 2010). For example, since the genital tract plays a central role in mother-
to-child and female-to-male sexual transmission of HIV, it is important to understand if it 
serves as a genetically distinct compartment from the blood plasma and if so, what the 
clinical and biological implications of this phenomenon could be (Bull et al., 2013). 
Compartmentalization has also been reported to exist at a cellular level among CD4+ and 
CD8+ T cells between different tissue types (Potter et al., 2006; Delobel et al., 2005; Fulcher 
et al., 2004; Heeregrave et al., 2009), suggesting the presence of differential immunological 
pressures between anatomical compartments.  
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Moreover, since the female genital immune system is responsible for protection of the 
reproductive system from pathogens and being tolerant to antigens such as sperm and 
embryo’s, specialized cells and antibodies responsible for this type of protection are required 
and have been reported to challenge HIV-1 viruses too (Hirbod & Broliden, 2007). Effective 
disease management is therefore greatly dependent on our knowledge of whether or not 
unique viruses are developing and persisting within different tissues, which in turn informs 
microbicide and vaccine development strategies that should ideally target viral strains in all 
tissue types equally (Bull et al., 2013; Hladik & Hope, 2009; Andreolétti et al., 2007).   
 
This study consequently focuses on the investigation of HIV-1 subtype C viral evolution in 
female participants longitudinally (up to 3.6 years post-infection), encompassing both acute 
and chronic stages of infection. A key aim of this study is to contribute towards our 
understanding of comparative HIV evolutionary dynamics in the female genital tract and 
blood stream over a lengthier period, compared to a cross-sectional view of these 
characteristics. Importantly all four participants studied here were not on any anti-retroviral 
medications throughout the duration of this study, which reduced a large possibility of drug-
resistant mutations arising in this particular data set. Given that selection mechanisms likely 
vary at least slightly between different tissues and cell types, the possibility that these 
differences might yield genetically distinct viral sub-populations in different anatomical 
compartments was investigated.  
Compartmentalization of viruses by tissue type is thought to arise from gradual 
diversification of the transmitted initial viral variant/s under differential tissue-specific 
selection pressures resulting in separate populations with distinct phenotypic characteristics 
(Sturdevant et al., 2012; Fulcher et al., 2004; Si-Mohamed et al., 2000). However distinct 
viral populations can only exist if there is no or limited mixing of viruses between anatomical 
compartments, which could only be possible in the presence of a barrier between the genital 
tract and blood stream, restricting the migration of viruses between these tissues. The 
mucosal linings of the female genital tract have been described as this sort of barrier; 
composed of squamous epithelial cells, these linings form a protective layer that serve to 
prevent HIV transmission from occurring (Hladik & Hope, 2009; Hirbod & Broliden, 2007).  
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To investigate this hypothesis, an additional aim of this study was to estimate the degree of 
viral movements longitudinally between tissue types, to evaluate evidence for the existence 
of such a barrier. Simply quantifying the relative rates at which viruses are migrating to and 
from the genital tract in different individuals would be a major step towards understanding 
patterns of HIV transmission in vivo. Framing these dispersal dynamics within the context of 
viral evolution during acute and chronic stages of infection could also provide additional 
potentially valuable information on the exact sites at which (and possibly even likely 
situations under which) important events leading to the loss of HIV-1 immunological control 
occurs.  
Previous studies on compartmentalization in the female genital tract have reported strong 
evidence of compartmentalization between the genital tract and blood plasma, however many 
of these have been cross-sectional in design, considering viruses sampled at a single time 
point only (Kemal et al., 2003; Bull et al., 2009; Andreolétti et al., 2007; De Pasquale et al., 
2003; Philpott et al., 2005; Tirado et al., 2005; Poss et al., 1998; Uvin & Caliendo, 1997). 
There have also been studies that found no evidence of distinct viral populations between the 
genital tract and blood plasma (Chomont et al., 2007). More recently, in a longitudinal study 
by Bull et al. (2013) that compared plasma RNA, PBMC DNA, genital RNA and DNA of 
HIV-1 found no statistical evidence for compartmentalization between these tissues and no 
evidence of tissue-specific differences in amino acid residues, co-receptor usage or immune 
selection signatures. Furthermore, it was shown that the presence of monotypic and low 
diversity variants inflated statistical measures of compartmentalization that when corrected 
for, significantly reduced the statistical support for evidence of distinct viral populations in 
these tissues (Bull et al., 2013). Rapid population turnover that results in relatively low intra-
patient viral genetic diversity is a commonly observed pattern over the course of HIV-1 
infection, with sequence variants from latter stage replicating viruses often rising to 
predominance and obscuring previously selected viral variants (Bull et al., 2009). As a 
consequence cross-sectional studies that offer only a momentary snapshot of sequence 
diversity through time (usually during the acute stage) are often not representative of the 
entire course of infection. To address this drawback, longitudinal studies that sample during 
acute and chronic stages of infection are necessary to reliably resolve the question of whether 
distinct viral populations do actually exist in the female genital tract of those infected.  
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1.1 The&human&immunodeficiency&virus&
1.1.1 History&and&epidemiology&of&HIV&
The HIV/AIDS pandemic is one of the most highly researched and globally funded 
socioeconomic, medical and governance affecting issues, with an impact on a large range of 
disciplines, including those of the natural sciences, economics, social sciences and medicine 
(Shaeffer, 1994; Over, 2001; Tawfik & Kinoti, 2006). The subject of HIV is a topic with 
more questions than answers, many uncorroborated theories and interests dating as far back 
as the late 1970’s (Gupta et al., 2003; Seiter et al., 2011; Lihana et al., 2012; Mousseau & 
Valente, 2012; Pantaleo, 2000). Although the aquired immune deficiency syndrome (AIDS) 
was first noted in communities of gay men, due to the presence of Kaposi’s sarcoma (a type 
of cancer) and pneumocystis carinii pneumonia (PCP), common in old people with 
compromised immune systems (Gupta et al., 2003; Seiter et al., 2011; SADC, 2013), and 
subsequently observed in heterosexual networks, drug users and mother-to-child 
transmissions, it was only in 1984 that HIV (initially known as HTLV-III) infection was 
discovered to be the result of a retrovirus capable of destroying lymphocytes (Gallo & 
Montagnier, 2003; Gupta et al., 2003). Various theories on the origin of HIV exist, including 
the OPV theory, which proposed that HIV transmission occurred through contamination of 
oral polio vaccines that were cultivated from chimpanzee tissues (Worobey et al., 2004), 
however this theory was refuted shortly after its release (Garrett, 1995; Karlen, 1995). HIV’s 
origins have been traced to zoonotic or cross-species transmission of SIV between humans 
and African primates, with studies in 1994 and 1998 reporting the presence of HIV-1 in blood 
samples dating back to 1959 and the early 1960’s respectively (Sharp & Hahn, 2011; 
Requejo, 2006; Buonaguro et al., 2007).  
 
The globally accepted use of penicillin and other antibiotics for treatment of sexual diseases 
(Lihana et al., 2012), coupled with a significant increase in the migration of people resulted 
in the formation of riskier sexual networks (Lihana et al., 2012; Rambaut et al., 2004; 
Pantaleo, 2000), allowing the virus to spread in humans through three prime transmission 
routes i.e. sexual, parenteral (blood-borne) and perinatal, creating many separate epidemics in 
distinct geographic origins (Gupta et al., 2003; SADC, 2013; Lihana et al., 2012; Rambaut et 
al., 2004; Pantaleo, 2000).  
 
 
 
 
 
 
! 5!
Many different types and frequencies of risk behaviors and practices such as unprotected sex 
with multiple partners or sharing drug injection equipment followed suite (Seiter et al., 2011; 
Engelman & Cherepanov, 2012; Mousseau & Valente, 2012; Rambaut et al., 2004; Pantaleo, 
2000). Individual factors such as biological, demographic and behavioural risk profiles also 
played a role in influencing HIV acquisition and spread. Social networks compounded the 
spread of the disease, adding to the diverse challenges that hindered interventions in epidemic 
expansion (Rothenburg et al., 2001).  
 
Recent studies estimate at least 35 million people are currently living with HIV/AIDS 
worldwide, 25 million of whom reside in sub-Saharan Africa (UNAIDS, 2013), yet it is this 
very continent that is still lacking the infrastructure required to effectively handle this 
pandemic (Visser, 2004; Lihana et al., 2012). On the African continent, South Africa is 
among the countries with the highest HIV prevalence rates in the world, however rates of 
citizen testing remains relatively low despite knowledge of testing services being high 
(Luseno & Wechsberg, 2009). In 2007, UNAIDS estimated 33 million people living with 
HIV/AIDS, where more than 96% of new HIV infections occur in middle and poorer income 
countries (Amo et al., 2010). Prevalence statistics have since increased to approximately 25.2 
million in sub-Saharan Africa, where approximately one fifth of South African women in 
reproductive age groups (i.e. between 15 and 49) are infected with HIV (UNAIDS, 2012; 
Shisana et al., 2014). In the general population, women are reported to have an increased risk 
of HIV transmission, which is negatively influenced by the presence of sexually transmitted 
diseases (STDs) (N’Galy et al., 1998; Broliden, 2010).   
 
1.1.2 HIV&among&women&
Early in the epidemic few women were diagnosed with HIV/AIDS, as many infected women 
that contracted HIV through injection drug use were not accurately diagnosed (CDC, 2008). 
At the end of 2002 more than 42 million people were living with HIV/AIDS (UNICEF, 2003) 
and by 2004 HIV infection was the fifth and sixth leading cause of death among women 
between 35 – 44 and 25 – 34 years respectively (CDC, 2008). The number of HIV infected 
women has been steadily rising on a global scale since then (National Institutes of Health, 
2008) with more than 90% of HIV infections having occurred through heterosexual 
intercourse, a mode of transmission that women are more vulnerable to because of the 
substantial mucosal exposure to seminal fluids (National Institutes of Health, 2008). 
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Pregnancy and childbirth further compound health risks faced by women, which require 
careful and consistent health care (World Health Organization, 2009). Furthermore, women 
have been at greater risk due to discrimination through inadequate education, poor pay, 
violence, abuse and exploitation by men (UNICEF, 2003; World Health Organization, 2009; 
UNFPA, 2013) making them more susceptible to HIV infection than men in the longer term. 
Men, both young and old with multiple sexual partners have also compounded the problem 
by having sexual relations with younger women, posing a greater risk to them than to older 
women (UNICEF, 2003).  
 
Although there have been several efforts in the past to promote discussion, strengthen social 
values and provide support, HIV prevalence and mortality statistics have continued to grow. 
Staggeringly, a recent study has reported that on average 50 young women are newly infected 
with HIV every hour (UNAIDS, 2013). The report went on to state that from the 50 countries 
that participated in the study, between 9 and 60% of women aged between 15 and 49 years 
had experienced violence in an intimate relationship within the last year, and these women 
were 50% more likely to acquire HIV than women who had not experienced violence 
(UNAIDS, 2013). A high prevalence of rape, physical violence and other forms of abuse 
were reported in several different countries frequently among sex workers, generally however 
women in “conflict-affected situations” tended to be particularly more vulnerable to sexual 
abuse (UNAIDS, 2013).  
 
1.1.3 HIV&classification&and&distribution&
HIV-1 belongs to the Lentivirus genus of the Retroviridae family, and is classified into four 
groups, i.e. M, N, O and P, with M being the main source of the global AIDS pandemic 
(Requejo, 2006; Abecasis et al., 2013). HIV-2 contains eight subtypes (A to H), however 
only subtypes A and B are linked to the HIV epidemic seen mainly in West Africa (Marx et 
al., 2001;!Santiago et al., 2005). HIV subtypes make it possible to track the course of the 
epidemic through the identification of specific markers in samples, or by detecting specific 
antibodies that bind to the virus (Requejo, 2006).  
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There has been an unprecedented and non-uniform increase in HIV-1 subtype C prevalence 
historically compared to all other subtypes (Novitsky et al., 2002). Subtype C is the most 
prevalent globally and represents approximately 52% of infections worldwide (Jacobs et al., 
2014). Predominantly found in Southern Africa, India and China, subtype C is the only 
subtype that accounts for prevalence rates as high as 20 to 40% in the general HIV positive 
population (Novitsky et al., 2002), while subtype B is the main genetic form in the northern 
hemisphere (Abecasis et al., 2013; Buonaguro et al., 2007).  
 
The geographic spread of HIV-1 subtypes C and B (considered to be the main cause of the 
HIV epidemic) is crucial for epidemiological HIV vaccine design and testing strategies, 
however viral diversity poses a major problem in this area as it significantly affects the 
“specificity and/or sensitivity of serological and molecular” tests (Buonaguro et al., 2007). 
 
Although multiple factors play a role in the rate of disease progression, patients infected with 
HIV have been classified into three main types of progressors (Kumar, 2013): 
• Rapid progressors – AIDS develops within 3 years after seroconversion. 
• Intermediate progressors – AIDS develops gradually between approximately 3 to 10 
years after seroconversion. 
• Long-term non-progressors – HIV infected individuals retain high CD4+ and CD8+ 
cell counts and remain off antiretroviral therapy until CD4+ cell counts decline, which 
can take more than 20 years. 
About 5 to 10% of HIV positive people are rapid progressors who display high levels of viral 
replication and a steep decline in CD4+ cell counts within two years of the initial HIV 
infection event, leading to the development of AIDS (Geubbels & Bowie, 2006). Another 5 
to 10% that are classified as long-term non-progressors are able to effectively control HIV, 
sometimes maintaining low viral loads and a competent immune system for more than 20 
years (Geubbels & Bowie, 2006), while the remaining proportion of HIV positive population 
progress from HIV to AIDS in approximately 8 to 10 years, dependent on socio-economic 
factors such as malnutrition or access to health care for example.  
 
! &
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1.1.4 HIV&cell&structure&and&replicative&cycle&
 
 
Figure 1.1 An overview of key components making up the HIV virion (adapted from NIAID, 
2012). HIV is composed of a capsid (core) that encapsulates two single stranded RNA 
molecules, three structural genes (gag, pol & env), six regulatory genes (tat, rev, nef, vif, vpr 
& vpu), three enzymes (reverse transcriptase, integrase & protease) and viral proteins (p24 & 
p17) enclosed by a lipid membrane containing several glycoproteins from both the host cell 
and the virus (NIAID, 2012; Arora & Seth, 2003; Requejo, 2006). 
 
Each of these components plays a role in the infection process eventually forcing host cells 
into manufacturing new copies of the virus. The viral envelope, is composed of two layers of 
fatty molecules known as lipids that are taken from the membrane of previously infected 
human CD4 cells when newly formed viruses bud from the host cell (NIAID, 2012). On 
average there are approximately 72 copies of a complex HIV protein known as Env 
embedded throughout the viral envelope that protrude through the surface of the the virus that 
consists of two glycoproteins, gp120 and gp41 (collectively referred to as the gp160 region), 
both of which have been the focal point of extensive vaccine development research (NIAID, 
2012). 
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Figure 1.2 Overview of the stages, enzymes and proteins involved in the HIV replicative 
cycle (adapted from NIAID, 2012). HIV replication takes place through seven basic steps as 
follows (Seiter et al., 2011; Engelman & Cherepanov, 2012): 
 
1. Binding – The gp120 glycoprotein on the HIV envelope binds to a CD4+ receptor and 
one co-receptor (either CCR5 or CXCR4) on the surface of a CD4+ cell.  
2. Fusion – The virus then fuses to the host CD4+ cell and releases its RNA into the 
CD4+ cell. 
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3. Reverse transcription – The reverse transcriptase enzyme converts the HIV single-
stranded RNA to a double-stranded DNA particle, also known as a pre-integration 
complex (PIC). 
4. Integration – The double-stranded DNA produced by the reverse transcriptase 
enzyme enters the CD4+ cell’s nucleus. PIC-associated integrase and host chromatin-
binding protein lens epithelium-derived growth factor (LEDGF) then assists in the 
integration of the double-stranded DNA into the host cell’s DNA, forming a provirus.  
5. Transcription – When the host cell (CD4+) receives a signal to become active, the 
provirus then uses RNA polymerase II (RNA Pol II), a host enzyme and positive 
transcription elongation factor b (P-TEFb) to create copies of HIV’s genomic material 
and different sizes of RNA strands known as messenger RNA (mRNA), which are 
used to create chains of HIV proteins.  
6. Assembly and budding – In the assembly stage, an HIV enzyme called protease cuts 
the long chains of HIV proteins into smaller individual proteins which combine with 
copies of HIV RNA to form new HIV particles. Newly assembled (immature) viruses 
then push their way out of the host cell in a process known as budding, mediated by 
ESCRT (endosomal sorting complex required for transport) complexes. These new 
viruses are encapsulated in part of the host cell’s outer envelope and are studded with 
glycoproteins (i.e. protein or sugar combinations), which allow the virus to bind to 
CD4+ receptors and co-receptors later on in the reproductive cycle.  
7. Maturation – In the final stage of replication, the protease enzyme that played a role 
in step 5 of the replicative process, completes cutting of HIV protein chains into 
individual proteins that combine to make a new mature/virulent HIV particle.  
This basic process ensures the ongoing persistence of HIV even in the presence of 
antiretroviral therapies (Sigal et al., 2011), which has been proposed to occur through two 
main routes, i.e. infection by cell-free virions or through direct cell-to-cell transmission 
(Sattentau, 2008, Monel et al., 2012). The replication process explained above describes the 
cell-to-cell mode of transmission, which is known to be more rapid and helps the virus avoid 
“several biophysical, kinetic and immunological barriers” within the host (Carr et al., 1995; 
Chen et al., 2007; Dimitrov et al., 1993; Sourisseau et al., 2007).  
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Alternatively, infection by cell-free virions has been proposed to occur by viruses that may 
have escaped from CD4 cells through pores that arise along the plasma membrane, instead of 
through extracellular budding (Monel et al., 2012; Sato et al., 1997), however this mode of 
replication is yet to be experimentally verified. 
  
1.1.5 HIV&envelope&region&
HIV envelope proteins have a significant role to play in how the immune system responds to 
invading immunogens and the production of infectious viral particles (Kantanen et al., 1995). 
More specifically, the gp160 envelope protein plays a fundamental role in the infection 
process, as it is responsible for HIV binding to the host cell’s surface (Land et al., 2003).  
 
 
Figure 1.3 Genetic sub-regions within the HIV gp160 envelope protein (Ganser-Pornillos et 
al., 2008). The gp160 region consists of two non-covalent sub-units: (1) gp120 (SU), that 
encodes for a surface protein which is soluble and binds to the chemokine receptor as well as 
the CD4 receptor on the host cell, and (2) gp41 (TM), that encodes for a transmembrane 
protein which anchors the glycoprotein to the viral membrane and mediates cell fusion (Land 
& Braakman, 2001). The surface protein gp120 (SU) assists the virus in attaching to the host 
cell by binding to the primary receptor (CD4), while forming a structural arrangement that 
creates a “high affinity binding site” for a chemokine co-receptor such as CCR5 or CXCR4 
(Miyauchi et al., 2009). The SU protein therefore, determines the tropism and specificity of 
the virus for a single receptor molecule (Coffin et al., 1997).  
 
The gp120 region includes five relatively conserved regions (C1-C5) that make up the core of 
the gp120 protein, and five hypervariable regions (V1-V5) that form flexible loop structures 
on the surface of the gp120 protein (Bunnik, 2010).  
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The V3-loop is the primary determinant of co-receptor tropism, while the V1V2-loops have 
been associated with the accumulation of potential N-linked glycosylation sites (PNLGs) 
during chronic infection, which directly contributes towards viral resistance and evasion from 
HIV-specific neutralizing antibodies (NAbs) (Yuan et al., 2013; Malherbe et al., 2013; van 
den Kerkhof et al., 2013; Go et al., 2009; Blay et al., 2006; Frost et al., 2005).  
 
1.2 HIV&evolution&and&viral&fitness&
1.2.1 AsparagineBlinked&glycosylation&
Eukaryotic cells contain enzymes that catalyse the construction of glycoproteins on the cells’ 
surface and assist in cellular processes including immune response and intercellular 
recognition (Connor & Imperiali, 1996). These glycoproteins are transported to the Golgi 
complex where they undergo progressive modification at the terminal carbohydrates (Dean, 
1999). In the HIV envelope glycoproteins, both Asparagine (N-linked) and Oxygen (O-
linked) glycosylations occur (Agnihotri, 2008). N-linked glycosylations occur as the peptide 
sequence is synthesised from mRNA on the ribosomes, and insertion into the endosplasmic 
reticulum is directed by the hydrophobic amino terminal sequence of the polypeptide chain 
(Andeweg et al., 1995). The glycans specifically form a complex that mediates receptor and 
co-receptor binding and the membrane fusion events that permit virus entry into host cells 
(Mascola & Montefiori, 2003).  
Potential N-linked glycosylation sites (PNLGs), also known as sequons, require the context 
of the amino acid pattern N-X-[S or T] where X can be any amino acid, followed by a Serine 
(S) or Threonine (T) (Zhang et al., 2004). A sequon will not be glycosylated if it contains or 
is followed by a Proline, and glycosylation may be inhibited by certain combinations of N-X-
S or when followed by specific amino acids (Zhang et al., 2004). The proteins that are 
targeted for N-linked glycosylation on the HIV-1 virus structure are the gp120 proteins, of 
which N-linked glycans constitute 50% (Hart et al., 2003). This high concentration of N-
linked glycans blocks antibody access to the conserved regions of gp120 making them a 
common focal point for studies investigating anti-viral strategies.  
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In 1992, Lee et al. investigated 24 N-linked glycosylation sites along the gp120 region of 
HXB2 to determine the relative importance of each site with respect to viral infectivity. Of 
the 24 sites studied, the majority were found to be “dispensable” or unimportant in terms of 
viral infectivity, whereas five sites that were linked to infectivity, were found to be located on 
the amino-terminal half of the env gp120 region leading to the conclusion that PNLG sites 
that infer infectivity are actually not randomly distributed along the gp120 region (Lee et al., 
1992).  
In a site-directed mutagenesis study by Ogert et al. (2001) in which specific N-linked 
glycosylation sites were compromised and subsequently evaluated in the context of viral 
infectivity, PNLG sites that were found to be “functionally critical” in the replicative process 
included N135, N141, N156, N160 and N301. Glycosylation sites near the V1V2-loops (i.e. 
N135, N141, N156, N160) were found to compromise the use of both CCR5 and CXCR4 co-
receptor usage, whereas a mutation at N301 resulted in a total loss of CCR5 binding activity 
while the use of CXCR4 remained at 50% (Ogert et al., 2001). In a similar approach Li et al. 
(2008) discovered three sites (i.e. N406, N448 and N463) that were of particular importance 
in the HIV replicative cycle with the loss of a glycan at PNLG site N448, resulting in a 
structural change within the C4 region, making it more resistant to proteolytic cleavage. Even 
though the distant C1C2 sites were not affected by the loss of a glycan, the highly localised 
effect still reduced CD4 cell recognition and therefore represented an important finding with 
respect to the development of potential future biological therapeutic agents (Li et al., 2008). 
The findings of Li et al. (2008) were consistent with those of François and Balzarini (2011), 
who observed that under site-directed mutagenesis, compromise of the highly conserved 
N260 site caused a significantly lower expression of gp120 and gp41 in the virus particle, 
leading to the recommendation that this site is a suitable target for therapeutic development. 
Previous studies had observed variation in the net number of sequons in the variable loop 
regions associated with patterns of co-receptor usage, and showed that a particular sequon in 
the V3-loop was highly conserved in CCR5-tropic viruses whereas other PNLG sites in the 
V1V2-loop appear to influence the use of the CXCR4 co-receptor usage (Zhang et al., 2004).  
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In another study by Toma et al. (2011), it was shown that the loss of N-linked glycosylation 
sites in the V5-loop region was associated with the CD4 antibody Ibalizumab, which was 
introduced to patients on failing drug regimens. Cells with fewer N-linked glycosylation sites 
in the V5-loop were found to be less susceptible to the antibody while those with more N-
linked sites were more susceptible, indicating that the glycosylation sites in the V5-loop may 
further act as target sites for therapeutics.  
Moreover, Balzarini et al. (2004) observed that the removal of several glycosylation sites 
along the gp120 region resulted in a more infectious virus compared with the parental wild-
type, and that mutation of the glycosylation site in the V3-loop (N301) can lead to a co-
receptor switch as a result of a higher affinity for the CXCR4 co-receptor. Thus, 
demonstrating that targeting the glycosylation sites may not necessarily result in a reduction 
in HIV-1 activity, highlighting the importance of long-term studies of glycosylation site 
patterns to infer their effect on HIV-1 activity.  
In a lipoprotein-specific study that investigated two asparagine-linked glycosylation sites at 
the amino and carboxy terminals of lipoprotein lipase and hepatic lipase (Ben-Zeev et al., 
1994), it was observed that glycosylation at the C-terminal domain is not essential for the 
expression of active lipases, but was imperative for active lipase secretion at the conserved 
N-linked glycosylation sites for these enzymes. What this indicates is that the conserved 
regions may contain N-linked glycosylation sites that can actually be compromised by 
targeting the enzymes associated with these sites. Furthermore, insertions at N-linked 
glycosylation sites and the resultant observations have become a growing area of research. 
One such study reported an insertion of arginine at amino acid site 11 on the gp120 region, 
which resulted in a loss of the N-linked glycosylation site responsible for acquiring CXCR4-
tropism (Tsuchiya et al., 2013).  
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Glycosylation analysis however, is becoming less feasible to perform through wet-bench 
analysis due to cost and time limitations, and since there is such a high volume of sequence 
data that is presently available, this has led to the development of several bioinformatics 
methods and tools for in silico glycosylation analysis on the gp120 region (Poon et al., 2007; 
Shaw & Zhang, 2013). Studies that employed these and other methods of analysing 
glycosylation sites have led to the hypothesis that the adaptive repertoire of the HIV-1 glycan 
shield is limited by functional interactions between the N-linked glycans (Poon et al., 2007).  
However, all algorithms have their respective strengths and weaknesses in their accuracy of 
predicting sites for viral targeting and therefore longitudinal immune pressures that may 
affect sequon accumulation should ideally be confirmed through wet lab experimentation.  
!
1.2.2 Recombination&in&HIV&
Recombination has long been described as one of the most important mechanisms through 
which retroviruses generate genetic diversity and rapidly rejuvenate sequences in a way than 
is unlikely through “stepwise accumulation of point mutations” (Simon-Loriere et al., 2010; 
Santoro & Perno, 2013). It is estimated that more than 20% of HIV-1 infections in Africa 
involve recombinant strains (Van der Kuyl & Cornelissen, 2007). Because HIV is uniquely 
diploid, each virion carries two complete RNA genomic strands that can undergo a series of 
recombination events, which along with other mutational events can uniquely modify the 
viral strain, often leading to fitter viral forms (Burke, 1997; Santoro & Perno, 2013). Even 
when just a single viral variant initiates an infection and the HIV population that arises within 
an individual during the acute phase of infection is usually relatively homogenous, as the 
infection progresses to the chronic phase however, viral diversity can increase rapidly 
(Herbeck et al., 2011; Kearney et al., 2009; Shankarappa et al., 1999). This diversification 
process is facilitated by HIV’s high mutation and recombination rates coupled with the 
persistence of powerful continually shifting selection pressures favouring the expansion of 
viral lineages that harbour viruses with the capacity to evade host humoral and cellular 
immune responses (Neher & Leitner, 2010; Abram et al., 2010; Levy et al., 2004; Armitage 
et al., 2012; Zhuang et al., 2002; Lau & Wong, 2013; Onafuwa-Nuga & Telesnitsky, 2009; 
Mostowy et al., 2011; Streeck et al., 2008).  
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Less fit viruses can also be produced through the division of favorable mutational 
combinations, since not all mutations lead to the production of fitter viruses, alternatively 
fitter viruses could also be produced from parental genomes with an overall lesser fitness 
(Santoro & Perno, 2013).  
Through recombination, infected host cells containing different proviral RNA strands give 
rise to a heterozygous, recombinant genomic strand capable of subsequent rounds of infection 
and outgrowth (Abrahams et al., 2009). The complexity of HIV diversification dynamics 
following multiple variant transmission events also increases with increasing genetic 
divergence of the founder viruses. Since the RNA genome allows for extensive template 
switching, this also makes it capable of giving rise to multiple subtypes of a virus across 
population groups (Carr et al., 2010). This phenomenon, coupled with the occurrence of 
polymorphisms present in viral genomes, has the potential to give rise to a completely new 
viral genome within a single round of replication. In cases where degrees of population-wide 
genetic diversity are high from the moment of transmission, recombination between the 
founder variants has the potential to increase diversity far faster than in single variant 
transmissions (Novitsky et al., 2011). Early recombination events contributed to the 
emergence of current ‘pure’ HIV-1 subtypes while later recombination events resulted in 
circulating recombinant forms (CRFs) that exist today (Carr et al., 2010), many of which are 
commonly found across populations in India, China, Myanmar and Central Africa (Neogi et 
al., 2012). There are now nine official ‘pure’ subtypes and at least 58 validated CRFs that 
have been identified and categorized through phylogenetic analyses, in existence today (Carr 
et al., 2010; Santoro & Perno, 2013). 
!
1.2.3 Selective&pressures&acting&on&HIV&
Although the clinical course of HIV is generally well-defined, considerable variability in 
rates of disease progression exist between patients, indicating differences in the nature of 
evolutionary paths between the viral population and the host immune system (Lemey et al., 
2007). Given that the nature of selection likely varies at least slightly between different 
tissues and cell types, it is plausible that these differences could yield genetically distinct 
viral sub-populations within different anatomical compartments. This enormous potential for 
evolutionary change in HIV populations occurs within a single individual (Lemey et al., 
2007).  
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Neutralizing antibodies (nAb) have also been reported to induce strong selective pressures 
that act on the env gene and control viral replication and disease progression (Chun et al., 
2014).  
 
Other factors affecting the rate of HIV evolution and replication include adaptive cytotoxic T 
cell (CTL) responses which have been reported to partially control HIV replication in vivo, 
and human leukocyte antigen (HLA) class I allelles, that have been linked to the control of 
disease progression (Koup et al., 1994; Carrington et al., 1999; Trachtenberg et al., 2003). 
One reported disadvantage of CTL responses however is its ability to frequently target 
epitopes in other viral genes more strongly (e.g. nef and gag), resulting in the proliferation of 
viral variants that escape CTL responses and consequently become more ‘virally fit’ (Lemey 
et al., 2007; Goulder & Watkins, 2004; Martinez-Picado et al., 2006; Leslie et al., 2004), 
however evolutionary escape is associated with a gain in relative fitness and not actually 
absolute fitness (Rambaut et al., 2004).   
 
Antiretroviral therapies also play a significant role in the development of drug resistant 
mutations that infer viral fitness over long-term infection (Mesplède et al., 2013). Amazingly, 
HIV is able to rapidly adapt to changing conditions within any individual, successfully 
evading host responses and therapeutic measures by accumulating numerous amino acid 
mutations, usually within the variable-loop regions on the env gene, while being able to 
maintain all other replicative functionalities (Lemey et al., 2007).  
!
1.2.4 Chemokine&receptors&CCR5&and&CXCR4&
To bind to and gain entry into host cells, HIV is dependent on the CD4 glycoprotein that it 
uses as a receptor and a 7-transmembrane-domain chemokine receptor such as CCR5 and/or 
CXCR4 that it uses as co-receptors (Cecilia et al., 2000; Schuitemaker et al., 2011). Co-
receptor usage has been shown to correlate with syncytium-inducing (SI) and non-syncytium-
inducing viruses, where CCR5 usage is linked to the later phenotype while multiple others 
including CXCR4, CCR3, CCR2B, CCR8, GPR15, STRL33, CX3CR1, and dual-tropic 
viruses (capable of using either CXCR4 or CCR5 co-receptors) are associated with the SI 
phenotype (Cecilia et al., 2000).  
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This variability in co-receptor usage modulates viral transmission and treatment response and 
there have been several studies that have associated a switch in co-receptor usage from CCR5 
to CXCR4 with disease progression (Cecilia et al., 2000; Lusso, 2006; Rambaut et al., 2004).  
 
It has also been reported that viruses tend to use CXCR4 co-receptors during the late stages 
of infection which has been linked to CD4 T cell depletion and rapid disease progression 
from HIV to AIDS (Connor et al., 1997; Penn et al., 1999). However, although multiple co-
receptors interact with HIV in vitro, CCR5 and CXCR4 have been found to be of particular 
relevance clinically (Schuitemaker et al., 2011; Lusso, 2006).  
 
1.3 Naturally&occurring&HIV&restriction&factors&
Although anti-retroviral therapy has dramatically reduced morbidity and mortality rates in 
HIV infection, there remains a great demand for alternative clinical strategies since ART 
entails lifelong therapy, toxicity issues, considerable costs and the emergence of drug-
resistant strains (Abdel-Mohsen et al., 2013; Alter & Moody, 2010). Naturally occurring HIV 
restriction factors have been shown to suppress HIV to undetectable levels in the absence of 
ART by interfering with the virus’ replicative cycle at various steps, and therefore represent a 
promising direction for a practical cure especially if combined with existing therapies to 
eradicate viral reservoirs (Chan et al., 2014; Abdel-Mohsen et al., 2013). Among these 
restriction factors are the widely studied inhibitors of HIV-1 known as APOBEC3G, TRIM5, 
Tetherin and SAMHD1 (Malim & Bieniasz, 2012; Santa-Marta et al., 2013; Chan et al., 
2014).  
!
1.3.1 APOBECBinduced&hypermutation&
Viral replication is dependent on the compromise of human intracellular defence mechanisms 
and the protection of viral gene products that are essential to viral invasion into host cells 
(Mangeat et al., 2003). It is therefore essential for a virus to negate the effect of these families 
of proteins known for their protective properties in host cells. Hypermutation is observed to 
be the result of mutational pressure, where a general predisposition to be adenine rich in 
association with reverse transcription is hypothesized (Müller & Bonhoeffer, 2005).  
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Guanine to adenine (G to A) hypermutation has a widespread association with significantly 
reduced plasma HIV RNA levels in vivo (Pace et al., 2006), highlighting that APOBEC has a 
similarly significant impact on viral loads as other retroviral restriction factors, which has 
been reported to be equivalent in response to infection on the same scale as therapies such as 
Zidovudine for example (Pace et al., 2006).  
 
The APOBEC proteins belong to a family of cytidine deaminases expressed in many cell 
types (Kourteva et al., 2012; Strebel, 2005; Noguchi et al., 2005), with APOBEC3G and 
APOBEC3F reported to be responsible for converting cytidine to uridine (Amoêdo et al., 
2011), which reflects as mutations from Guanine to Adenine (Noguchi et al., 2005). The 
APOBEC3G (A3G) and APOBEC3F (A3F) proteins are frequently reported as inhibitors of 
HIV-1 (Kourteva et al., 2012; Yu et al., 2003) where reported targets for APOBEC3G are 
sequences that are complementary to CGG and TGG, wherein it specifically focuses on 
mutating G’s to A’s (Yu et al., 2003).  
 
On average hypermutation occurs in 20% of proviral sequences but significant patient-to-
patient variability has been reported. Nevertheless, although A3G mutation patterns are 
present in 95% of hypermutated sequences, hypermutation alone cannot explain the control 
of viremia and viral suppression is thought to occur through a combination of other viral and 
host factors, including CTL responses and other immunological factors (Ghandi et al., 2008). 
The question of whether A3G-induced mutations are always lethal to the virus or may occur 
at sub-lethal frequencies was investigated by Armitage et al. (2012), who found that even a 
single incorporated “A3G-unit” is likely to cause extensive and inactivating levels of HIV 
hypermutation, and that hypermutation is typically a discrete phenomenon.   
!
1.3.2 Broadly&cross&neutralizing&antibodies&
HIV infection inherently elicits a humoral immune response in the human body, prompting 
the generation of a complex mixture of antibody isotopes with varying specificities (Tomaras 
& Haynes, 2009). However unlike other antibody responses, HIV-specific antibodies have 
been reported to take a longer time to develop, usually arising long after HIV latency has 
been established (Tomaras & Haynes, 2009).  
  
 
 
 
 
! 20!
Although the present study does not explore this particular aspect of disease progression, 
previous work in this domain has recently been conducted for one of the participants studied 
here (i.e. CAP177) in whom well-developed broadly cross-neutralizing (BCN) antibodies 
were found to target glycans at amino acid site 332 on the gp120 env gene (Moore et al., 
2012). Viruses that lacked a glycan at amino acid position 332 were found to be resistant to 
the BCN antibody PGT128, whereas viruses that harboured a glycan at this position were 
sensitive to PGT128 (Moore et al., 2012).  
 
In a larger scale investigation by Gray et al. (2011) where other participants from the same 
cohort studied here were analysed, antibodies that neutralized more than 40% of viruses were 
discovered in 7 out of 40 participants tested. Longitudinal analysis also revealed that the 
extent of cross-neutralizing antibody activity developed gradually over time from around the 
second year post-infection. Two participants showed particularly high neutralization activity, 
i.e. CAP257 and CAP256, both of whom demonstrated variant neutralization breadths of 
82% and 77% respectively, however neutralization activity was found to peak at 4 years post-
infection after which there was no increase in activity (Gray et al., 2011). Simliar to Moore et 
al. (2012), Gray et al. (2011) also reported evidence of antibody activity dependent on the N-
linked glycan present at amino acid site 332 on the gp120 env region, in addition to another 
antibody (similar to PG9/16) that was found to be linked to a glycan at aa site 160. 
Furthermore, in a more recent study of participants from the same cohort studied here, four 
PNLG sites linked to antibody neutralization sensitivity with strong statistical support in 
participant CAP177 at amino acid sites 209, 332, 334 and 683 were reported (Lacerda et al., 
2013). However, despite all of these findings Gray et al. (2011) concluded that less than 20% 
of subtype C infections lead to the development of cross-neutralizing antibodies and if 
antibodies do arise, they tend to target different regions of the HIV-1 envelope region, 
including regions that are yet to be fully characterized. 
!
! &
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1.3.3 Other&well&known&restriction&factors&
Several other cellular proteins capable of impeding viral replication have been identified, 
aside from the APOBEC protein family, which act on different steps of the HIV replicative 
cycle. The TRIM (Tripartite Motif) family of proteins is one of these and is characterized by 
a highly conserved structure on the amino-terminal region (Santa-Marta et al., 2013). Several 
TRIM family members incl. TRIM5, TRIM11, TRIM15, TRIM19, TRIM22, etc. have been 
reported to be involved in numerous biological processes such as innate immunity, cell 
differentiation, and transcriptional regulation (Santa-Marta et al., 2013). Among these 
TRIM5 is the most widely studied protein, as it blocks HIV infection at an early stage in 
infection by binding to the virus’s capsid and inducing premature disassembly before reverse 
transcription occurs (Stremlau et al., 2004). The mechanism through which TRIM5 does this 
however, is still not fully understood.  
 
Tetherin is another naturally occurring restriction factor that is widely known for its antiviral 
activity against numerous enveloped virus families, whose main target is the lipid bilayer on 
the outermost layer of the host cell (Swiecki et al., 2012). Tetherin physically binds to 
budding viral cells preventing the release of new viruses by anchoring them to the host cell 
(Chan et al., 2014). It has however, also been suggested that it could likewise play the 
opposite role in cell-to-cell transmission by bringing viruses and host cells closer to each 
other, since viruses have previously demonstrated the ability to escape tetherin restriction 
(Santa-Marta et al., 2013).  
 
Finally, a factor that has been reported to reduce the intracellular dNTP (deoxynucleotide 
triphosphate) levels to the point where it becomes too low to support HIV-1 reverse 
transcription, is the SAMHD1 (sterile alpha motif and histidine-aspartate domain-containing) 
hydrolase (Santa-Marta et al., 2013). SAMHD1 is a dNTP hydrolase that is activated when 
GTP binds to it, causing it to cleave into deoxynucleoside and triphosphate products. Once 
this happens, the level of dNTP immediately declines in the host cell, limiting HIV-1 reverse 
transcription during the replicative cycle (Santa-Marta et al., 2013). Although there have 
been studies that focused on therapeutic manipulation of dNTP pools and the development of 
SAMHD1 inhibitors as potential anti-retroviral therapies, there remains a lack of clinical 
analyses in this direction (Santa-Marta et al., 2013).  
! &
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1.4 Viral&reservoirs&
1.4.1 HIV&Latency&
Current drug regimens suppress HIV replication, but are unable to eradicate the virus 
completely (Chun & Fauci, 2012). They render the infected CD4 T-cells in a state of ‘rest’, 
but these infected cells are still carried in infected individuals. Latent HIV reservoirs are the 
principal barriers preventing the eradication of HIV infection (Bandyopadhyay et al., 2006) 
and pose as a constant danger to infected individuals as viral replication may potentially be 
re-initiated, especially when immature T cells (thymocytes) are exported into the blood 
(Brooks et al., 2001). Latency also provides a mechanism through which viruses escape 
immune recognition (Siliciano & Greene, 2011). 
 
Viral reservoirs typically constitute less than 1 per 1x106 cells (Brooks, 2001), but may be 
stable for the entire natural lifespan of the host (McNamara & Collins, 2011; Alexaki et al., 
2008). It is therefore imperative to understand how latency is able to persist, given that 
cellular lifespans may be very short and may be susceptible to intrusion by other cellular 
invaders such as bacteria or other viruses. The spread of HIV requires only one cell to give 
rise to an infectious virus (Erdmann, 2010), however HIV does not have a gene that codes for 
latency, it simply “remembers” certain antigens encountered even in their latent state and 
undergoes polymorphisms to evade these antigens when replicating (Erdmann, 2010). To 
eradicate HIV reservoirs, latent viruses need to be reactivated and eliminated through the 
body’s immune response system and to do this there are several pharmacological compounds 
that have been reported to reverse latency without activating T cell activation across the host 
(Shan et al., 2012). Nonetheless HIV is known to actively replicate throughout the course of 
infection and the major mechanism by which it escapes host immune responses is through 
rapid evolution of mutations more frequently than through latency (Siliciano & Greene, 
2011).  
 
! &
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1.4.2 Persistent&viremia&
The large flux of new information relating to HIV after the introduction of antiretroviral 
therapy has improved the outlook for controlling the HIV pandemic. Even though it is still 
impossible to definitively cure HIV/AIDS, barring a few exceptions, it is possible to suppress 
viral loads, partially restoring the body’s immune function and inhibiting the progression of 
HIV (Laprise et al., 2013).  
 
Persistent viral infection brings about an almost constant dysfunction of the T-cell 
lymphocytes (Brockman et al., 2009), which in turn inhibits the immune response and 
compromises the host’s ability to protect itself against the invasion of replicating HIV. The 
body’s “natural killer (NK) cell phenotype” that is responsible for lowering viral loads to 
undetectable levels within the host, becomes less expressed during ongoing viral replication 
(Brunetta et al., 2010). More specifically, it has been found that eliminating a cells ability to 
produce an enzyme known as “NKG2A” decreases its capability to lower viremia levels 
(Brunetta et al., 2010).   
 
When antiviral therapies are introduced, HIV RNA undergoes a decay (Iglesias-Ussel & 
Romerio, 2011), initially at a rapid pace coinciding with the half-life of the virus within host 
cells, and then at a slower pace, which coincides with the lessening of longer lived infected 
cells. A study by Murray et al., (2007) as cited by Iglesias-Ussel and Romerio (2011) went on 
to report that under monotherapy with Raltegravir for example, there was actually no second 
phase decay of HIV RNA levels, which led to the belief that this second phase was due to 
new infections arising from long lived cells or activated latently infected cells. Iglesias-Ussel 
and Romerio (2011) hypothesized that HIV infection may occur when infected cells escape 
the cytopathic effect of virus-immune responses and clonal expansion and then become latent 
memory cells containing the provirus, however this theory remains controversial. In practice, 
long-term therapy has been associated with a loss of antibodies, as was discovered in the 
Visconti cohort, while the absence of therapy was linked to a rapid viral rebound and disease 
progression in patients with a low-level of viremia (Sáez-Cirión et al., 2013). Only in rare 
individuals has post-therapy control been observed, mostly in patients that received therapy 
during early infection (Sáez-Cirión et al., 2013).  
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Evidence of long-term viral supression has also previously been associated with a lack of 
viral replication, suggesting that low level viremia is most likely the result of virus 
production from reservoirs as opposed to new rounds of replication (Dinoso et al., 2009). 
Ultimately however, only through cell death is a viral reservoir depleted, therefore it becomes 
important for the host to undergo virologic suppression to protect itself from developing drug 
resistant viruses (Laprise et al., 2013) even though HAART antiviral therapy may assist in 
lowering viral loads in infected individuals, it is unable to prevent the establishment of viral 
reservoirs over time (Iglesias-Ussel & Romerio, 2011).  
!
1.5 TissueBspecific&viral&compartmentalization&
HIV resides in a wide variety of tissues and compartmentalization of distinct viral 
populations has been reported in both the male and female genital tracts (Zhu et al., 1996; 
Kemal et al., 2003; Philpott et al., 2005; Diem et al., 2008; Bull et al., 2009; Avery et al., 
2013; Bull et al., 2013), the digestive tract (Zhang et al., 2002; van Marle et al., 2007; 
Imamichi et al., 2011), the brain (Korber et al., 1994; Ohagen et al., 2003; Ritola et al., 2005; 
Pillai et al., 2006; Salemi et al., 2005; Smith et al., 2010; Harrington et al., 2011; Sturdevant 
et al., 2012), the lungs (Itescu et al., 1994; Heath et al., 2009; Lewis et al., 2013), the spleen 
(Wong et al., 1997), the breast (Gantt et al., 2010) and the kidneys (Marras et al., 2002). If 
compartmentalization arises from the diversification of transmitted viral variant(s) under 
differential tissue-specific selection pressures such as those exerted by the immune system, 
host cell availability and cellular differences in viral replication rates, then it might be 
expected that viruses derived from different anatomical compartments might possess distinct 
phenotypic characteristics (Pillai et al., 2006; Harrington et al., 2011; Heath et al., 2009; 
Schnell et al., 2010). Such characteristics potentially include host cell preferences, the extent 
of glycosylation and degrees of drug resistance (Zhu et al., 1996; Bull et al., 2009).  
 
Tissue-specific viruses are characterized by host cell characteristics, anti-retroviral drug 
penetration and region-specific immunological pressure among other stimuli (Pillai et al., 
2006). In the absence of viral migration it is expected that anatomical compartments serve as 
sanctuary sites for viruses, where they evolve independently and adapt to local 
immunological or cellular characteristics (Clarke et al., 2000; Bull et al., 2009).  
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As a result effective prevention, treatment or control strategies are dependent on an accurate 
understanding of how HIV evolves in specialized tissues, and whether compartment-specific 
pressures contribute to the diversity and fitness of viral subpopulations (Kemal et al., 2003; 
Clarke et al., 2000).   
 
Although most published studies on viral compartmentalization in the female genital tract 
have been cross-sectional in design, considering viruses sampled at only a single time point, 
compartmentalization of viruses in the female genital tract has previously been detectable in 
around 33% of chronically infected women (Overbaugh et al., 1996; Kemal et al., 2003; 
Philpott et al., 2005; Andreolétti et al., 2007; Boeras et al., 2011; Chaudhary et al., 2012) and 
has been reported in studies of both subtype B and C infections (Adal et al., 2005; Chomont 
et al., 2007). Philpott et al. (2005) for example found that among the five women studied, 
strong evidence of compartmentalization was found in four of the women using phylogenetic 
methods even though no statistically significant difference in co-receptor usage or N-linked 
glycosylation patterns between cervical and plasma derived viruses was evident. Similarly, 
Chaudhary et al. (2012) found that among the six women studied, although no tissue-specific 
difference in co-receptor usage was discovered, sequences clustered together by tissue type 
on maximum likelihood phylogenetic trees in women with higher CD4 T cell counts, 
suggesting that the immune response plays a fundamental role in the compartmentalization of 
viral populations.  
 
Despite these findings however, the only three published longitudinal studies involving 
viruses sampled between 1.5 and 3.5 years post-infection have still been unable to 
conclusively establish whether compartmentalization is the rule (detectable in 3/3 individuals 
studied by Poss et al., 1998) or the exception (detectable in 4/14 individuals studied by 
Sullivan et al., 2005) using rigorous analytical methods (Bull et al., 2013). Among the 
longitudinal studies that investigated both genotypic and phenotypic differences between 
viral populations from the cervix and blood stream, contradictory results were reported (Poss 
et al., 1998; Sullivan et al., 2005; Bull et al., 2013). In the most recent longitudinal study by 
Bull et al. (2013) in which co-receptor usage, migration events and PNLG site accumulation 
was analysed in cervical and blood plasma sequences from eight women, no definitive tissue-
specific differences were reported. Although a greater number of PNLGs were discovered 
within cervical sequences in six of the eight women analysed, when PNLG sites were 
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excluded from the sequences and reanalysed, the clustering of sequences on phylogenetic 
trees did not change (i.e. sequences remained intermingled on all clades) (Bull et al., 2013). 
Sullivan et al. (2005) and Poss et al. (1998) focused on genetic diversity, divergence and 
evolution of cervical and blood plasma sequences, and found that there was no clear 
distinction between viruses from either tissue type in 10 of the 17 data sets analysed, however 
the methodologies employed in these studies were not extensive and came before the 
introduction of advanced phylogenetic methods.  
 
Numerous approaches have been developed to predict the importance of “sanctuary sites”, 
HIV persistence and virus trafficking between compartments including mathematical and 
statistical models (Clarke et al., 2000). In a review of the most appropriate statistical methods 
to detect viral compartmentalization, Zárate et al. (2007) describes phylogenetic methods as 
fundamental to establishing whether viruses migrate between compartments, especially as the 
viral load increases, since there is a likely sampling bias when samples are taken during 
periods when viral loads are high. Zárate et al. (2007) further observed that the 
compartmentalization of HIV was not confined to specific disease stages and that there is 
actually no ideal method to detect compartmentalization. Phylogenetic tree-based methods 
however, such as the Slatkin-Maddison (SM) test (Slatkin & Maddison, 1989) and Simmonds 
association index (AI) (Wang et al., 2001) are generally considered to have greater power in 
detecting compartmentalization than distance-based methods such as the Wright’s FST 
(Wright, 1943) and AMOVA tests (Excoffier et al., 1992; Zárate et al., 2007). However, it is 
also recommended if a phylogenetic approach is adopted, that screening for recombination 
and the use of reliable phylogenetic models is imperative to obtain a better understanding of 
viral compartmentalization and infection dynamics, as these factors could influence 
phylogenetic inferences (Zárate et al., 2007).  
 
In a study employing phylogenetic and Slatkin-Maddison analyses, Gantt et al. (2010), found 
limited compartmentalization of HIV-1 in breast milk specimens, suggesting extensive 
interchange of viruses between breast milk and the blood plasma. HIV-1 viruses were 
compartmentalized within breast milk in 35% of the sequences obtained from nine women 
through Slatkin-Maddison testing, while phylogenetic analyses demonstrated extensive 
mixing between viral sequences from milk and blood plasma samples.  
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Monotypic sequences were found to be overrepresented in HIV-1 populations from milk 
specimens and accounted for half of the inferred compartmentalization, however local HIV-1 
production within the breast was later linked to inflammation (Gantt et al., 2010). In another 
investigation that analysed sequence data for evidence of tissue-specific 
compartmentalization, Marras et al. (2002) compared peripheral blood mononuclear cells 
(PBMC’s) and kidney-derived sequences from two patients sampled cross-sectionally and 
found strong evidence of tissue-specific HIV evolution in the kidney. Phylogenetic analyses 
revealed kidney-derived sequences formed tissue-specific “subclusters” that were surrounded 
by blood-derived sequences. This pattern combined with evidence of HIV-1-specific proviral 
DNA and mRNA that was detected in kidney cells only, pointed towards the existence of a 
“renal viral reservoir”, (Marras et al., 2002).  
 
Research into viral compartmentalization patterns in other tissue types such as the liver has 
also suggested that tissue-specific selection pressures that drive viral adaptation in the liver’s 
microenvironment may be responsible for tissue-specific compartmentalization in this organ 
compared to viral populations sampled from the blood stream (Blackard et al., 2011). HIV 
compartmentalization has been exhibited in the brain as well. In a study by Salemi et al. 
(2005) in which a local-molecular-clock analysis was performed, the authors reported 
evidence that HIV-1 subpopulations in the meninges and temporal lobe respectively evolve 
about 30 to 100 times faster than viral populations in other parts of the brain. In contrast, 
Imamichi et al. (2011) found no evidence of viral compartmentalization between viruses in 
the gut colon and ileum or between the gut and peripheral blood, and the presence of HIV-1 
sequences in both the gut and peripheral blood at the same time points tested suggested 
ongoing viral replication in both compartments.! 
 
In another study that investigated the existence of genetically distinct HIV-1 populations 
within different tissue compartments including the central nervous system, the reproductive 
tract and gastrointestinal mucosa, Potter et al. (2004) found no convincing evidence for this 
phenomenon suggesting that the emergence of phylogenetic structure in different 
compartments over time in HIV-infected individuals is likely to arise from a continual 
process of migration of infected cells into each compartment, followed by localized 
expansion and evolution of each population.  
 
 
 
 
! 28!
Nevertheless, although well-documented differences between HIV populations from different 
tissue-specific compartments in the same individual have been reported, including between 
the genital tract and blood plasma (Philpott et al., 2005; Kemal et al., 2003; Zhu et al., 1996; 
Diem et al., 2008), it has been suggested that many of these studies failed to rigorously test 
for compartmentalization (Bull et al., 2009) and results from a more recent longitudinal study 
(Bull et al., 2013) that tested for this phenomenon, has cast doubt on the generality of 
previous findings, suggesting that further investigation into the dynamics of viral 
subpopulations over long-term infection are required. This study therefore aimed to address 
the methodological gap in previous studies through the use of both distance and tree based 
methods (including advanced phylogenetic reconstruction models as implemented in BEAST, 
tMRCA and substitution rate estimation, etc.) while contributing to the limited knowledge on 
compartmentalization dynamics over long-term HIV infection in treatment naïve patients.  
 
 
!
 
 
! !
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Chapter(2!
Methodology!
!
2.1 Participant&background&
HIV-1 env gp120 sequences analysed in this study, were obtained in collaboration with the 
National Institute for Communicable Diseases (NICD) and the Centre for the AIDS 
Programme of Research in South Africa (CAPRISA). Cervico-vaginal lavage (CVL) and 
blood plasma samples were obtained from participants enrolled in the CAPRISA 002 Acute 
Infection study in Durban, Kwa-Zulu Natal. The cohort, originally containing 245 uninfected 
high-risk women was initiated in 2004 to investigate the natural history of HIV-1 during 
acute infection (van Loggerenberg, 2008). The subset of participants included in this study 
consisted of four women anonymously identified as CAP177, CAP217, CAP261 and 
CAP270, all of whom had no previous exposure to anti-retroviral therapy. All CVL samples 
obtained from these women were collected only when they were not menstruating, during 
their luteal phase. Participants were aged between 18 and 37 years old and were also tested 
for sexually transmitted infections (incl. vaginosis, HSV type 2, syphilis, gonorrhoea, etc.) in 
addition to having their viral loads and CD4 cell counts in the blood plasma measured at each 
clinical visit.  
 
2.2 Ethics&
All sequences analysed in this study have been passed through an ethics committee and 
approved through the CAPRISA cohort. Ethics approval has been received from three South 
African Universities (University of KwaZulu-Natal Ref: E013/04, 5 July 2004; University of 
the Witwatersrand Ref: MM040202, 22 April 2004; University of Cape Town Ref: 
025/2004CA, 23 June 2004), and all samples were anonymously recorded.  
 
! &
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2.3 Sample&processing&&
All HIV-1 samples were sent to the AIDS Virus Research Unit at the National Institute for 
Communicable Diseases (NICD) where RNA extraction, cDNA synthesis, PCR and 
sequencing were conducted. In order to obtain the CVL sample, both the vagina and cervix 
were washed repeatedly with 10ml phosphate buffered saline (PBS) before centrifuging the 
PBS to separate cellular components from supernatant. The supernatant was then checked for 
blood contamination with Roche Cobas combur dipsticks before being aliquoted into 2ml 
portions and stored at -700C. Although CVL samples were taken during acute and chronic 
infection, it was not possible to amplify env sequences from every sample taken possibly due 
to inconsistent HIV-1 shedding in the female genital tract.  
 
RNA was extracted between 0.6 and 1.6ml of the CVL supernatant and 140µl of plasma 
using the Qiagen QIAmp viral RNA MiniKit according to the manufacturer’s protocol. For 
extraction from CVL samples, an on-the-column DNase digestion step was included to 
ensure that all amplified env sequences were obtained from cDNA and not DNA during RNA 
purification. cDNA synthesis and the complete HIV-1 envelope were amplified in a nested 
PCR reaction according to the protocol described by Salazar-Gonzalez et al. (2008). The 
protocol for single genome amplification (SGA) was then followed, as sequences from 
individual viruses were required for the purposes of this study. PCR reactions were continued 
until at least 15 amplicons were obtained for each sample or until all the cDNA was used. As 
CVL samples contain relatively very few viruses compared to the blood plasma, it was often 
not possible to amplify the required number of amplicons.  
 
PCR products were cleaned with the Qiagen PCR product purification kit and directly 
sequenced with the ABI PRISM Big Dye Terminator V3.1 Cycle Sequencing Ready Reaction 
Kit (Applied Biosystems) and resolved on a 3100 Automatic Capillary Sequencer (Applied 
Biosystems). Sequence analysis was then performed using the Sequencher V4.5 program to 
form contiguous sequences for the complete HIV-1 env region, where amplicons containing 
double peaks or interrupted reading frames were excluded from downstream analyses.  
 
! &
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2.4 Multiple&sequence&alignment&
HIV-1 env sequences from participants CAP177, CAP217, CAP261 and CAP270 were 
obtained from the NICD and were arranged into four sets of alignments per participant for 
subsequent analyses (Table 2.1). Intrapatient sequence alignments were generated using 
ClustalX v2 (Larkin et al., 2007) in multiple alignment mode with HXB2 as the reference 
sequence. ClustalX is an open-source software package that aligns sequences in pairs to 
generate a distance matrix that is used to construct a rough initial phylogenetic tree of the 
sequences, from which a multiple sequence alignment is progressively created based on the 
branching order of a guide tree (Thompson et al., 1997). Subsequent visual inspection and 
manual editing of the alignments was then performed using the Se-Al v2.0a11 
(http://tree.bio.ed.ac.uk/software/seal/) sequence alignment editor (Rambaut, 2002; Abecasis 
et al., 2007). Intrapatient sequence alignments were then codon aligned in Se-Al to avoid the 
inclusion of DNA encoding frame shifts and mistranslated sequences that would affect the 
results of downstream analyses.  
 
Table 2.1 Intrapatient multiple sequence alignments organized into four qualitative data sets 
categorized by env region and presence or absence of monotypic and low diversity sequences. 
The first data set included all HIV-1 env gp120 sequences while the second excluded 
monotypic sequences and third excluded both monotypic and low diversity sequences. The 
fourth data set contained separated V-loop regions from each intrapatient alignment within 
data set 1 only.  
Data'set' Content' Description'
1'
Intrapatient!full.length!HIV.1!
env!gp120!alignments!
Included!all!sequences.!
2' Excluded!monotypic!sequences!(included!low!diversity!
sequences).!
3' Excluded!both!monotypic!and!low!diversity!sequences.!
4' Intrapatient!HIV.1!env!V.loop!
alignments!
Variable!loop!regions!V1.V5!from!all!sequences!(including!
monotypic!and!low!diversity!sequences).!
 
! &
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2.4.1 Monotypic&and&low&diversity&sequence&removal&
The presence of identical (monotypic) and genetically similar (low diversity) sequences has 
been shown to bias statistical tests for compartmentalization towards false positives (Bull et 
al., 2009; Gantt et al., 2010), and monotypic sequences have also been proposed to be 
associated with recent bursts of replicating viruses, or with proliferation of provirus 
containing host cells in discrete tissue types (Bull et al., 2009; Boeras et al., 2011; Gantt et 
al., 2010). Monotypic and low diversity sequences were therefore reduced to a single 
representative sequence to eliminate any potential false positives in the compartmentalization 
results.  
 
A total of 101 monotypic env sequences were detected among all participants during 
assembly of data sets excluding monotypic sequences (i.e. data sets 2 and 3; Table 2.1), the 
majority of which were found in participant CAP177 and were distributed across all six time 
points sampled 14 (n=13), 28 (n=17), 378 (n =3), 560 (n=4), 924 (n=2) and 1295 (n= 10) 
days post-infection. In CAP217, 32 monotypic sequences were detected at four sampling time 
points 14 (n=15), 63 (n = 11), 770 (n = 3) and 1316 (n= 3), with only six monotypic 
sequences found in CAP261 at 63 days post-infection. In CAP270, 14 monotypic sequences 
were detected at 56 (n = 8), 147 (n =2), 406 (n =2) and 903 (n =2) days post-infection. A 
single sequence was used to represent several monotypic sequences, resulting in a total of 23 
representative sequences that remained and 78 monotypic sequences that were omitted.  
 
Low diversity sequences were defined as sequences with a less than 0.1% pairwise genetic 
distance between other sequences within each participant data set. A total of 50 low diversity 
sequences were identified in participants CAP177 and CAP217, whereas none were present 
in CAP261 and CAP270. More than half of these sequences were detected in CAP177 at 14 
(n=5), 28 (n=10), 196 (n=3), 378 (n=7) and 1295 (n=3) days post-infection, while in CAP217 
low diversity sequences were present at 14 (n=3), 63 (n=15) and 420 (n=4) days post-
infection. Similar to the way monotypic sequences were handled, a single sequence was used 
to represent multiple low diversity sequences, resulting in a total of 12 representative 
sequences that remained (i.e. in data set 3; Table 2.1) while 38 low diversity sequences were 
omitted. Alignments were then analysed via the pipeline described in Figure 2.1.  
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Figure 2.1 Graphical representation of the analysis pipeline followed for each qualitative data set. Blood plasma and CVL sequence alignments, 
prepared using ClustalX and Se-Al (section 2.4) were analysed through four main streams as illustrated above. Full-length env gp120 sequences 
were analysed for pairwise genetic distances, Poisson distributions, hypermutation, potential N-linked glycosylation, recombination, ML and 
BMCMC phylogenetic structure, substitution rates, time to the Most Recent Common Ancestor, PNLGs accumulation patterns, viral population 
migration and codon-based selection. Three of the four intrapatient alignments were also used for distance-based and tree-based tissue-specific 
viral compartmentalization analyses, while V-loop regions were evaluated for co-receptor tropism and length variation.   
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2.5 Phylogenetic/evaluation/of/viral/compartmentalization/
Phylogenies were constructed using Bayesian methods for longitudinal analysis and 
Maximum Likelihood (ML) methods for cross-sectional analysis. Bayesian methods included 
Markov Chain Monte Carlo (BMCMC) inference as implemented in the BEAST v1.8.0 
(Bayesian Evolutionary Analysis of Sampling Trees, http://code.google.com/p/beast-
mcmc/downloads/list/) software package (Drummond et al., 2002, Drummond & Rambaut, 
2007) and MrBayes v3.2 (http://mrbayes.sourceforge.net/, Huelsenbeck & Ronquist, 2001). 
Bayesian analysis uses what is scientifically known about the data with predefined 
parameters known as ‘priors’ to determine probability assessments of the hypothesis, known 
as the ‘posterior’, through the use of Bayes theorem (Newton & Raftery, 1994; Drummond & 
Rambaut, 2007; Kitchen et al., 2004): 
 
p(θ | Y) = p(Y | θ) × p(θ) ⁄ p(Y) 
 
Bayes theorem states that the posterior distribution (θ) is proportional to the sampling density 
of the data, given θ multiplied by the prior distribution of θ, where the prior distribution 
incorporates any scientific knowledge about θ before observing the data, while the 
denominator p(Y) represents a normalizing factor that ensures the posterior density totals 1 
(Weiss et al., 1997; Suchard et al., 2001; Kitchen et al., 2004).  
 
Unlike the Maximum Likelihood approach that provides a single estimate of the most likely 
tree, the Bayesian MCMC method produces a posterior distribution of trees, from which 
samples are taken using either the Gibbs or Metropolis-Hastings (MH) MCMC sampling 
methods. For this analysis, the MH algorithm was used (as implemented in the BEAST 
v1.8.0 software package), which samples from the distribution of trees by making use of a 
“full joint density function and (independent) proposal distributions” for each variable being 
studied. Although the Gibbs sampling method is more frequently used, one of the limitations 
of this technique is its inefficiency in handling local regions with high densities, where 
“mixing” of the Gibbs sampling chain is very slow (Gelfand et al., 1990; Lynch, 2007; 
Yildirim, 2012). Sampling chains are considered to have limited mixing when successive 
samples are highly correlated, resulting in a very slowly changing value from one sample to 
the next.  
  
 
 
 
 
! 35!
Alternatively, the MH algorithm is designed around two main constraints, (1) “the sampler 
should not tend to visit higher probability areas under the full joint density” and (2) “the 
sampler should explore the space and avoid getting stuck at one site”, (Yildirim, 2012). The 
MH method ensures that there is a sampling balance by satisfying these constraints, which 
guarantees that the resulting stationery distribution of the MH algorithm is actually the target 
posterior distribution of trees that is required for this type of analysis. 
 
For this analysis, all phylogenies were constructed under the best-fit nucleotide substitution 
model as identified by ModelTest. 
 
2.5.1 Nucleotide/substitution/model/selection/
The best-fit nucleotide substitution model was identified using ModelTest v3.7, which uses 
log likelihood scores to determine the most appropriate model of DNA evolution that fits the 
data (Posada & Crandall, 1998). A total of twelve nucleotide substitution models were tested 
using full-length HIV-1 env gp120 intrapatient alignments (data set one; Table 2.1) as input, 
before the GTR+G model was determined as the best-supported model for all participants.  
 
2.5.2 Evolutionary/model/selection/
Model selection is a crucial step in molecular phylogenetics and Bayesian estimation methods 
as it influences estimated substitution rates, phylogenies and posterior probabilities among 
other model parameters (Posada & Buckley, 2004). Model selection however, is simply a 
way of approximating evolutionary relationships, rather than identifying them explicitly, 
choosing an appropriate evolutionary model is essential for confidence in the results obtained 
from phylogenetic analysis (Wang et al., 2001; Posada & Buckley, 2004).  
 
To determine the best evolutionary model for each intrapatient alignment in data set one 
(Table 2.1), four different evolutionary models were investigated in BEAST including non-
parametric (Bayesian skyline plot) and parametric (constant population size) demographic 
models, as well as the strict and uncorrelated lognormal relaxed molecular clock models. The 
Markov chain length was set to 200 million iterations with trees sampled at every 20,000 
steps, producing a posterior distribution of 10,000 trees.  
 
 
 
 
 
! 36!
Resultant log files from BEAST were viewed in Tracer v1.5, where burn-in limits were 
adjusted individually to ensure that effective sample size (ESS) scores of all model 
parameters were above 200, indicating ample mixing of the Markov chain and convergence 
to the stationery distribution. Bayes Factor (BF) testing was then applied to identify the 
evolutionary model with the best statistical support for each alignment (Drummond & 
Rambaut, 2007). The models with the highest log10 BF score (i.e. closest to 100) were 
selected as the best evolutionary models for each of the data sets analysed, and all Bayesian 
phylogenetic analyses were performed on the supercomputing cluster at the South African 
National Bioinformatics Institute (SANBI). 
 
2.5.3 Bayesian/probabilistic/modeling/of/viral/evolution/
For full intrapatient env alignments (data set one; Table 2.1) a posterior distribution of 
phylogenetic trees were inferred using the best fit nucleotide substitution and evolutionary 
models (identified in sections 2.5.1 and 2.5.2) with BEAST v1.8.0 to estimate (1) the 
ancestral relationships, (2) the time to the most recent common ancestor (tMRCA) and (3) 
nucleotide substitution rates for HIV-1 env sequences from the blood plasma and CVL from 
each participant. BEAST input files were created in BEAUti v1.8.0, where the Markov chain 
length was set to 100 million steps and trees were sampled at intervals of 10,000. Resulting 
log files were viewed in Tracer v1.5 to determine burn-in limits and improve overall ESS 
scores as described above. Maximum clade credibility trees were then interpreted from the 
posterior distribution of 10,000 trees after discarding the first 1,000 trees as burn-in, using the 
TreeAnnotator v1.8.0 program. All trees were then further annotated in FigTree v1.4.0 to 
illustrate tissue-specific evolutionary patterns. 
 
2.5.4 Maximum/likelihood/phylogenetic/reconstruction/
Maximum likelihood (ML) phylogenetic structure was estimated using sequences from the 
earliest time point where sequences from both tissue types were available for each 
participant, in a cross-sectional sample design with PhyML (http://www.atgc-
montpellier.fr/phyml/). The GTR+G nucleotide substitution model was used for this analysis 
with nodal support assessed through bootstrapping (i.e. 1,000 replicates). All ML trees were 
then annotated in FigTree v1.4.0 (http://tree.bio.ed.ac.uk/software/figtree/) and remained 
unrooted. 
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2.6 Statistical/evaluation/of/viral/compartmentalization/and/population/
migration/
2.6.1 TreeGbased/compartmentalization/testing/
One of the most common phylogenetic methods used to test the number of state changes 
between compartments is the parsimony approach implemented in the Fitch algorithm that 
calculates the parsimony score (PS) and association index (AI) statistics (Slatkin & 
Maddison, 1989; Fitch, 1971; Parker et al., 2008). The Slatkin-Maddison (S-M) test for 
compartmentalization was used to evaluate viral segregation between blood plasma and 
cervical tissues using a Bayesian Markov chain Monte Carlo approach as implemented in the 
Bayesian Tip-association Significance testing software tool BaTS v2 (Esbjörnsson et al., 
2011; Gantt et al., 2010; Parker et al., 2008; Huelsenbeck & Ronquist, 2001). This method 
has been previously used to detect intra-host compartmentalization of HIV between various 
tissue types (McGrath et al., 2001, Kemal et al., 2003, Gantt et al., 2010). 
 
BaTS takes as input either a single ML tree or a posterior sample of trees and calculates three 
metrics of phylogeny-trait correlations; (1) the parsimony score of Slatkin and Maddison 
(1989) (PS) which represents the number of times that a trait under investigation is gained or 
lost (Fitch 1971), (2) the Simmonds association index (AI) which assesses the degree of 
population structure within a phylogenetic tree (Slatkin & Maddison, 1989; Wang et al., 
2001; Zárate et al., 2007), and (3) the monophyletic clade (MC) statistic (Salemi et al., 2005) 
which quantifies the maximum clade size on the MCC tree comprised of samples that share a 
single trait such as tissue type. Associated p-values for these three statistics are determined by 
permuting sequences between tissue compartments (Parker et al., 2008). Since the trait of 
interest (host-tissue type) can be considered a “location” within the participant, a tight 
phylogeny-trait correlation (low AI and PS values and a high MC value) suggests low lineage 
dispersal between the cervix and blood plasma (Parker et al., 2008), indicative of viral 
compartmentalization.  
/
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For this analysis, Bayesian MCMC trees were generated with MrBayes v3.2.1 (Huelsenbeck 
& Ronquist, 2001) using the GTR+G substitution model for all participants (data set one; 
Table 2.1) where the Markov chain length was set to one million steps and trees were 
sampled at intervals of 1,000. A 50% burn-in limit was then applied to the posterior sample 
of trees to exclude phylogenies with high p-values from the distribution. A posterior sample 
of 5,000 trees was then analysed with BaTS using 1,000 null distributions to test the 
significance of the observed phylogeny-trait correlations between viral populations in the 
blood plasma and cervix in each participant. Observed phylogeny-trait correlations were 
compared to those found in 1,000 randomly generated trees in which the sequences had been 
randomly arranged and considered significant when less than 1% of the randomized trees 
required the same or a fewer number of migration events as for the sample data.  
 
2.6.2 DistanceGbased/compartmentalization/testing/
While tree-based methods are dependent on the structure of a phylogenetic tree, which can be 
confirmed by subjectively examining the trees, distance-based tests are good indicators of 
genetic similarity between tissue-specific samples that are independent of the evolutionary 
path (Heath et al., 2009). Although there have been multiple studies that simply examined 
clustering of tissue-specific clades on phylogenetic trees to classify compartmentalization 
patterns, this feature is sometimes not obvious and it is vital to confirm results from tree-
based methods with mathematical distance-based methods (Zárate et al., 2007; Heath et al., 
2009). To do this, Hudson’s Nearest Neighbor (Snn) and Wright’s measure of population 
subdivision (FST) statistics were used (Hudson, 2000; Wright, 1943; Slatkin, 1993; Zárate et 
al., 2007; Heath et al., 2009; Edo-Matas et al., 2010).  
 
The Snn statistic was used to compare genetic distances within and between sequences from 
different tissue types independent of phylogenetic inferences (Bull et al., 2009) by measuring 
“how often the nearest neighbor (in sequence space) sequences are from the same locality in 
geographic space”, (Heath et al., 2009), where geographic space refers to the sampled tissue 
type and locality is a particular region within the env gene. Whereas, the FST statistic 
compares the mean pairwise genetic distance between sequences from different tissue types 
to mean distances between sequences from the same tissue type (Zárate et al., 2007; Edo-
Matas et al., 2010).  
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Both Snn an FST tests for viral compartmentalization were performed longitudinally and by 
time point with data sets that included or excluded monotypic and low diversity sequences 
(data sets one, two and three; Table 2.1). Alignments were analysed using the HyPhy v2.2 
software package (Pond et al., 2005) and tested with 1,000 permutations, to determine if 
significant evidence of compartmentalized structure existed for viruses sampled from the two 
tissue types investigated (Bull et al., 2009; Pond et al., 2005).  
 
2.6.3 Structured/coalescentGbased/migration/estimation/
The coalescence-based program Migrate-n v3.3.0 (http://popgen.sc.fsu.edu/Migrate/Migrate-
n.html) was used to estimate the amount of gene flow between viral populations in the cervix 
and blood plasma (Beerli & Felsenstein, 1999). Migrate-n uses Bayes Factors to compute the 
marginal likelihoods of two hypotheses (i.e. state 1 and state 2) and addresses complex 
questions such as whether explicit migration between different populations exists (Beerli & 
Palczewski, 2010). In this study a full model with two population sizes and two migration 
rates (i.e. in and out of the blood plasma (state 1) and cervical tissue (state 2) was used. 
Migrate-n input files were created for each participant from full-length gp120 sequences (data 
set one; Table 2.1) using a Python script before being tested for significance with 1,000 null 
replicates.!
!
2.7 Calculating/average/pairwise/genetic/distances/
The degree of sequence variation between different gene loci can help to determine what 
types of evolutionary mechanisms and mutational factors affect specific genomic regions 
(Castresana, 2002). Average pairwise genetic distances were calculated using the p-
uncorrected model in MEGA v5.2.2 (http://www.megasoftware.net/). MEGA estimates 
pairwise genetic distances by calculating the proportion of nucleotide differences between 
pairs of sequences (Tamura et al., 2013). Changes in tissue-specific genetic diversity in each 
participant over time were then visualized using boxplots.  
 
! /
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2.8 Poisson/distribution/fitting/
Although most HIV transmission events involve a single viral variant, up to 50% of 
transmissions are estimated to represent multiple variant infections (Gottlieb et al., 2008; 
Keele et al., 2008; Ritola et al., 2004). The clinical implications of multiple variant infections 
are important to the rate of disease progression, as more diverse viral populations have 
previously been associated with rapid disease progression (Gottlieb et al., 2004; Grobler et 
al., 2004; Sagar et al., 2003; Abrahams et al., 2009). To test whether each of the participants 
analysed here were likely infected by more than one HIV variant, the approach described by 
Keele et al. (2008) and Abrahams et al. (2009) was used, in which multiple variant infections 
did not follow a Poisson distribution, suggesting that infection with multiple variants does not 
usually occur through independent events, but rather to high transmission rates (Abrahams et 
al., 2009).  
 
When formulating a hypothesis about the specific distribution of a variable of interest (in this 
case the number of transmitted variants), variables whose values are determined by an infinite 
number of independent random events are said to follow a normal distribution, for example 
the height of a person is the result of many independent factors such as genetic 
predisposition, nutrition, diseases, etc. therefore height tends to be normally distributed 
within population groups (StatSoft, 2013). Alternatively, if a variable’s values are the result 
of rare events, then the variable will be distributed according to the Poisson distribution, for 
example an accident that is the result of a series of unlikely events (StatSoft, 2013). As a 
result the Poisson distribution is sometimes referred to as the distribution of rare events and is 
defined as follows: 
f(x)'='(?x*e,?)/x!,'for'x'='0,1,2,...,'0'<'?!
where ? = (lambda) is the expected value of x (the mean), and e is the base of the natural 
algorithm sometimes referred to as “Euler’s e” (StatSoft, 2013). 
  
 
 
 
 
! 41!
For this analysis, to determine the pattern of modality, where a bimodal distribution (i.e. the 
presence of two or more peaks in the Poisson distribution) was hypothesized to be an 
indication of HIV infection by more than one viral variant, and a unimodal distribution (i.e. 
the presence of a single peak in the Poisson distribution) was hypothesized to indicate 
infection by a single HIV variant, the Poisson Fitter tool (http://www.hiv.lanl.gov/) was used 
to estimate distribution patterns as implemented in the Los Alamos HIV Sequence Database 
(Rose & Korber, 2000; Dixit & Perelson, 2004), which analyses the frequency of Hamming 
distances by calculating the best fitting distribution using the Goodness of Fit test (GOF) and 
maximum likelihood method (Novitsky et al., 2011). Mean substitution rates obtained from 
BEAST analysis (in section 2.5.3) were used as input values per participant and Poisson 
distributions were visualized as a line charts with Hamming distances plotted as histograms.   
 
2.9 Potential/NGlinked/glycosylation/site/prediction/
The number and distribution of PNLGs were determined using an in-house Python v2.7.2 
script (Appendix I) that combined the algorithm implemented in the HIV LANL N-glycosite 
tool (http://www.hiv.lanl.gov/) along with additional criteria from the literature describing the 
identification of N-linked glycosylation sequons. While the N-glycosite tool searches for 
sequons satisfying the tri-peptide consensus of NX(S/T), where N is asparagine, S is serine, T 
is threonine and X is any amino acid except proline, the Python script used in this study 
searched for sequons conforming to the NX(S/T)Y consensus, where X & Y respresent any 
amino acid except proline, and where in the NX(S) context, X could not be tryptophan (W), 
aspartic acid (D), glutamic acid (E) or leucine (L) (Zhang et al., 2004; Kasturi et al., 1997; 
Rao & Bernd, 2010). These additional criteria were specified to ensure the exclusion of 
sequons that have previously been reported to be poorly glycosylated in vitro (Rao & Bernd, 
2010).  
 
HXB2 was used as the reference sequence for this analysis, since PNLGs have already been 
biochemically defined for this HIV subtype (Zhang et al., 2004). Once PNLG sites were 
predicted, the total number and distribution of PNLGs across the full-length gp120 and V-
loop regions were statistically compared between tissue types at all sampling points over the 
course of infection in each participant.  
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Non-parametric Mann-Whitney and Wilcoxin signed-rank tests were used to assess whether 
the number of PNLGs in env subregions displayed significant differences between the tissue 
types investigated, and were considered significant if p-values were less than or equal to 0.05. 
 
2.9.1 Clustering/of/potential/NGlinked/glycosylation/sites/
To determine if PNLGs accumulated consistenly or emerged at specific time points or 
infection stages, in both or a single tissue type throughout the course of infection, Bayesian 
MCC trees (produced in section 2.5.3), were used to illustrate the presence of selected 
glycosylation sites that demonstrated an increasing occurrence in blood plasma or CVL 
viruses in each participant. Annotation files containing binary data indicating the presence or 
absence of a specific PNLG site were first created using Python before being used as an 
annotation file in the Interactive Tree of Life (iTol) v2 tool (Letunic & Bork, 2011). Trees 
were then examined visually before selected trees were reannotated in Figtree v1.4.0 to 
illustrate closely related sequences that shared specific PNLGs, some of which are known to 
have an impact on neutralizing antibody response. This information was then linked to 
predicted recombination events to determine whether recombination played a role in the 
accumulation of PNLGs and/or if PNLGs emerging later in the course of infection explicitly 
coincided with predicted recombination events or recombinant regions within blood plasma 
or CVL sequences.  
 
2.10 Recombination/detection/
Detection of potential recombinant sequences, identification of likely parental sequences and 
localization of possible recombination breakpoints within full-length gp120 sequences (data 
set one; Table 2.1) was achieved using the RDP, Geneconv, Bootscan, Maximum Chi Square, 
Chimaera, Sister Scan and 3Seq recombination detection methods as implemented in RDP4 
(http://darwin.uvigo.es/rdp/rdp.html) (Martin et al., 2010).  
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The RDP method scans through multiple sequence alignments searching for evidence of 
recombination based on three fundamental sets of criteria (Martin et al., 2010; Varsani et al., 
2006): 
• All non-informative sites are discarded, e.g sites that are identical between any three 
sequences, different in all three sequences, or unique to the three sequences that is 
also not present in the reference sequence or any other sequences in the alignment. 
• Informative sites are analysed by a sliding window that scans through one nucleotide 
at a time and then calculates an average percentage identity between paired sequences 
in a set of three sequences, for example where sequence A is compared to sequence B, 
sequence B compared to sequence C, and sequence C compared to sequence A. 
Regions are considered potentially recombinant if the average percentage identity 
between sequence A and B or B and C is higher than that of C and A. 
• Using the binomial distribution, the probability that nucleotide identities might have 
occurred by chance is also assessed and a p-value is calculated from this probability 
by multiplying it with the total number of unique windows examined. The p-value is 
then Bonferroni-corrected by multiplying it with the total number of nucleotide 
triplets (codons) examined in the alignment. 
For this analysis, the default parameter settings were used for all detection methods except 
RDP, where a window size of 15 nucleotides was set and only events detected by three or 
more methods were considered as credible evidence of recombination. The breakpoint 
positions and recombinant sequence(s) inferred for every potential recombination event was 
then manually checked and adjusted where necessary using the extensive phylogenetic and 
recombination signal analysis features available in RDP4. 
 
All full-length gp120 intrapatient sequences were analysed for patterns based on the 
distribution of recombination breakpoints across tissue types and sampled timepoints. 
Recombinants were considered unique if only a single sequence showed evidence of a 
breakpoint, and enriched if more than one sequence contained the same breakpoint.  
 
! /
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2.11 CodonGbased/selection/analysis/
One of the fundamental processes driving the rapid evolution of HIV is natural selection, 
which plays a pivotal role in viral diversity, differentiation and adaptation (Poon et al., 2009). 
Most recent codon-based techniques that infer selection are based on a probabilistic approach 
that check whether the “nonsynonymous substitution rate at a specific site is faster or slower 
than the neutral rate, which is typically set to the synonymous rate at the same site (or to the 
mean synonymous rate for the entire alignment)”, (Murell et al., 2013; Pond & Frost, 2005). 
To determine if there were any specific codons that were under positive or negative selection 
in blood plasma or CVL-derived viruses during disease progression, the Fast Unconstrained 
Bayesian AppRoximation (FUBAR), Single Likelihood Ancestor Counting (SLAC), Mixed 
Effects Model of Evolution (MEME) and Fixed Effect Likelihood (FEL) methods were used to 
analyse full-length gp120 intrapatient alignments (data set one; Table 2.1) as implemented on 
the Datamonkey web server (Pond & Frost, 2005; Murrell et al., 2013). Intrapatient 
alignments were first run through the Genetic Algorithm for Recombination Detection 
(GARD) tool to infer recombination breakpoints using the HKY85 model, with all other 
parameters kept at their default settings. FUBAR, FEL and MEME analyses were conducted 
using GARD inferred trees and the HKY85 model, where default probability cut offs were set 
for all analyses. Based on recommendations from other authors, only sites that were 
identified by at least three methods with a p-value less than or equal to 0.05 were considered 
as credible evidence for positive or negative selection (Wlasiuk & Nachman, 2010; de Matos 
et al., 2013; Castel et al., 2014). 
 
2.12 Genotypic/HIVG1/coGreceptor/tropism/prediction/
The entry of viruses into human host cells is dependent on specific protein interactions that 
occur during the binding of the HIV-1 gp120 protein to the CD4 cellular receptor and co-
receptor proteins. The type of co-receptor protein that is used by the virus, usually the CCR5 
or CXCR4 chemokine receptors, has a “prognostic value”, which has been previously 
associated with disease progression (Dybowski et al., 2010). Patients with viruses that use the 
CXCR4 co-receptor protein have been linked to faster disease progression and accelerated 
CD4 cell decline, compared to those with CCR5-tropic viruses (Paraschiv et al., 2014; 
Shepherd et al., 2008). Co-receptor usage has also been reported to shift from CCR5 co-
receptor usage in the early stages of infection, to CXCR4 usage during the later stages of 
infection (Esbjörnsson et al., 2010).  
 
 
 
 
! 45!
The identification of phenotypically distinct viruses is therefore crucial in our understanding 
of HIV pathogenesis and treatment options, and as a result the identification of co-receptor 
tropism through predictive sequence-based algorithms has improved dramatically in recent 
years (Schuitemaker et al., 2011; Dybowski et al., 2010).  
 
For this analysis, co-receptor tropism was predicted from the translated HIV-1 env V3-loop 
sequences of all blood plasma and CVL viruses using three different tools (Table 2.2). Input 
files complying with the formatting requirements for Geno2pheno and Wetcat were produced 
using Python v2.7.2 (http://python.org/).  
 
Table 2.2 Summary of the tools and methods used in the analysis of co-receptor tropism 
prediction. Three alternative tools were used for result comparison, each comprising machine 
learning and rule-based methods. 
Tool' URL' Method/s'
Geno2pheno'(Sing'et#al.,'2007)' http://coreceptor.bioinf.mpi;
inf.mpg.de/index.php!!
FPR!5%!
FPR!10%!
WebPSSM'(Jensen#et#al.,'2003)' http://indra.mullins.microbiol.washington.ed
u/webpssm/!!
PSSM!
Wetcat'(Pillai'et#al.,'2003)' http://genomiac2.ucsd.edu:8080/wetcat/v3.h
tml!!
SVM!!
ChargeRule!
 
Geno2Pheno has been reported by several studies to have a high sensitivity compared to other 
prediction methods as it is capable of predicting co-receptor tropism in all HIV-1 genotypes 
and includes adjustable cut-offs (Simon et al., 2010; Crous et al., 2012). However different 
prediction tools have demonstrated varying strengths and weaknesses in identifying R5 and 
X4 viruses. In a review of genotypic prediction methods by Cheuca et al. (2009), the SVM 
(Support Vector Machine) method showed a high sensitivity to detecting CXCR4 viruses 
while its specificity was fairly low whereas the PSSM method displayed a higher specificity 
than sensitivity in detecting CCR5 viruses. For this analysis, the original “g2p” co-receptor 
tool was used combined with two different false positive rates (Table 2.2). FPR (false 
positive rate) scores below 10% (i.e. for an analysis with a FPR cutoff of 10%) indicated 
CXCR4 co-receptor usage, and FPR scores above 10% indicated CCR5 co-receptor usage.  
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Alternatively, WebPSSM predicts HIV-1 co-receptor usage by using one of two available 
position-specific scoring matrices (PSSM) that searches for particular motifs on the V3-loop 
sequence. The selected PSSM uses a null model that serves as a baseline model and consists 
of sequences with known properties which WebPSSM uses to compare to query sequences 
(Jensen et al., 2003). The comparison generates a score that indicates the likelihood of the 
query sequence possessing the known property. WebPSSM classifies viruses associated with 
CXCR4 usage in a matrix containing V3-loop sequences for synctium-inducing viruses (SI), 
and for CCR5 usage in a matrix containing V3-loop sequences for nonsynctium-inducing 
viruses with higher scores, implying closer relation to known CXCR4 or CCR5-trophic 
viruses (Jensen et al., 2003).  
 
Because of the difficulty of finding appropriate cut-off values for co-receptor prediction, a 
quantitative phenotypic prediction by Support Vector Machines (SVM) in Wetcat was also 
used. This machine learning technique is used for regression problems with many free 
variables (in this case, sequence positions) and a target variable (resistance factor) subject to 
considerable noise (Fouchier et al., 1992). Lastly, the ChargeRule method is based on 
statistical analysis of the V3-loop and its phenotypic characteristics, and suggests that the 
presence of a positively charged residue at position 11 and/or 25 base position confers the 
ability to bind with CXCR4, however if these conditions are not met, CCR5 co-receptor 
usage is inferred (Fouchier et al., 1992).  
 
2.13 APOBECGinduced/hypermutation/detection//
All blood plasma and CVL sequences were analysed for evidence of APOBEC-induced 
hypermutation using a combination of both the original and Hypermut v2.0 software tool 
(http://www.hiv.lanl.gov/) as implemented in the Los Alamos HIV Sequence Database (Rose 
& Korber, 2000). Hypermut identifies G to A mutations among the many regularly occurring 
mutations in both a dinucleotide and codon context by comparing every sequence in the 
alignment to the first sequence while searching for changes between neighbouring locations 
(Rose & Korber, 2000; Janini, 2001). For this analysis, a consensus sequence was first 
generated for each intrapatient alignment and saved in FASTA format. The conservative 
default settings were then used to analyse each intrapatient alignment (data set one; Table 
2.1). Results were then exported in tab-delimited format for downstream analysis.  
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2.14 Length/variation/within/the/env/VGloop/regions/
Although interactions between the HIV env gene and host cells are complex and have not yet 
been comprehensively described, it is well documented that this gene changes considerably 
over the course of infection in a single individual (Curlin et al., 2010). Insertions and 
deletions (indels) that are subject to positive or negative selection occur regularly throughout 
the env gene and particularly within the variable loop regions, which subsequently affects V-
loop length variation (Sagar et al., 2006; Dosenovic et al., 2009; Curlin et al., 2010). Since 
variable regions have been reported to influence co-receptor affinity, cellular tropism and 
sensitivity to neutralizing antibodies, changes within these regions are potentially important 
markers in increasing our understanding of selective pressures and their role in viral 
evolution (Brown et al., 2011; Curlin et al., 2010).  
 
To determine if there were any tissue-specific changes within the env V-loop regions 
longitudinally, intrapatient sequence alignments were divided into subregions V1 – V5 using 
Se-Al v2.0a11 (data set four; Table 2.1) based on UniProt guidelines for the env glycoprotein 
gp160 region (http://www.uniprot.org/uniprot/P04578) as described in Table 2.3.  
 
Table 2.3 Nucleotide and amino acid base position ranges (relative to HXB2) outlining the 
V-loop regions that were analysed for length variation in blood plasma and CVL sequences 
along the course of infection.   
HIV,1'env'V,loop'region' Position'relative'to'HXB2'
' Nucleotide!(bp)! Amino!acid!(bp)!
V1' 391!–!468! 131!–!156!
V2' 469!–!588! 157!–!196!
V3' 886!–!990! 296!–!330!
V4' 1153!–!1254! 385!–!418!
V5' 1381!–!1413! 461!–!471!
!
All V-loop sequences were translated from nucleotide to protein bases before the lengths 
were calculated using a Python v2.7.2 script that counted the number of amino acid bases in 
each V-loop region per sequence from all participants, while excluding gap regions 
(Appendix II). V-loop lengths were then statistically tested (section 2.15) to determine if 
there were any significant region or tissue-specific differences between V-loop lengths in 
blood plasma and CVL viruses over the sampling periods.   
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2.15 Significance/testing/
Non-parametric tests are prescribed when sample sizes of below 100 are available per 
variable and when nothing about the parameters of interest is known in the population 
(StatSoft, 2013). Based on methods described in other compartmentalization studies, 
genotypic and phenotypic differences between viral populations were statistically assessed 
using the Mann–Whitney U test, which compares medians between two unpaired groups of 
data and assumes that each population follows the same distribution shape (Evering et al., 
2014; Ramirez et al., 2009; Pillai et al., 2006; Ottander et al., 1997; Motulsky, 2003). 
Intrapatient tissue-specific differences were also assessed using the Wilcoxon signed-rank 
test, which is used to compare differences between two paired groups, assuming all samples 
are independent of each other and differences are equally distributed around the median per 
group (Motulsky, 2003; Pillai et al., 2006). Since samples were obtained from the blood 
plasma and cervix independently of each other, associations between V-loop length variation, 
pairwise genetic distances, and potential N-linked glycosylation sites were assessed using 
both of these tests as implemented in the Graphpad Prism v6 software package (Parker et al., 
2008). 
Correlation calculations were also performed using Spearman’s rank order correlation and the 
Fisher’s Exact test to evaluate tissue-specific differences in phenotypic traits. However, 
“while it is customary to adjust p-values for multiple comparisons when making positive 
claims, the uncorrected p-values reported here are conservative with respect to the negative 
conclusions derived in this study” (Heath et al., 2009), i.e. that compartmentalization does 
not exist over long-term HIV infection.!  
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Chapter(3!
Results!
 
3.1 Study/population/and/clinical/indicators/
HIV-1 samples were obtained from the cervix and blood plasma of four female participants 
sampled anonymously as part of the CAPRISA cohort in Durban, Kwa-Zulu Natal (Table 
3.1). All participants involved in this study were heterosexually infected with HIV-1 subtype 
C and remained treatment naïve throughout the sampling period.  
 
Table 3.1 Overview of participant sequences and time points sampled longitudinally during 
acute and chronic infection stages. A total of 459 individual HIV-1 env sequences were 
amplified, 206 generated from cervical and 253 from blood plasma-derived samples between 
14 and 1316 days post-infection. Time points where it was not possible to amplify viruses are 
indicated with a “–” symbol.  
Participant'ID' Age'(t0)' Fiebig'stages' Days'p.i.' Number'of'sequences' Total'unique'sequences'
' ' ' ' Blood'plasma' CVL' '
CAP177' 37! I/II;!III! 14! 18! –! 5!
' ! ! 28! 12! 18! 13!
' ! ! 196! 11! –! 11!
' ! ! 378! 11! 19! 27!
' ! ! 560! 8! 5! 9!
' ! ! 924! 4! 1! 3!
' ! ! 1295! 18! 19! 27!
CAP217' 20! IV;!VI! 14! 18! –! 17!
' ! ! 63! 20! 20! 29!
' ! ! 420! 6! 5! 11!
' ! ! 770! 6! 5! 8!
' ! ! 1316! 19! 19! 35!
CAP261' 18! VI! 63! 19! 19! 32!
' ! ! 413! 11! 12! 23!
' ! ! 945! 10! 10! 20!
CAP270' 24! V! 56! 11! 14! 11!
' ! ! 105! –! 1! 1!
' ! ! 147! 8! 8! 14!
' ! ! 231! 14! 3! 17!
' ! ! 406! 12! 11! 21!
' ! ! 595! 7! 5! 12!
' ! ! 903! 10! 12! 20!
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Although there were time points at which the env gene could not be amplified and sequenced 
from samples, viral load, CD4 cell counts and STI information was still available for these 
time points. Further analysis conducted by collaborators at the NICD later confirmed that 
three of the four female participants studied here were defined as intermediate progressors 
while the fourth participant, CAP270, was classified as a rapid progressor and subsequently 
placed on antiretrovirals after 903 days post-infection.  
 
To avoid repetition, please note that all references to sampled time points in this chapter refer 
to the time in days post-infection.  
'
'
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Figure 3.1 Line charts indicating changes in viral load and CD4 cell counts during the sampling period in each participant. Viral load counts are 
shown on the primary y-axis (red) with CD4 cell counts on the secondary y-axis (black) set at a major limit of 700 cells/µl) in all participants. 
Breaks in line charts for CAP177 and CAP261 indicate time points where CD4 cell count data was not available, at 252 and 126 days 
respectively.!
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In all participants except CAP261, there was a noticeable decline in CD4 cells as the infection 
progressed. At the baseline, viral loads were considerably higher in CAP217 (3,260,000 
copies/mL), CAP261 (821,000 copies/mL) and CAP177 (359,000 copies/mL) compared to 
CAP270 (76,800 copies/mL), however as the infection progressed viral loads increased 
substantially (by 98%) to 3,710,000 copies/mL in CAP270 at 595 days, coinciding with the 
lowest recorded CD4 cell count (161 cells/µl) in this participant over the entire sampling 
period. Generally, although viral loads and CD4 cell counts appeared to fluctuate in all 
participants during the course of infection, viral loads remained relatively constant in 
CAP177, CAP217 and CAP261.  
 
Disease progression was more pronounced in CAP270 than any of the other participants, as 
evidenced by the rapid rise in viral loads and decline of CD4 cells, eventually leading to this 
participant being defined as a rapid progressor, however it is unclear what occurred between 
595 and 903 days that could have led to the decline in viral loads seen at 903 days, as there 
were no sequences available between these time points, i.e. the least number of sampled time 
points were available for CAP270 (n=19), compared to CAP177 (n=36), CAP217 (n=37) and 
CAP261 (n=36). Overall CAP261 demonstrated the greatest control of HIV infection in terms 
of CD4 cell count and viral load stability compared to all other participants, having started 
with a CD4 cell count of 311 cells/µl at 63 days that gradually rose to 578 cells/µl at the final 
sampling time point (2513 days), whereas CD4 cell counts continued to decline in all other 
participants.  
!
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Figure 3.2 Stacked column charts illustrating all sexually transmitted infections that each participant tested positive for during the course of 
infection, where different colours represent different STIs. Participants were tested for the presence of HSV type 2 (using two different methods), 
Syphilis, B. vaginosis, T. vaginalis, N. gonorrhoea, C. trachomatis and M. genitalium. Time points at which participants tested negative for all 
STIs are indicated by a space on the graph.  
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Participant CAP177 tested positive for STIs at all but two of the time points sampled, with a 
consistent HSV type 2 and B. Vaginosis infection present at all time points except 1113 days 
(Figure 3.2). T. Vaginalis and M. Genitalium infections appeared at 378 and 749 days, along 
with the HSV and Vaginosis, establishing both viral and bacterial infections in CAP177 
during almost the entire course of HIV infection.  
 
CAP217 tested positive for STIs at all time points, except 189 days (Figure 3.2). Similar to 
CAP177, HSV type 2 infection persisted in CAP217, accompanied by the presence of M. 
genitalium during six out of the nine time points sampled. In addition to this, B. vaginosis was 
detected at four time points, three of which were during consecutive visits (i.e. 420, 609, 784 
days). An isolated case of C. trachomatis was also found at 966 days, demonstrating 
simultaneous bacterial and viral infections in this participant too.!!
!
CAP261 tested positive for STIs at all time points, with a consistent B. vaginosis and HSV 
type 2 infection present at all time points except 1239 days (Figure 3.2). Rare cases of M. 
genitalium and C. trachomatis infections were also detected at 413 and 1239 days 
respectively, and a Syphilis infection arising around 413 days that remained present until 959 
days, after which another new infection (T. vaginalis) was found in CAP261.! 
!
Alternatively, CAP270 tested positive for only two of the eight STI’s that were screened for, 
i.e. HSV type 2 and B. vaginosis (Figure 3.2). No STI’s were found at 105 and 147 days, 
whereas dual infections were observed at 56, 231 and 406 days. CAP270 thereafter remained 
infected with HSV type 2 at 595 and 903 days, while B. vaginosis was no longer detectable.  
!
 
 
 
 
! 55!
3.2 Phylogenetic/evaluation/of/viral/compartmentalization/
3.2.1 Nucleotide/substitution/model/selection/
For all four HIV-1 subtype C env datasets the general time reversible nucleotide substitution) 
model with gamma distributed rate variation 4 (GTR + G4) was identified as the best-fit 
nucleotide substitution model using ModelTest (Posada & Crandall, 1998). 
!
3.2.2 Evolutionary/model/selection/
Bayes factor tests (Kass & Rafterty, 1995), based on the ratio of the marginal likelihoods of 
the alternative models provided by BEAST, revealed that an uncorrelated lognormal relaxed-
clock, constant population size model provided the best fit to the data for three of the four 
alignments tested. For sequences obtained from participant CAP217, a lognormal relaxed-
clock Bayesian skyline plot model was identified as the best fit. 
 
3.2.3 Bayesian/phylogenetic/reconstruction/
To determine if the female genital tract represented a distinct compartment during acute and 
chronic HIV infection, env sequences from all sampled time points were analysed per 
participant. It was hypothesized that if the female genital tract did serve as a distinct viral 
compartment, CVL-derived sequences should have clustered together as monophyletic clades 
on trees with high statistical support, independent from blood plasma sequences at multiple 
time points over the course of infection.  
 
On time-scaled maximum clade credibility (MCC) trees, viral sequences generally clustered 
together by sampling time point and displayed substantial divergence between time points 
(Figures 3.3a-d). A few exceptions to this pattern were seen in CAP177, CAP217 and 
CAP270. In participant CAP177 blood plasma sequences from time points at 196 and 560 
days clustered together with >70% posterior support. In participant CAP217 genital tract 
sequences from successive sampling points at 770 and 1316 days clustered together on the 
tree with >90% posterior support while for participant CAP270 blood plasma sequences 
sampled at 147 and 231 days clustered together on MCC trees with <70% posterior support.  
 
In participant CAP177, strong evidence of a second highly divergent low frequency HIV 
variant (96-cvl-28days) was found in the CVL at 28 days.  
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This sequence was distinctly separated from all other blood plasma and CVL sequences 
obtained from this participant during the early stages of infection by an extremely long 
branch length, more clearly illustrated on the cross-sectional tree for this time point 
(Appendix III, Figure 3.4a). Furthermore it was clear that a closely related variant of 96-cvl-
28days established a systemic infection that yielded at least two main genetically distinct 
lineages (>90% posterior probability) with closely related variants in both the blood plasma 
and CVL that persisted until at least 560 days (Figure 3.3a). While the other main lineage 
persisted and continued to diversify up until the final sampling point at 1295 days, the 
descendant members of the lineage founded by the putative ancestor of 96-cvl-28days was no 
longer detectable in either tissue type. It was also apparent that by 28 days, the main lineage 
that persisted until 1295 days also initially comprised of more than one viral variant (Figure 
3.3a).  
 
Similar patterns were observed in participant CAP261, where at 63 days (the earliest 
sampling point in this participant) the presence of at least two distinct HIV variants forming 
separate well-supported clades was clearly evident (Appendix III, Figure 3.4b) and 
descendants from only one of the highly divergent founding lineages persisted through to the 
final sampling point at 945 days (Figure 3.3b). Phylogenetic analyses for CAP217 and 
CAP270 revealed an interspersion of blood plasma and CVL sequences on both trees 
(Figures 3.3c and 3.3d) and sequences generally clustered together by time point instead of 
tissue type in a ladder-like topology, indicative of infection by a single HIV variant 
(Appendix III, Figures 3.4c and 3.4d) (Novitsky et al., 2011).  
 
In all participants, monophyletic clades generally contained few sequences and were mainly 
interspersed among sequences from both tissue-types, similar to patterns observed by Bull et 
al. (2013). MCC tree topologies differed substantially between inferred single and multiple 
HIV variant infected participants. For participants CAP217 and CAP270, sequences yielded 
trees with classic ladder-like topologies and poorly supported short interior branches, 
characteristic of patterns generated by a single variant transmission event and subsequent 
diversification (Keele et al., 2008). In contrast, MCC trees generated from CAP177 and 
CAP261 sequences displayed long, well supported internal branches sprouting from the basal 
nodes, a pattern characteristic of an initial transmission event involving more than one viral 
variant (Keele et al., 2008; Novitsky et al., 2011). 
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Figure 3.3a Time-scaled Bayesian maximum clade credibility tree for CAP177, constructed 
under the GTR + G4 substitution model and a constant population size relaxed-clock 
evolutionary model. Branches are coloured according to the most probable state of their 
tissue origin where red represents viruses from the blood plasma and black indicates viruses 
from the cervix. Posterior probabilities > 90% are indicated by a filled circled and > 70% by 
an open circle at the nodes, with branch labels coloured according to the time points sampled.   
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132-cvl-28days
6-blood-1295days
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Figure 3.3b Time-scaled Bayesian maximum clade credibility tree for CAP261, constructed 
under the GTR + G4 substitution model and a constant population size relaxed-clock 
evolutionary model. Branches are coloured according to the most probable state of their 
tissue origin where red represents viruses from the blood plasma and black indicates viruses 
from the cervix. Posterior probabilities > 90% are indicated by a filled circled and > 70% by 
an open circle at the nodes, with branch labels coloured according to the time points sampled. ! !
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Figure 3.3c Time-scaled Bayesian maximum clade credibility tree for CAP217, constructed 
under the GTR + G4 substitution model and a Bayesian skyline plot relaxed-clock 
evolutionary model. Branches are coloured according to the most probable state of their 
tissue origin where red represents viruses from the blood plasma and black indicates viruses 
from the cervix. Posterior probabilities > 90% are indicated by a filled circled and > 70% by 
an open circle at the nodes, with branch labels coloured according to the time points sampled. 
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Figure 3.3d Time-scaled Bayesian maximum clade credibility tree for CAP270, constructed 
under the GTR + G4 substitution model and a constant population size relaxed-clock 
evolutionary model. Branches are coloured according to the most probable state of their 
tissue origin where red represents viruses from the blood plasma and black indicates viruses 
from the cervix. Posterior probabilities > 90% are indicated by a filled circled and > 70% by 
an open circle at the nodes, with branch labels coloured according to the time points sampled. 
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The highest mean nucleotide substitution rates were estimated in participants CAP177 (3.09 x 
10-2 substitutions per site per year; 95% HPDs = 2.44 x 10-2 – 3.77 x 10-2) and CAP270 (2.20 x 
10-2 substitutions per site per year; 95% HPDs = 1.77 x 10-2 – 2.67 x 10-2), while the lowest 
substitution rates were estimated in CAP217 (9.58 x 10-3 substitutions per site per year; 95% 
HPDs = 7.95 x 10-3 – 1.13 x 10-2) and CAP261 (1.09 x 10-2 substitutions per site per year; 95% 
HPDs = 7.26 x 10-3 – 1.46 x 10-2). All rates were within the range of previously reported rates 
of intrahost HIV evolution (Novitsky et al., 2013; Carvajal-Rodríguez et al., 2008; Aulicino 
et al., 2011; Lemey et al., 2007; Lukashov & Goudsmit, 1997). Overall, considering env 
sequence datasets derived from all four participants collectively, approximately 74 tissue-
specific clades were identified longitudinally, comprised of highly similar sequences with 
mean pairwise genetic diversities ranging between 0% in CAP217 and 2.30% in CAP177 on 
MCC trees. 
 
3.2.4 Estimation/of/the/time/to/the/Most/Recent/Common/Ancestor//
Estimates of the mean time to the most recent common ancestor (tMRCA) for participants 
CAP217 (mean = 1311 days; 95% HPDs = 1303–1324 days) and CAP270 (mean = 914 days; 
95% HPDs = 878–964 days) accurately reflected the known time of infection as estimated 
using laboratory staging (Table 3.2), however for CAP177 (mean = 1977 days; 95% HPDs = 
1590–2454 days) and CAP261 (mean = 2029 days; 95% HPDs = 1482–2687 days) the mean 
tMRCA’s predated the known time of infection by 53% and 115% respectively, a pattern 
which is characteristic of an infection founded by more than one HIV-1 variant (Novitsky et 
al., 2011; Sturdevant et al., 2012).  
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Table 3.2 TMRCA and known time post-infection comparisons in each participant over 
chronic and acute infection stages. The known time of infection is shown in blue text with the 
estimated mean tMRCA’s shown in red text. All values quoted below represent the time in 
days post-infection. 
Statistic' CAP177! CAP261' CAP217! CAP270'
Known'time'post7infection' 1295! 945! 1316! 903!
Mean'tMRCA' 1977! 2029! 1311! 914!
Std'error'of'mean' 5.97! 9.60! 0.20! 0.32!
Median' 1930! 1981! 1309! 909!
Geometric'mean' 1963! 2005! 1311! 914!
95%'HPD'lower' 1590! 1482! 1303! 878!
95%'HPD'upper' 2454! 2687! 1324! 964!
 
It is notable that the lower and upper 95% HPD parameters for participants CAP217 and 
CAP270 were found to be within close proximity to the known time of infection, whereas in 
participants CAP177 and CAP261 they were not. Furthermore, based on rigorous methods 
followed by Novitsky et al. (2011) in the identification of single and multiple HIV variants in 
which the geometric means of the tMRCA estimate was interpreted, transmission of multiple 
variants in participants CAP177 and CAP261 were evident.  
 
3.3 Statistical/evaluation/of/viral/compartmentalization/and/population/
migration//
3.3.1 TreeFbased/compartmentalization/analysis/
In phylogenetic tree-based statistical analyses performed using BaTS (Parker et al., 2008) on 
longitudinally sampled data from each participant, the null hypothesis of panmixis (i.e. free 
movement of viruses) between the blood plasma and cervical compartments was rejected in 
three of the four participants by all tests applied (Table 3.3). Overall, significantly lower than 
expected values were obtained for the PS and AI statistics and significantly higher than 
expected values for the MC (Blood) statistic, given a model of random movement of viruses 
between compartments (i.e. a movement model with unrestricted migration between 
compartments). In participants CAP177 and CAP217, the MC (CVL) statistic was also 
significantly higher than expected while in participant CAP261, only the PS statistic was 
significantly lower than that expected (Table 3.3). 
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When monotypic (identical) sequences were removed from longitudinal data sets for CAP261 
(n = 6) and CAP270 (n = 14), almost no evidence of statistically significant structure by 
tissue type remained however when monotypic sequences were similarly removed from 
CAP177 (n = 49) and CAP217 (n = 32) data sets, the PS and AI statistics remained 
significantly different from null expectations (Table 3.3).   
 
The removal of both monotypic and low diversity (<0.1% divergent) sequences (such that 
low diversity, tissue-specific clades were collapsed to a single sequence) in CAP177 (n = 28) 
and CAP217 (n = 22) made almost no difference compared to the structure detected when 
only monotypic sequences were excluded, with the exception of statistically significant 
structure becoming visible in the MC (CVL) in CAP177 (Table 3.3). To further investigate if 
any of the significant evidence for compartmentalization was influenced by sequences from 
mid or later stages of infection in each participant, data sets were separated by time point and 
analysed independently. 
 
!
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Table 3.3 Longitudinal compartmentalization results using tree-based statistics AI, PS and MC in BaTS for all participants. Data set types are 
indicated by roman numerals I, II and III (where I = monotypic and low diversity sequences included; II = monotypic sequences removed; III = 
monotypic and low diversity (<0.01% divergence) sequences removed), with significant p-vlaues shown in red text.  
 
Participant)ID) Data)
set)
n)(Blood)) n)(CVL)) Statistic) Observed)
mean)
Lower)95%)CI) Upper)95%)CI) Null)mean) Lower)95%)CI) Upper)95%)CI) pCvalue)
CAP177) I! 68! 62! AI! 2.50! 1.81! 3.23! 6.25! 5.21! 7.30! 0.0000!
) ! ! ! PS! 23.64! 21.00! 26.00! 42.08! 37.94! 45.92! 0.0000!
) ! ! ! MC!(Blood)! 7.16! 4.00! 9.00! 4.30! 3.20! 5.94! 0.0320!
) ! ! ! MC!(CVL)! 7.22! 7.00! 9.00! 3.25! 2.41! 4.34! 0.0050!
) II! 60! 42! AI! 2.86! 2.26! 3.52! 4.85! 3.84! 5.85! 0.0010!
) ! ! ! PS! 23.31! 21.00! 26.00! 32.24! 28.31! 35.73! 0.0000!
) ! ! ! MC!(Blood)! 3.94! 3.00! 4.00! 4.15! 3.09! 5.68! 0.5400!
) ! ! ! MC!(CVL)! 4.08! 4.00! 5.00! 3.00! 2.09! 4.16! 0.1380!
) III! 50! 33! AI! 2.74! 2.28! 3.25! 3.78! 2.89! 4.70! 0.0190!
) ! ! ! PS! 20.99! 19.00! 23.00! 25.88! 22.59! 28.90! 0.0090!
) ! ! ! MC!(Blood)! 3.86! 3.00! 4.00! 4.04! 3.00! 5.95! 0.4330!
) ! ! ! MC!(CVL)! 3.64! 3.00! 4.00! 2.73! 2.00! 4.02! 0.0740!
CAP217) I! 66! 49! AI! 3.20! 2.26! 4.16! 5.22! 4.30! 6.11! 0.0000!
) ! ! ! PS! 30.00! 27.00! 33.00! 37.10! 33.78! 40.14! 0.0010!
) ! ! ! MC!(Blood)! 4.74! 4.00! 7.00! 4.38! 3.41! 6.64! 0.5670!
) ! ! ! MC!(CVL)! 8.00! 8.00! 8.00! 3.14! 2.41! 4.08! 0.0020!
) II! 52! 38! AI! 2.68! 1.900! 3.48! 4.14! 3.27! 5.02! 0.0000!
) ! ! ! PS! 24.11! 22.00! 27.00! 28.81! 25.48! 31.75! 0.0100!
) ! ! ! MC!(Blood)! 4.54! 4.00! 7.00! 4.19! 3.11! 6.21! 0.4710!
) ! ! ! MC!(CVL)! 6.01! 6.00! 6.00! 2.96! 2.17! 4.05! 0.0150!
) III! 45! 29! AI! 2.25! 1.61! 2.91! 3.32! 2.52! 4.10! 0.0190!
) ! ! ! PS! 19.13! 17.00! 21.00! 22.88! 19.83! 25.61! 0.0180!
) ! ! ! MC!(Blood)! 4.20! 4.00! 5.00! 4.36! 3.02! 6.47! 0.5530!
) ! ! ! MC!(CVL)! 5.67! 5.00! 6.00! 2.68! 1.97! 4.01! 0.0070!
!
!
!
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Participant)ID) Data)
set)
n)(Blood)) n)(CVL)) Statistic) Observed)
mean)
Lower)95%)CI) Upper)95%)CI) Null)mean) Lower)95%)CI) Upper)95%)CI) pCvalue)
CAP261) I! 40! 41! AI! 2.81! 2.31! 3.32! 3.55! 2.51! 4.47! 0.1100!
) ! ! ! PS! 22.39! 21.00! 23.00! 26.90! 23.00! 30.48! 0.0200!
) ! ! ! MC!(Blood)! 4.00! 4.00! 4.00! 3.25! 2.08! 5.77! 0.2360!
) ! ! ! MC!(CVL)! 4.00! 4.00! 4.00! 3.31! 2.17! 5.52! 0.2400!
) II! 40! 37! AI! 3.36! 2.78! 3.92! 3.56! 2.57! 4.56! 0.3890!
) ! ! ! PS! 23.31! 22.00! 24.00! 25.64! 21.94! 29.15! 0.1200!
) ! ! ! MC!(Blood)! 4.00! 4.00! 4.00! 3.42! 2.13! 5.97! 0.2350!
) ! ! ! MC!(CVL)! 3.02! 3.00! 3.00! 3.19! 2.02! 5.03! 0.6110!
CAP270) I! 62! 57! AI! 4.61! 3.79! 5.45! 5.73! 4.65! 6.78! 0.0440!
) ! ! ! PS! 34.36! 32.00! 37.00! 39.46! 35.53! 43.42! 0.0120!
) ! ! ! MC!(Blood)! 6.68! 6.00! 7.00! 3.94! 2.88! 5.54! 0.0080!
) ! ! ! MC!(CVL)! 3.84! 3.00! 5.00! 3.65! 2.59! 5.11! 0.3040!
) II! 61! 46! AI! 4.54! 3.76! 5.35! 5.05! 4.07! 6.03! 0.1910!
) ! ! ! PS! 31.18! 29.00! 34.00! 34.52! 30.72! 37.91! 0.0600!
) ! ! ! MC!(Blood)! 6.44! 9.00! 9.00! 4.32! 3.17! 5.80! 0.0360!
) ! ! ! MC!(CVL)! 3.52! 3.00! 5.00! 3.19! 2.23! 4.65! 0.5880!
 
!
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In cross-sectional analyses where the data for each time point was treated as fully 
independent and analysed separately, there was strong evidence of compartmentalization at 
all sampling time points in HIV sequences derived from participant CAP177 whereas, in 
CAP261 and CAP217, statistically significant structure by tissue type was only detected at 
the final sampling points (945 and 1316 days respectively, Table 3.4). In participant CAP270 
the only statistics that were significantly different to null expectations were MC (Blood) at 
147 days, and MC (CVL) and MC (Blood) at 406 days (Table 3.4) 
 
The removal of monotypic sequences from CAP177 led to a reduction in the number of 
significant results obtained at 28 and 378 days but not at 560 days, and completely removed 
all statistical evidence for compartmentalization at the final sampling point taken at 1295 
days (Table 3.4), whereas in CAP217 and CAP261, removal of monotypic sequences had no 
effect on the results obtained and significant structure by tissue type remained detectable at 
1316 and 945 days respectively.  
 
In contrast, the removal of both monotypic and low diversity sequences in CAP217, resulted 
in compartmentalization no longer being detectable at any of the time points containing low 
diversity sequences (i.e. 63 and 420 days), whereas in participant CAP177 statistically 
significant structure was still detectable at 28 days within CVL populations (Table 3.4). 
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Table 3.4 Cross-sectional compartmentalization results using tree-based statistics AI, PS and MC in BaTS for all participants. Data set types are 
indicated by roman numerals I, II and III (where I = monotypic and low diversity sequences included; II = monotypic sequences removed; III = 
monotypic and low diversity (<0.01% divergence) sequences removed), with significant p-vlaues shown in red text. 
Participant)ID) Data)
set)
Days)p.i.) n)(Blood)) n)(CVL)) Statistic) Observed)
mean)
Lower)95%)CI) Upper)95%)CI) Null)
mean)
Lower)95%)CI) Upper)95%)CI) pEvalue)
CAP177) I! 28! 12! 18! AI! 0.22! 0.00! 0.48! 1.32! 1.00! 1.57! 0.0000!
) ! ! ! ! PS! 2.94! 2.00! 3.00! 9.34! 8.02! 10.35! 0.0000!
) ! ! ! ! MC!(Blood)! 4.31! 2.00! 8.00! 2.00! 1.65! 2.48! 0.0180!
) ! ! ! ! MC!(CVL)! 0.22! 0.00! 0.48! 1.32! 1.00! 1.57! 0.0000!
) ! 378! 11! 19! AI! 0.53! 0.15! 0.94! 1.05! 0.64! 1.44! 0.0140!
) ! ! ! ! PS! 7.35! 6.00! 8.00! 8.93! 7.06! 10.42! 0.0460!
) ! ! ! ! MC!(Blood)! 2.92! 2.00! 3.00! 1.70! 1.12! 2.89! 0.0220!
) ! ! ! ! MC!(CVL)! 4.00! 4.00! 4.00! 3.31! 1.84! 6.00! 0.2750!
) ! 560! 8! 5! AI! 0.27! 0.27! 0.27! 0.53! 0.25! 0.86! 0.1870!
) ! ! ! ! PS! 2.00! 2.00! 2.00! 3.88! 2.80! 4.81! 0.0140!
) ! ! ! ! MC!(Blood)! 2.00! 2.00! 2.00! 2.13! 1.19! 4.00! 0.6770!
) ! ! ! ! MC!(CVL)! 4.00! 4.00! 4.00! 1.46! 1.00! 2.00! 0.0090!
) ! 1295! 18! 19! AI! 1.06! 0.83! 1.19! 1.99! 1.34! 2.62! 0.0070!
) ! ! ! ! PS! 8.30! 8.00! 9.00! 12.26! 9.93! 14.34! 0.0020!
) ! ! ! ! MC!(Blood)! 4.01! 3.00! 5.00! 2.74! 1.98! 4.06! 0.0660!
) ! ! ! ! MC!(CVL)! 7.00! 7.00! 7.00! 2.91! 2.03! 4.54! 0.0080!
) II! 28! 12! 18! AI! 0.22! 0.00! 0.48! 1.32! 1.00! 1.57! 0.0000!
) ! ! ! ! PS! 2.94! 2.00! 3.00! 9.34! 8.02! 10.35! 0.0000!
) ! ! ! ! MC!(Blood)! 4.31! 2.00! 8.00! 2.00! 1.65! 2.48! 0.0180!
) ! ! ! ! MC!(CVL)! 0.22! 0.00! 0.48! 1.32! 1.00! 1.57! 0.0000!
) ! 378! 11! 17! AI! 0.39! 0.10! 0.68! 1.00! 0.58! 1.38! 0.0130!
) ! ! ! ! PS! 6.04! 6.00! 7.00! 8.63! 6.80! 10.31! 0.0230!
) ! ! ! ! MC!(Blood)! 2.94! 3.00! 3.00! 1.82! 1.10! 3.33! 0.0690!
) ! ! ! ! MC!(CVL)! 4.00! 4.00! 4.00! 3.10! 1.65! 5.01! 0.2970!
) ! 560! 7! 4! AI! 0.30! 0.30! 0.30! 0.51! 0.05! 0.83! 0.2310!
) ! ! ! ! PS! 2.00! 2.00! 2.00! 3.14! 2.00! 4.00! 0.0820!
) ! ! ! ! MC!(Blood)! 2.00! 2.00! 2.00! 2.15! 1.32! 4.00! 0.7490!
) ! ! ! ! MC!(CVL)! 3.00! 3.00! 3.00! 1.33! 1.00! 2.00! 0.0200!
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Participant)ID) Data)
set)
Days)p.i.) n)(Blood)) n)(CVL)) Statistic) Observed)
mean)
Lower)95%)CI) Upper)95%)CI) Null)
mean)
Lower)95%)CI) Upper)95%)CI) pEvalue)
) ! 1295! 18! 11! AI! 1.09! 0.84! 1.31! 1.50! 0.87! 2.08! 0.1250!
) ! ! ! ! PS! 8.32! 8.00! 9.00! 8.70! 6.94! 10.26! 0.2460!
) ! ! ! ! MC!(Blood)! 3.73! 3.00! 5.00! 3.25! 2.00! 4.93! 0.7030!
) ! ! ! ! MC!(CVL)! 3.00! 3.00! 3.00! 2.03! 1.07! 3.20! 0.1620!
) III! 28! 3! 5! AI! 0.21! 0.01! 0.38! 0.35! 0.21! 0.40! 0.1060!
) ! ! ! ! PS! 1.89! 1.00! 2.00! 2.28! 1.88! 2.53! 0.3790!
) ! ! ! ! MC!(Blood)! 1.00! 1.00! 1.00! 1.20! 1.00! 1.39! 1.0000!
) ! ! ! ! MC!(CVL)! 2.78! 1.00! 5.00! 1.80! 1.38! 2.77! 0.0010!
) ! 378! 9! 14! AI! 0.55! 0.44! 0.79! 0.77! 0.34! 1.20! 0.1320!
) ! ! ! ! PS! 6.06! 6.00! 7.00! 7.03! 5.28! 8.59! 0.1370!
) ! ! ! ! MC!(Blood)! 2.89! 2.00! 3.00! 1.63! 1.00! 3.12! 0.0600!
) ! ! ! ! MC!(CVL)! 2.64! 2.00! 3.00! 2.75! 1.24! 4.64! 0.4220!
) ! 1295! 18! 9! AI! 1.13! 0.89! 1.35! 1.29! 0.69! 1.85! 0.3260!
) ! ! ! ! PS! 8.15! 8.00! 9.00! 7.46! 5.87! 8.93! 0.7540!
) ! ! ! ! MC!(Blood)! 3.90! 3.00! 5.00! 3.53! 2.05! 5.30! 0.7520!
) ! ! ! ! MC!(CVL)! 1.75! 1.00! 2.00! 1.75! 1.00! 3.00! 0.2780!
CAP217) I! 63! 20! 20! AI! 1.23! 0.55! 1.93! 1.91! 1.44! 2.29! 0.0120!
) ! ! ! ! PS! 11.55! 9.00! 14.00! 13.24! 11.48! 14.56! 0.1080!
) ! ! ! ! MC!(Blood)! 3.55! 3.00! 6.00! 2.75! 2.25! 3.50! 0.2270!
) ! ! ! ! MC!(CVL)! 3.17! 2.00! 5.00! 2.76! 2.25! 3.49! 0.2350!
) ! 420! 6! 5! AI! 0.31! 0.15! 0.55! 0.53! 0.15! 0.80! 0.0930!
) ! ! ! ! PS! 3.68! 3.00! 4.00! 3.51! 2.00! 4.59! 0.8810!
) ! ! ! ! MC!(Blood)! 2.11! 2.00! 3.00! 1.85! 1.05! 3.04! 0.3730!
) ! ! ! ! MC!(CVL)! 1.87! 1.00! 2.00! 1.51! 1.00! 3.00! 0.1950!
) ! 770! 6! 5! AI! 0.40! 0.10! 0.57! 0.47! 0.12! 0.66! 0.4070!
) ! ! ! ! PS! 2.81! 2.00! 3.00! 3.55! 2.15! 4.63! 0.2510!
) ! ! ! ! MC!(Blood)! 1.00! 1.00! 1.00! 1.74! 1.00! 3.04! 1.0000!
) ! ! ! ! MC!(CVL)! 3.00! 3.00! 3.00! 1.48! 1.00! 3.00! 0.0480!
) ! 1316! 19! 19! AI! 1.06! 0.81! 1.41! 1.92! 1.23! 2.58! 0.0230!
) ! ! ! ! PS! 8.32! 7.00! 9.00! 12.67! 10.19! 15.00! 0.0030!
) ! ! ! ! MC!(Blood)! 3.34! 2.00! 4.00! 2.71! 1.91! 4.23! 0.0530!
) ! ! ! ! MC!(CVL)! 10.00! 10.00! 10.00! 2.76! 1.93! 4.93! 0.0020!
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Participant)ID) Data)
set)
Days)p.i.) n)(Blood)) n)(CVL)) Statistic) Observed)
mean)
Lower)95%)CI) Upper)95%)CI) Null)
mean)
Lower)95%)CI) Upper)95%)CI) pEvalue)
) II! 63! 19! 13! AI! 0.81! 0.29! 1.36! 1.52! 1.05! 1.91! 0.0050!
) ! ! ! ! PS! 8.01! 6.00! 10.00! 10.03! 8.61! 11.33! 0.0190!
) ! ! ! ! MC!(Blood)! 4.38! 3.00! 8.00! 3.11! 2.50! 4.02! 0.0520!
) ! ! ! ! MC!(CVL)! 2.88! 2.00! 5.00! 2.15! 1.59! 3.17! 0.0680!
) ! 770! 6! 3! AI! 0.47! 0.41! 0.61! 0.27! 0.01! 0.47! 0.7530!
) ! ! ! ! PS! 2.82! 2.00! 3.00! 2.39! 1.87! 3.00! 1.0000!
) ! ! ! ! MC!(Blood)! 1.00! 1.00! 1.00! 1.89! 1.00! 5.00! 1.0000!
) ! ! ! ! MC!(CVL)! 1.01! 1.00! 1.00! 1.11! 1.00! 1.80! 1.0000!
) ! 1316! 19! 17! AI! 1.06! 0.81! 1.40! 1.81! 1.15! 2.51! 0.0320!
) ! ! ! ! PS! 8.30! 7.00! 9.00! 11.86! 9.32! 14.21! 0.0100!
) ! ! ! ! MC!(Blood)! 3.35! 2.00! 4.00! 2.84! 1.99! 5.02! 0.0940!
) ! ! ! ! MC!(CVL)! 8.00! 8.00! 8.00! 2.55! 1.62! 4.98! 0.0020!
) III! 63! 14! 5! AI! 0.56! 0.11! 1.02! 0.71! 0.44! 1.01! 0.2200!
) ! ! ! ! PS! 4.48! 3.00! 5.00! 4.35! 3.54! 4.92! 1.0000!
) ! ! ! ! MC!(Blood)! 3.63! 2.00! 6.00! 3.64! 2.66! 7.42! 0.8120!
) ! ! ! ! MC!(CVL)! 1.34! 1.00! 2.00! 1.31! 1.05! 2.08! 1.0000!
) ! 420! 5! 4! AI! 0.21! 0.15! 0.47! 0.44! 0.05! 0.69! 0.0910!
) ! ! ! ! PS! 3.00! 3.00! 3.00! 2.81! 2.00! 3.95! 0.6930!
) ! ! ! ! MC!(Blood)! 1.99! 2.00! 2.00! 1.69! 1.00! 3.00! 0.2100!
) ! ! ! ! MC!(CVL)! 1.85! 1.00! 2.00! 1.43! 1.00! 2.33! 0.0940!
CAP261) I! 63! 19! 19! AI! 1.69! 1.24! 2.05! 1.77! 1.13! 2.38! 0.4500!
) ! ! ! ! PS! 12.09! 11.00! 13.00! 12.62! 10.07! 14.82! 0.3120!
) ! ! ! ! MC!(Blood)! 2.59! 2.00! 3.00! 2.57! 1.98! 4.09! 0.1420!
) ! ! ! ! MC!(CVL)! 3.99! 4.00! 4.00! 2.56! 1.98! 4.09! 0.0680!
) ! 413! 11! 12! AI! 0.82! 0.75! 0.99! 1.05! 0.51! 1.52! 0.1840!
) ! ! ! ! PS! 6.99! 7.00! 7.00! 7.51! 5.21! 9.10! 0.3600!
) ! ! ! ! MC!(Blood)! 3.00! 3.00! 3.00! 2.20! 1.05! 4.00! 0.2110!
) ! ! ! ! MC!(CVL)! 4.00! 4.00! 4.00! 2.45! 1.10! 4.01! 0.1200!
) ! 945! 10! 10! AI! 0.38! 0.32! 0.41! 0.94! 0.40! 1.47! 0.0510!
) ! ! ! ! PS! 3.95! 4.00! 4.00! 6.60! 4.95! 8.04! 0.0100!
) ! ! ! ! MC!(Blood)! 4.00! 4.00! 4.00! 2.17! 1.00! 4.00! 0.0950!
) ! ! ! ! MC!(CVL)! 4.99! 5.00! 5.00! 2.18! 1.00! 4.00! 0.0160!
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Participant)ID) Data)
set)
Days)p.i.) n)(Blood)) n)(CVL)) Statistic) Observed)
mean)
Lower)95%)CI) Upper)95%)CI) Null)
mean)
Lower)95%)CI) Upper)95%)CI) pEvalue)
) II! 63! 19! 15! AI! 2.12! 1.68! 2.47! 1.61! 0.96! 2.25! 0.9180!
) ! ! ! ! PS! 12.40! 11.00! 13.00! 11.15! 8.97! 13.09! 0.9420!
) ! ! ! ! MC!(Blood)! 2.53! 2.00! 3.00! 2.78! 2.00! 4.19! 0.3450!
) ! ! ! ! MC!(CVL)! 2.17! 2.00! 3.00! 2.25! 1.25! 3.39! 0.7310!
CAP270) I! 56! 11! 14! AI! 0.99! 0.50! 1.50! 1.18! 0.76! 1.58! 0.1580!
) ! ! ! ! PS! 7.54! 6.00! 9.00! 8.09! 7.07! 9.14! 0.5210!
) ! ! ! ! MC!(Blood)! 2.25! 2.00! 3.00! 2.09! 1.59! 2.55! 0.5280!
) ! ! ! ! MC!(CVL)! 3.04! 2.00! 5.00! 2.64! 2.00! 3.08! 0.1510!
) ! 147! 8! 8! AI! 0.46! 0.38! 0.63! 0.73! 0.28! 1.16! 0.1020!
) ! ! ! ! PS! 3.00! 3.00! 3.00! 5.20! 3.66! 6.91! 0.0150!
) ! ! ! ! MC!(Blood)! 4.34! 4.00! 5.00! 2.03! 1.01! 3.87! 0.0250!
) ! ! ! ! MC!(CVL)! 2.33! 2.00! 3.00! 2.03! 1.01! 3.99! 0.5200!
) ! 231! 14! 3! AI! 0.44! 0.15! 0.68! 0.45! 0.14! 0.74! 0.4780!
) ! ! ! ! PS! 2.77! 2.00! 3.00! 2.70! 2.00! 3.00! 1.0000!
) ! ! ! ! MC!(Blood)! 3.07! 2.00! 4.00! 4.34! 2.68! 8.97! 0.8330!
) ! ! ! ! MC!(CVL)! 1.14! 1.00! 2.00! 1.10! 1.00! 1.69! 1.0000!
) ! 406! 12! 11! AI! 0.80! 0.57! 0.94! 1.21! 0.66! 1.75! 0.1550!
) ! ! ! ! PS! 5.04! 5.00! 5.00! 7.52! 5.63! 9.30! 0.0190!
) ! ! ! ! MC!(Blood)! 6.00! 6.00! 6.00! 2.50! 1.57! 4.30! 0.0120!
) ! ! ! ! MC!(CVL)! 3.90! 3.00! 4.00! 2.27! 1.30! 3.95! 0.0490!
) ! 595! 7! 5! AI! 0.46! 0.07! 0.65! 0.52! 0.20! 0.82! 0.2580!
) ! ! ! ! PS! 3.89! 3.00! 4.00! 3.76! 2.66! 4.87! 0.7040!
) ! ! ! ! MC!(Blood)! 1.78! 1.00! 3.00! 1.97! 1.09! 3.97! 1.0000!
) ! ! ! ! MC!(CVL)! 1.98! 2.00! 2.00! 1.44! 1.00! 2.21! 0.0770!
) ! 903! 10! 12! AI! 1.00! 0.82! 1.31! 1.01! 0.49! 1.54! 0.5990!
) ! ! ! ! PS! 7.86! 7.00! 8.00! 7.19! 5.13! 8.96! 0.7700!
) ! ! ! ! MC!(Blood)! 1.47! 1.00! 2.00! 2.03! 1.00! 4.00! 1.0000!
) ! ! ! ! MC!(CVL)! 2.00! 2.00! 2.00! 2.48! 1.12! 5.00! 0.6250!
) II! 56! 11! 8! AI! 0.89! 0.43! 1.36! 0.87! 0.57! 1.16! 0.5420!
) ! ! ! ! PS! 6.25! 5.00! 8.00! 6.01! 5.08! 6.78! 0.5200!
) ! ! ! ! MC!(Blood)! 2.44! 2.00! 4.00! 2.47! 1.85! 3.13! 0.9100!
) ! ! ! ! MC!(CVL)! 1.84! 1.00! 3.00! 1.80! 1.39! 2.36! 0.3200!
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Participant)ID) Data)
set)
Days)p.i.) n)(Blood)) n)(CVL)) Statistic) Observed)
mean)
Lower)95%)CI) Upper)95%)CI) Null)
mean)
Lower)95%)CI) Upper)95%)CI) pEvalue)
) ! 147! 8! 7! AI! 0.47! 0.38! 0.64! 0.64! 0.27! 0.99! 0.1530!
) ! ! ! ! PS! 3.00! 3.00! 3.00! 4.87! 3.45! 6.00! 0.0260!
) ! ! ! ! MC!(Blood)! 4.32! 4.00! 5.00! 2.03! 1.02! 3.99! 0.0430!
) ! ! ! ! MC!(CVL)! 1.36! 1.00! 2.00! 1.71! 1.01! 3.87! 1.0000!
) ! 406! 11! 11! AI! 0.80! 0.57! 0.92! 1.19! 0.63! 1.75! 0.1740!
) ! ! ! ! PS! 5.03! 5.00! 5.00! 7.30! 5.17! 8.94! 0.0230!
) ! ! ! ! MC!(Blood)! 5.00! 5.00! 5.00! 2.38! 1.36! 3.96! 0.0290!
) ! ! ! ! MC!(CVL)! 3.90! 3.00! 4.00! 2.32! 1.34! 3.96! 0.0460!
) ! 903! 10! 11! AI! 1.25! 1.06! 1.56! 0.99! 0.47! 1.49! 0.8530!
) ! ! ! ! PS! 7.87! 7.00! 8.00! 6.92! 5.04! 8.67! 0.8540!
) ! ! ! ! MC!(Blood)! 1.47! 1.00! 2.00! 2.09! 1.01! 4.00! 1.0000!
) ! ! ! ! MC!(CVL)! 2.00! 2.00! 2.00! 2.37! 1.11! 4.70! 0.5820!
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3.3.2 Distance,based/compartmentalization/analysis/
To further test the hypothesis that HIV-1 is compartmentalized in the cervix or blood plasma, distance-based tests were also performed on gp120 
env sequences from each participant using Wright’s measure of population subdivision (FST) and Hudson’s Nearest-Neighbor (Snn) statistics.  
 
Table 3.5 Longitudinal compartmentalization results using distance-based statistics FST and Snn in HyPhy in all participants. Data set types are 
indicated by roman numerals I, II, and III (where I = monotypic and low diversity sequences included; II = monotypic sequences removed; III = 
monotypic and low diversity (<0.01% divergence) sequences removed). Statistically significant evidence of compartmentalization for the FST test 
was determined based on guidelines described by Josefsson  et al. (2013), where p-value <0.05 and bootstrap value >0.95, whereas for the Snn 
test p-values below 0.05 were considered to be significant. Significant p-vlaues are shown in red text. 
Participant)ID) Data)set) n)(Blood)) n)(CVL)) Statistic) Observed)
value)
pEvalue) Bootstrap)
mean)
Bootstrap)
median)
Bootstrap)standard)
deviation)
Bootstrap)95%)CI)
CAP177) I! 68! 62! FST! 0.013! 0.049! 0.019! 0.017! 0.011! 0.005!–!0.054!
) ! ! ! Snn! 0.743! 0.008! 0.845! 0.845! 0.028! 0.791!–!0.907!
) II! 60! 42! FST! 0.001! 0.314! 0.011! 0.009! 0.007! 0.001!–!0.025!
) ! ! ! Snn! 0.715! 0.010! 0.864! 0.864! 0.033! 0.797!–!0.924!
) III! 50! 33! FST! ?0.001! 0.458! 0.011! 0.010! 0.007! 0.001!–!0.028!
) ! ! ! Snn! 0.687! 0.003! 0.857! 0.855! 0.037! 0.783!–!0.928!
CAP217) I! 66! 49! FST! 0.009! 0.196! 0.018! 0.016! 0.015! ?0.004!–!0.064!
) ! ! ! Snn! 0.654! 0.009! 0.847! 0.844! 0.030! 0.800!–!0.919!
) II! 52! 38! FST! ?0.000! 0.361! 0.011! 0.009! 0.010! ?0.003!–!0.036!
) ! ! ! Snn! 0.583! 0.108! 0.843! 0.845! 0.038! 0.766!–!0.917!
) III! 45! 29! FST! 0.006! 0.181! 0.019! 0.017! 0.013! 0.001!–!0.054!
) ! ! ! Snn! 0.566! 0.261! 0.852! 0.852! 0.043! 0.764!–!0.932!
CAP261) I! 40! 41! FST! 0.001! 0.308! 0.014! 0.012! 0.008!! 0.003!–!0.032!
) ! ! ! Snn! 0.584! 0.145! 0.839! 0.840! 0.041! 0.761!–!0.916!
) II! 40! 37! FST! 0.004! 0.197! 0.017! 0.015! 0.010! 0.003!–!0.043!
) ! ! ! Snn! 0.498! 0.564! 0.827! 0.831! 0.044! 0.738!–!0.909!
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Participant)ID) Data)set) n)(Blood)) n)(CVL)) Statistic) Observed)
value)
pEvalue) Bootstrap)
mean)
Bootstrap)
median)
Bootstrap)standard)
deviation)
Bootstrap)95%)CI)
CAP270) I! 62! 57! FST! 0.004! 0.149! 0.013! 0.012! 0.006! 0.003!–!0.029!
) ! ! ! Snn! 0.560! 0.154! 0.840! 0.841! 0.033! 0.777!–!0.902!
) II! 61! 46! FST! 0.006! 0.162! 0.015! 0.014! 0.009! 0.000!–!0.039!!
) ! ! ! Snn! 0.522! 0.456! 0.822! 0.822! 0.036! 0.755!–!0.894!
 
In distance-based compartmentalization analyses performed on longitudinally sampled data from each participant using HyPhy (Pond et al., 
2005), statistically significant evidence of genetic differentiation between blood plasma and CVL viral populations was found in CAP177 and 
CAP217 with the Snn test, whereas no such evidence was detected in CAP261 and CAP270 by either test (Table 3.5). Although the FST test 
predicted a single p-value below 0.05 in CAP177, the mean bootstrap value did not exceed 0.95, therefore implying a lack of evidence to support 
the existence of genetically distinct viral populations between the two tissue types. In total, the Snn and FST tests predicted fewer significant p-
values compared to tree-based tests (Table 3.3) as expected, since distance-based tests have been reported to be less sensitive than tree-based 
tests (Zárate et al., 2007), however significant compartmentalization was detected in participants CAP177 and CAP217, consistent with tree-
based tests (Tables 3.3 and 3.5).  
 
When monotypic and low diversity sequences were removed from longitudinal data sets for CAP177 (n = 49) and CAP217 (n = 32), statistical 
evidence to support compartmentalized structure was no longer detected in CAP217, although in CAP177 statistical structure remained present 
(Table 3.5). As a result, cross-sectional analyses were performed on data sets from CAP177, to determine if compartmentalized structure was 
driven by sequences from particular time points only. 
 
!
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Table 3.6 Cross-sectional compartmentalization results using distance-based statistics FST and Snn in HyPhy for participant CAP177. Data set 
types are indicated by roman numerals I, II, and III (where I = monotypic and low diversity sequences included; II = monotypic sequences 
removed; III = monotypic and low diversity (<0.01% divergence) sequences removed). Statistically significant evidence of 
compartmentalization for the FST test was determined based on guidelines described by Josefsson et al. (2013), where p-value <0.05 and 
bootstrap value >0.95, whereas for the Snn test p-values below 0.05 were considered to be significant. Significant p-vlaues are shown in red text.  
Participant)ID) Data)set) Days)
p.i.)
n)(Blood)) n)(CVL)) Statistic) Observed)
value)
pEvalue) Bootstrap)
mean)
Bootstrap)
median)
Bootstrap)
standard)deviation)
Bootstrap)
95%)CI)
CAP177) I! 28! 12! 18! FST! ?0.072! 0.392! 0.028! ?0.059! 0.134! ?0.087!–!0.297!
) ! ! ! ! Snn! 0.938! 0.032! 0.970! 0.967! 0.023! 0.933!–!1.000!
) ! 378! 11! 19! FST! 0.001! 0.377! 0.034! 0.029! 0.023! ?0.000!–!0.097!
) ! ! ! ! Snn! 0.817! 0.001! 0.871! 0.880! 0.060! 0.753!–!0.967!
) ! 560! 8! 5! FST! 0.283! 0.006! 0.358! 0.339! 0.117! 0.166!–!0.574!
) ! ! ! ! Snn! 0.846! 0.015! 0.948! 0.962! 0.059! 0.846!–!1.000!
) ! 1295! 18! 19! FST! 0.048! 0.001! 0.077! 0.073! 0.025! 0.040!–!0.141!
) ! ! ! ! Snn! 0.757! 0.001! 0.877! 0.865! 0.048! 0.795!–!1.000!
) II! 28! 12! 18! FST! ?0.071! 0.437! 0.031! ?0.021! 0.098! ?0.070!–!0.229!
) ! ! ! ! Snn! 0.904! 0.032! 0.916! 0.915! 0.042! 0.839!–!0.990!
) ! 378! 11! 17! FST! 0.013! 0.194! 0.053! 0.047! 0.028! 0.009!–!0.140!
) ! ! ! ! Snn! 0.821! 0.001! 0.894! 0.893! 0.064! 0.780!–!1.000!
) ! 560! 7! 4! FST! 0.228! 0.017! 0.299! 0.277! 0.131! 0.094!–!0.609!
) ! ! ! ! Snn! 0.818! 0.067! 0.923! 0.909! 0.072! 0.818!–!1.000!
) ! 1295! 18! 11! FST! ?0.029! 0.977! 0.000! ?0.003! 0.015! ?0.022!–!0.041!
) ! ! ! ! Snn! 0.690! 0.053! 0.831! 0.828! 0.061! 0.707!–!0.983!
) III! 28! 3! 5! FST! ?0.153! 0.395! 0.057! ?0.026! 0.191! ?0.158!–!0.445!
) ! ! ! ! Snn! 0.688! 0.111! 0.835! 0.875! 0.107! 0.625!–!1.000!
) ! 378! 9! 14! FST! 0.000! 0.388! 0.043! 0.034! 0.030! 0.004!–!0.110!
) ! ! ! ! Snn! 0.783! 0.005! 0.870! 0.870! 0.070! 0.739!–!1.000!
) ! 1295! 18! 9! FST! ?0.040! 0.996! ?0.006! ?0.009! 0.018! ?0.039!–!0.051!
) ! ! ! ! Snn! 0.648! 0.168! 0.812! 0.815! 0.072! 0.636!–!0.963!
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In cross-sectional distance-based compartmentalization analyses for participant CAP177, 
where sequences from each time point was treated as fully independent and analysed 
separately, significant structure was detected at all time points when monotypic and low 
diversity sequences were included (Table 3.6). After the removal of monotypic sequences 
statistically significant evidence for compartmentalization was no longer detectable at 560 
and 1295 days, following which, the removal of both low diversity and monotypic sequences 
resulted in almost no statistical evidence for compartmentalized structure between blood 
plasma and CVL populations, except at 378 days (p < 0.05).  
!
3.3.3 Structured*coalescent0based*migration*analysis*
In maximum likelihood-based migration analysis performed using Migrate-n 
(http://popgen.sc.fsu.edu/Migrate/Migrate-n.html), unequal migration rates between 
anatomical compartments were found in all participants during acute and chronic infection 
stages (Table 3.7). 
 
Table 3.7 Longitudinal analyses of viral migration patterns between matched blood plasma 
and cervical compartments in each participant. 
Participant)ID) n)(Blood)) n)(CVL))) Median)Slice)Sample)(M)) Mean)Slice)Sample)(M))
) ! ! Blood!to!CVL! CVL!to!Blood! Blood!to!CVL! CVL!to!Blood!
CAP177) 68! 62! 273.0! 761.0! 272.7! 760.8!
CAP217) 66! 49! 876.3! 318.3! 861.9! 331.8!
CAP261) 40! 41! 515.0! 609.0! 516.4! 611.3!
CAP270) 62! 57! 215.7! 871.7! 217.7! 866.4!
  
In CAP261, an almost equal rate of movement was predicted between viruses in the blood 
plasma and cervical compartment, while in CAP177 and CAP270 almost four times as many 
viruses were estimated to migrate from the cervical compartment into the blood plasma 
compared to the number migrating into the cervical compartment from the blood plasma 
(Table 3.7). In contrast, higher migration rates were predicted to have occurred from the 
blood plasma into the cervix in participant CAP217. 
 
To further investigate if the presence of monotypic sequences caused a decrease in estimates 
of the effective migration rates between tissue types, monotypic sequences were excluded 
from all data sets and reanalysed using Migrate-n.  
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Table 3.8 Longitudinal analyses of viral migration patterns between blood plasma and 
cervical compartments in each participant, after the exclusion of monotypic sequences.  
Participant)ID) n)(Blood)) n))(CVL)) Median)Slice)Sample)(M)) Mean)Slice)Sample)(M))
) ! ! Blood!to!CVL! CVL!to!Blood! Blood!to!CVL! CVL!to!Blood!
CAP177) 60! 42! 424.3! 300.3! 439.3! 302.7!
CAP217) 52! 38! 201.0! 735.0! 221.3! 739.6!
CAP261) 40! 37! 720.3! 879.0! 716.9! 869.0!
CAP270) 61! 46! 942.3! 827.0! 926.0! 825.8!
  
After the removal of monotypic sequences there was a reversal of migration patterns in 
CAP177, CAP217 and CAP270, despite the estimated number of migrants in either direction 
being within close proximity to previous estimations for CAP177 and CAP270 (i.e. in the 
presence of monotypic sequences). A drastic change in migratory patterns was observed in 
CAP217 where a considerable number of viruses appeared to be migrating from the cervix to 
blood plasma, while an almost equal proportion of viruses were predicted to migrate between 
the blood plasma and cervical compartments in CAP261 once again (Table 3.8).  
 
To determine if migration patterns varied between acute and chronic stages of infection, 
sequences were separated by time point and analysed independently.  
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Table 3.9 Cross-sectional analyses of viral migration patterns between blood plasma and 
cervical compartments in each participant.  
Participant)ID) Days)p.i.) n)(Blood)) n)(CVL))) Median)Slice)Sample)(M)) Mean)Slice)Sample)(M)))
) ! ! ! Blood!to!
CVL!
CVL!to!
Blood!
Blood!to!
CVL!
CVL!to!
Blood!
CAP177) 28! 12! 18! 245.0! 223.7! 280.8! 265.2!
) 378! 11! 19! 344.3! 73.7! 372.2! 123.3!
) 560! 8! 5! 316.3! 203.0! 373.8! 264.0!
) 1295! 18! 19! 811.0! 210.3! 800.2! 212.4!
CAP217) 63! 20! 20! 112.3! 918.3! 168.2! 902.5!
) 420! 6! 5! 744.3! 329.0! 718.7! 389.5!
) 770! 6! 5! 225.7! 589.7! 318.5! 551.6!
) 1316! 19! 19! 55.0! 407.0! 58.7! 427.2!
CAP261) 63! 19! 19! 206.3! 884.3! 236.7! 846.6!
) 413! 11! 12! 424.3! 203.7! 476.3! 363.6!
) 945! 10! 10! 528.3! 197.0! 516.9! 202.6!
CAP270) 56! 11! 14! 198.3! 881.7! 272.8! 854.9!
) 147! 8! 8! 277.0! 893.0! 344.2! 864.0!
) 231! 14! 3! 761.0! 130.3! 728.2! 208.2!
) 406! 12! 11! 619.0! 349.7! 623.6! 396.3!
) 595! 7! 5! 209.7! 698.3! 293.1! 676.6!
) 903! 10! 12! 117.0! 620.3! 125.1! 633.1!
  
Although the sample size was greatly reduced in cross-sectional analyses, the accuracy of 
estimates obtained based on the coalescent approach implemented in Migate-n is more 
dependent on the number of “independent loci than on sample size” (Bradic et al., 2012; 
Felsenstein, 2006). When sequences were analysed individually per time point, at all four 
times where sequences from both tissues were available for CAP177, a greater number of 
viruses were predicted to migrate from the blood plasma into the cervical compartment 
(Table 3.9), consistent with patterns observed in longitudinal analyses after the removal of 
monotypic sequences (Table 3.8). More viruses were estimated to migrate from the blood 
plasma into the cervical compartment in CAP261 too, at two of the three time points sampled 
(Table 3.9), however this was not consistent with longitudinal migration patterns (Tables 3.7 
and 3.8).  
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In CAP217 and CAP270, although migratory patterns varied between sampling points, 
generally a larger number of viruses were estimated to migrate from the cervix into the blood 
plasma (i.e. at approximately 70% of time points tested) (Table 3.9), unlike longitudinal 
migration patterns for these participants (Table 3.8). Nevertheless, exchange of viruses 
between anatomical compartments was evident in all participants both longitudinally and per 
time point, in the presence and absence of monotypic sequences. 
!
3.4 Intrapatient*viral*diversity*
Pairwise genetic distances between full-length gp120 blood plasma and CVL-derived 
sequences increased over the infectious period measured in all participants (Figure 3.5). 
CAP261 and CAP177 displayed higher pairwise genetic distances in their viral populations 
compared to CAP270 and CAP217 throughout the entire infection period. As a result the 
highest increases in genetic diversity between consecutive sampling time points were 
observed in CAP177 between 924 and 1295 days, and between 413 and 945 days in CAP261 
(Figure 3.5). Another major increase in diversity was also detected in CAP177 between 28 
and 196 days, (Figure 3.5).  
 
Levels of genetic diversity in CVL viral populations from CAP177 fluctuated between 378 
and 1295 days, where viruses that were noticeably more divergent than the mainstream 
population appeared as outliers at 28, 378 and 1295 days (Figure 3.5). Diversities varied 
between blood plasma-derived viruses too, where there was a large rise in diversity between 
28 and 1295 days in this participant, coinciding with outliers at 28, 560 and 924 days. No 
differences in diversity between viral populations in the blood plasma and cervix was evident 
in CAP177, however generally pairwise genetic distances were considerably lower between 
viruses in the cervix than those present in blood plasma towards the later stages of infection 
(Figure 3.5). 
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! !!
Figure 3.5 Box-and-whisker plots depicting intrapatient HIV-1 pairwise genetic distances between blood plasma (red) and CVL (grey) derived 
viruses in each participant over the course of infection. The median pairwise genetic distance is indicated by a bold horizontal line at the centre 
of the box, with the upper and lower limits of each box corresponding to the 75th and 25th percentiles, and whiskers extending to the upper and 
lower adjacent values respectively, stratified by sampling time points per tissue type as indicated on the x-axis. Outliers are represented by filled 
circles above and below box plots.  
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There was a steady increase in genetic diversity in CAP217, predominantly between 63 and 420 
days in both blood plasma and CVL sequences, however viruses in the cervix were generally less 
diverse than those from the blood plasma throughout the infection period until 1316 days, when the 
diversity in CVL viruses overtook the diversity in blood plasma viruses (Figure 3.5). Upper and 
lower limits of pairwise genetic distances overlapped between blood plasma and CVL sequences 
over all time points except 770 days in CAP217 indicating a large degree of similarity between 
tissue-specific samples. No consistent tissue-specific differences were seen in CAP217, except at 
770 days when the diversity in CVL-derived viruses was noticeably lower than viral populations 
from the blood plasma.  
 
Although there were only three time points at which matched samples were available for CAP261 
(i.e. sequences from both tissue types), a more diverse viral population was clearly evident in the 
cervix at 63 days (Figure 3.5). At 413 days, viral diversity in both tissue types increased, until 945 
days when both populations were genetically very similar. Despite these observations, viruses in the 
cervix of CAP261 were more diverse than those in the blood plasma at all time points sampled.   
 
In CAP270 a large rise in diversity was evident at 147 days, which continued to increase steadily in 
both tissue types at all subsequent time points, with the exception of CVL viruses sampled at 231 
days, however the lower diversity in CVL viruses at 231 days was likely due to the limited number 
of viruses amplified (n=6) at that particular time point (Figure 3.5).  
 
Viral populations harboured significant tissue-specific differences in pairwise genetic distances at 
10 of the 17 time points where samples from both tissue types were obtained as identified through 
statistical testing (Table 3.10).  
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Table 3.10 Statistical assessment of tissue-specific differences between pairwise genetic distances, 
using the Mann-Whitney and Wilcoxin signed-ranked non-parametric tests. Time points where 
significant differences in genetic diversity between blood plasma and CVL viruses were determined 
by both statistical tests are indicated in red text.  
Participant)ID) Days!p.i.! n!(Blood)! n!(CVL)! Mann7Whitney!U!test! Wilcoxin!signed7rank!!
) ) ) ) U)value) p1value) W)value) p1value)
CAP177) 28! 12! 18! 5414! 0.3433! –! –!
) 378! 11! 19! 5348! 0.0667! 1227! <!0.0001!
) 560! 8! 5! 269! <!0.0001! 45! 0.0039!
) 1295! 18! 19! 19817! <!0.0001! !11781! <!0.0001!
CAP217) 63! 20! 20! 25513! <!0.0001! !4465! <!0.0001!
) 420! 6! 5! 95! 0.2825! 745! 0.0039!
) 770! 6! 5! 123! 0.0076! 45! 0.0039!!
) 1316! 19! 19! 17897! 0.0003! 77546! <!0.0001!
CAP261) 63! 19! 19! 17517! 0.0015! 79086! <!0.0001!
) 413! 11! 12! 2447! 0.0010! 71414! <!0.0001!
) 945! 10! 10! 1391! 0.0022! 71035! <!0.0001!
CAP270) 56! 11! 14! 4166! <!0.0001! 1485! <!0.0001!
) 147! 8! 8! 500! 0.0748! 7178! 0.0003!
) 231! 14! 3! 254! 0.0103! 73! 0.5000!
) 406! 12! 11! 2107! 0.1237! 71225! <!0.0001!
) 595! 7! 5! 120! 0.5321! 755! 0.0020!
) 903! 10! 12! 1927! 0.0078! 1035! <!0.0001!
 
Significant tissue-specific differences between population diversity was detected in all participants 
at isolated time points in CAP177, CAP217 and CAP270, and at all time points in CAP261, 
although data from only three time points were available in this participant. In contrast the least 
number of significant tissue-specific differences in pairwise genetic distances was detected in the 
participant with the most number of sampled time points, i.e. CAP270.  
 
The mean and median pairwise genetic distances between viral populations in the blood plasma and 
CVL did not demonstrate any consistent differences in pairwise genetic diversity, however blood 
plasma viruses from CAP177 appeared to be more diverse than those sampled from the CVL, 
whereas in CAP261 the opposite pattern was observed (Table 3.11).   
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Table 3.11 Mean and median pairwise genetic distances between blood plasma and CVL viruses 
from each participant over the entire sampling period.  
Participant)ID) Days)p.i.) Blood)plasma) CVL)
) ) Mean) Median) Mean) Median)
CAP177) 28! 0.0005! 0.0003! 0.0035! 0.0007!
) 378! 0.0124! 0.0149! 0.0117! 0.0120!
) 560! 0.0135! 0.0135! 0.0022! 0.0009!
) 1295! 0.0162! 0.0139! 0.0097! 0.0109!
CAP217) 63! 0.0012! 0.0012! 0.0007! 0.0010!
) 420! 0.0030! 0.0018! 0.0040! 0.0040!
) 770! 0.0062! 0.0070! 0.0022! 0.0028!
) 1316! 0.0068! 0.0070! 0.0078! 0.0082!
CAP261) 63! 0.0100! 0.0070! 0.0143! 0.0090!
) 413! 0.0180! 0.0162! 0.0265! 0.0250!
) 945! 0.0141! 0.0140! 0.0192! 0.0203!
CAP270) 56! 0.0014! 0.0012! 0.0006! 0.0004!
) 147! 0.0042! 0.0041! 0.0052! 0.0061!
) 231! 0.0049! 0.0049! 0.0027! 0.0024!
) 406! 0.0063! 0.0069! 0.0075! 0.0078!
) 595! 0.0097! 0.0100! 0.0105! 0.0109!
) 903! 0.0145! 0.0153! 0.0124! 0.0128!
 
3.4.1 Association-between-viral-diversity-and-viral-loads-
To determine if there were any significant associations between viral genetic diversity and viral 
loads, average pairwise genetic distances were calculated for each time point sampled and 
compared to viral load measurements from the corresponding time points. CAP177 was the only 
participant in whom a statistically significant correlation between average pairwise genetic diversity 
and viral load was found (p < 0.0141). In all other participants, p-values were not significant (p > 
0.05) using Spearman’s rank correlation (Table 3.12).  
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Table 3.12 Correlation between average genetic distances and viral loads in all participants over the 
sampling period. Participants in whom a significant correlation between viral loads and viral 
diversity was found are indicated in red text. 
Participant)ID) Days)p.i.) Plasma)
viral)load)
Average)genetic)
distance)
Spearman’s)
rho)
p1value) 95%)CI) DF)
CAP177) 14! 359000! 0.0004! 70.8555! 0.0141! 70.9783!to!70.2877!! 6!
) 28! 698000! 0.0036! ! ! ! !
) 196! 152000! 0.0172! ! ! ! !
) 378! 42100! 0.0182! ! ! ! !
) 560! 59200! 0.0180! ! ! ! !
) 924! 43800! 0.0174! ! ! ! !
) 1295! 38800! 0.0212! ! ! ! !
CAP217) 14! 3260000! 0.0001! 70.6119! 0.2727! 70.9703!to!0.5878! 4!
) 63! 75600! 0.0014! ! ! ! !
) 420! 18400! 0.0058! ! ! ! !
) 770! 1940! 0.0088! ! ! ! !
) 1316! 30000! 0.0130! ! ! ! !
CAP261) 63! 821000! 0.0115! 70.9893! 0.0931! Requires!more!than!
3!data!points!
2!
) 413! 65400! 0.0203! ! ! !
) 945! 27500! 0.0193! ! ! ! !
CAP270) 56! 76800! 0.0009! 0.5164! 0.2942! 70.5083!to!0.9358! 5!
) 147! 687000! 0.0051! ! ! ! !
) 231! 310000! 0.0051! ! ! ! !
) 406! 738000! 0.0083! ! ! ! !
) 595! 3710000! 0.0120! ! ! ! !
)) 903! 1290000! 0.0156! !! !! ! !!
 
The strongest associations were detected in CAP177 (p < 0.0141) and CAP261 (p > 0.0931) where 
there was a clear rise in genetic diversity as participants progressed into the chronic phase of 
infection (suggesting a more rapid rate of disease progression in these participants), whereas the 
weakest associations were noted in CAP217 (p > 0.2727) and CAP270 (p > 0.2942) (Table 3.12).  
 
! -
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3.5 Poisson-distribution-fitting-
To determine the number of transmitted viral variants that likely infected each participant, 
frequency distributions illustrating intersequence Hamming distances (difference in base positions 
between two genomes (Keele et al., 2008)) were obtained and analysed per participant, using the 
Poisson Fitter tool (Rose & Korber, 2000). Blood plasma and CVL sequences from the earliest time 
points sampled were analysed and deviation from the Poisson model was considered as evidence of 
infection by more than one viral variant. CAP177 and CAP261 were among the participants that 
deviated from the Poisson distribution, whereas CAP217 and CAP270 appeared to follow a 
unimodal distribution (Figure 3.6), consistent with patterns by single variant founded infections 
(Novitsky et al., 2011).  
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Figure 3.6 Bar charts illustrating Hamming distances between blood plasma and CVL sequences at the earliest sampling time point where 
sequences from both tissues were available for each participant. Although unimodal lines were fitted along frequency distributions predicted in 
all participants, multiple peaks were clearly visible in CAP177 and CAP261. This is because the Poisson-Fitter provides a null model that 
assumes early HIV-1 infection initiated by a single variant by default, prior to the onset of intrahost selection (Wolinsky et al., 1992; Novitsky et 
al., 2011). Well-defined peaks were observed in CAP177 and CAP261 at 28 and 63 days respectively, indicative of infection by more than one 
viral variant, whereas in CAP217 and CAP270 single unimodal distributions were evident at 63 and 56 days, suggesting infection by a single 
viral variant in these participants (Novitsky et al., 2011). 
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3.6 Accumulation.of.potential.N3linked.glycosylation.sites.
In total the frequencies of around 42.90% of the inferred PNLG’s did not change (i.e. sites 
that remained either present or absent in all env gp120 sequences consistently), 23.70% 
increased in frequency (i.e. sites that began to appear in an increasing number of sequences 
with time), and 10.33% decreased in frequency (i.e. sites that were no longer detectable in an 
increasing number of sequences over time) between the first and last time point sampled, 
while 23.06% fluctuated randomly along the course of infection (Figure 3.7).  
 
Table 3.13 Summary of the average number of PNLG sites predicted in the V1V2, V4 and 
V5-loops of blood plasma and CVL sequences among the four participants over time. 
Sampling time points where sequences from the blood plasma or CVL were not available are 
indicated by the “–” symbol.  
Participant)ID) n) Days)p.i.) V1V2) V4) V5)
) ! ! Blood)
plasma)
CVL) Blood)
plasma!
CVL! Blood)
plasma!
CVL!
CAP177) 18! 14! 4.05! –! 3.05! –! 2.00! –!
) 30! 28! 4.00! 4.05! 3.00! 3.00! 2.00! 1.94!
) 11! 196! 3.82! –! 3.00! –! 2.00! –!
) 30! 378! 5.10! 4.47! 2.90! 3.00! 1.80! 1.68!
) 13! 560! 5.38! 4.20! 1.88! 1.20! 2.00! 1.20!
) 5! 924! 6.75! 7.00! 2.75! 2.00! 1.75! 3.00!
) 37! 1295! 7.71! 8.68! 2.39! 3.58! 1.61! 1.37!
CAP217) 18! 14! 5.84! –! 3.05! –! 2.00! –!
) 20! 63! 5.80! 5.50! 2.90! 3.00! 2.00! 1.85!
) 11! 420! 4.33! 4.40! 3.00! 3.00! 1.00! 1.20!
) 11! 770! 4.83! 4.00! 3.00! 3.00! 1.17! 1.80!
) 38! 1316! 6.32! 5.95! 2.89! 3.00! 1.00! 1.11!
CAP261) 38! 63! 6.80! 6.84! 3.37! 3.58! 0.95! 1.00!
) 23! 413! 7.45! 6.00! 4.27! 3.92! 0.55! 0.50!
) 20! 945! 7.80! 8.00! 4.30! 4.70! 1.00! 1.00!
CAP270) 25! 56! 6.91! 7.00! 4.90! 4.80! 1.00! 1.00!
) 1! 105! –! 7.00! –! 5.00! –! 1.00!
) 16! 147! 6.75! 6.75! 3.50! 3.50! 1.00! 1.00!
) 17! 231! 7.00! 6.83! 3.93! 4.17! 1.00! 1.00!
) 23! 406! 6.92! 6.73! 4.00! 4.00! 1.00! 1.00!
) 12! 595! 6.86! 6.80! 4.00! 4.00! 1.00! 1.00!
) 22! 903! 6.30! 6.25! 3.90! 3.75! 0.90! 0.91!
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Both the largest PNLGs frequency increases and decreases occurred in the V-loop regions in 
all participants (range = 64 – 86%), and of these, more increased (range = 36 – 67%) than 
decreased (range = 13 – 29%) over the sampling periods analysed (Figure 3.7). Generally 
however, the number of PNLGs within the V-loop regions did not differ consistently between 
blood plasma and CVL sequences in any of the participants over time (Table 3.13).
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Figure 3.7 Total numbers of PNLG sites within the V1V2, V4 and V5-loops of blood plasma and CVL sequences throughout the sampling 
period among all participants. The actual number of PNLG sites predicted per sample is presented on the scatterplot, separated by tissue type for 
each V-loop region, where the number of PNLG sites is shown on the y-axis and the time in days post-infection on the x-axis.  
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Changes in the frequency of selected PNLG sites varied considerably between participants 
during their respective infectious periods. While some PNLGs in all of the participants 
appeared to randomly fluctuate in frequency around the population mean, others displayed 
systematic and often quite substantial changes in frequency between the first and last 
sampling time points (Figure 3.7). For example, in CAP270, the PNLG site located at N400 
in the V4-loop, was present in 96% of the sequences at 56 days but no longer detected at 903 
days, whereas a PNLG site at N407 also in the V4-loop that was present in all sequences at 
56 days in this participant remained present in only 33% of sequences by the final sampling 
point at 903 days. Similarly in CAP217, the presence of a PNLG site at N463 varied in blood 
plasma and CVL sequences over the sampling period, decreasing from a frequency of 100% 
to 5% between 14 and 1316 days, while a PNLG site at N131 increased from a presence of 
0% to 49% during the same period.  
 
In CAP217, PNLGs at positions N130, N131 and N142 were detected for the first time at the 
final sampling point (1316 days) in approximately 29% of the sequences obtained from this 
time point. In CAP270, several PNLGs at N130, N135, N186, N187, N413, N460, N637 and 
N674 that were not present at the first sampling time point (i.e. 56 days) increased in 
frequency over the sampling period in both blood plasma and CVL viruses from this 
participant, where approximately 67% of these PNLGs occurred in the V-loop regions, with 
the exception of PNLGs at N130, N460, N637 and N674 that were located in the C1, C4 and 
C5 subregions respectively. 
 
As was previously reported, the presence and frequency of PNLGs at N332 and N334 were 
inversely related over the course of infection in participant CAP177 (Moore et al., 2012) 
(Figure 3.8). All sequences obtained at 14 and 28 days from both tissue types showed the 
presence of a PNLGs at N334 and absence of a PNLGs at N332 until 196 days, when both 
the N332 and N334 PNLGs were present in 9% of all sequences. By 378 days, PNLGs at 
N334 were no longer detected in any of the sequences, while PNLGs at N332 were present in 
91% of the sequences, and by 560 days had reached complete fixation before declining again 
to being no longer detected in any of the sequences at 1295 days (Figure 3.8). Over the same 
period, the presence of PNLGs at N234 increased from a 0% to 95% frequency in blood 
plasma and CVL sequences from CAP177.  
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In CAP261, PNLGs that occurred outside of V-loop regions included N356, which increased 
in frequency from being present in 53% of sequences at 63 days to 100% at 945 days, while 
PNLGs at sites N460 and N743 decreased from complete fixation at 63 days to complete 
extinction at 945 days. Although there were some distinct changes in the frequency of 
PNLGs, sites that remained present in all four participants included N156, N160, N301 and 
N386, with similar patterns observed only at PNLG sites N156 (V1-loop) and N301 (V3-
loop), both of which remained present in blood plasma and CVL sequences throughout the 
sampling period. 
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Figure 3.8 Time-ordered Bayesian maximum clade credibility (MCC) tree for CAP177 under 
the GTR + G4 substitution model and a constant population size relaxed clock evolutionary 
model, with branches coloured according to the presence of a PNLG site at position N332 
(red) or N334 (black) on the translated gp120 region. Posterior probabilities > 90% are 
indicated by a filled circled and > 70% by an open circle at the nodes, with branch labels 
coloured according to the time points sampled. 
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PNLG changes were initially evaluated within the V-loop regions, as this is where 
considerable changes in glycosylation accumulation were expected. To do this, the total 
number of PNLGs in blood plasma sequences was compared to those in CVL sequences at 
each of the time points sampled per participant (Table 3.14).  
 
Table 3.14 Statistical assessment of tissue-specific differences in the total number of PNLGs 
within the V-loop regions, using the Mann-Whitney and Wilcoxin signed-ranked non-
parametric tests. Tests where the standard deviation was equal to zero or where an “invalid 
floating point operation” error was received (i.e. where GraphPad was unable to fit the data 
using the selected model and options (Motulsky, 2003)), are indicated by the “–” symbol. P-
values below 0.05 for both tests were considered as credible evidence of significant tissue-
specific differences between PNLGs numbers. 
 
Participant)ID) HIV.1)env)region) Days)p.i.) Mann.Whitney)U)test! Wilcoxin)signed.rank)
) ! ! U!value! p/value! W!value! p/value!
CAP177) V1V2! 28! –! –! –! –!
) ! 378! 128! 0.1170! 21! 0.2500!
) ! 560! 42! 0.0191! 10! 0.1250!
) ! 1295! 254! 0.0078! /61! 0.0327!
) V4! 28! –! –! –! –!
) ! 378! 104! 0.4606! –! –!
) ! 560! 34! 0.0244! –! –!
) ! 1295! 289! 0.0002! /105! 0.0001!
) V5! 28! –! –! –! –!
) ! 378! 106! 0.5340! 1! >!0.9999!
) ! 560! –! –! –! –!
) ! 1295! 213! 0.1503! 18! 0.2500!
CAP217) V1V2! 63! 260! 0.0515! 27! 0.0547!
) ! 420! 17! 0.7621! 0! >!0.9999!
) ! 770! –! –! –! –!
) ! 1316! 241! 0.0600! 51! 0.2435!
) V4! 63! –! –! –! –!
) ! 420! –! –! –! –!
) ! 770! –! –! –! –!
) ! 1316! –! –! –! –!
) V5! 63! –! –! –! –!
) ! 420! –! –! –! –!
) ! 770! 25! 0.0578! –! –!
) ! 1316! –! –! –! –!
!
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Participant)ID) HIV.1)env)region) Days)p.i.) Mann.Whitney)U)test! Wilcoxin)signed.rank)
) ! ! U!value! p/value! W!value! p/value!
CAP261) V1V2! 63! 191! 0.6646! 3! 0.8438!
) ! 413! 102! 0.0216! 26! 0.0313!
) ! 945! 55! 0.!7071! /4! 0.6250!
) V4! 63! 219! 0.2058! /22! 0.2754!
) ! 413! 85! 0.1771! 10! 0.1875!
) ! 945! 53! 0.8146! /4! 0.5000!
) V5! 63! –! –! –! –!
) ! 413! 69! 0.8590! 3! 0.8125!
) ! 945! –! –! –! –!
CAP270) V1V2! 56! –! –! –! –!
) ! 147! 32! 0.9443! 0! >!0.9999!
) ! 231! –! –! –! –!
) ! 406! 78! 0.4203! 9! 0.3125!
) ! 595! 18! 0.9294! 4! 0.6250!
) ! 903! 62! 0.9281! 0! >!0.9999!
) V4! 56! 86! 0.4096! –! –!
) ! 147! 34! 0.8577! 0! >!0.9999!
) ! 231! 49! 0.4256! /3! 0.5000!
) ! 406! –! –! –! –!
) ! 595! –! –! –! –!
) ! 903! 69! 0.4020! 3! 0.5000!
) V5! 56! –! –! –! –!
) ! 147! –! –! –! –!
) ! 231! –! –! –! –!
) ! 406! –! –! –! –!
) ! 595! –! –! –! –!
) ! 903! 64! 0.6981! 0! >!0.9999!
 
Significant differences in PNLGs between blood plasma and CVL viruses in the V-loop 
regions were found at five isolated time points among all participants, as confirmed through 
Mann-Whitney and Wilcoxin signed-rank testing. In CAP177, significant tissue-specific 
differences in the number of PNLGs were detected in the V1V2 and V4-loops of viruses 
sampled at 560 and 1295 days. Similar differences were identified in CAP261 within the 
V1V2-loops at 413 days, whereas no such differences were detected in participants CAP217 
and CAP270.  
 
When comparing PNLGs across the full-length gp120 region however, significant differences 
between PNLGs numbers in blood plasma and CVL sequences were evident in all 
participants predominantly towards the later stages of infection (Table 3.15). 
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Table 3.15 Statistical assessment of tissue-specific differences in the total number of PNLGs 
along the HIV-1 env gp120 region, using the Mann-Whitney and Wilcoxin signed-ranked 
non-parametric tests. Tests where the standard deviation was equal to zero or where an 
“invalid floating point operation” error was received (i.e. where GraphPad was unable to fit 
the data using the selected model and options (Motulsky, 2003)), are indicated by the “–” 
symbol. P-values below 0.05 for both tests were considered as credible evidence of 
significant tissue-specific differences between PNLGs numbers. 
 
Participant)ID) HIV.1)env)region) Days)p.i.) Mann.Whitney)U)test! Wilcoxin)signed.rank)
) ) ) U)value) p.value) W)value) p.value)
CAP177) Full/length!gp120! 28! –! –! –! –!
) ! 378! 127! 0.1331! 23! 0.0469!
) ! 560! 38! 0.0092! 15! 0.0625!
) ! 1295! 282! 0.0007! /126! 0.0003!
CAP217) Full/length!gp120! 63! 247! 0.1556! 30! 0.2661!
) ! 420! 18! 0.6233! /2! 0.8750!
) ! 770! 18! 0.6411! 2! 0.7500!
) ! 1316! 249! 0.0382! 67! 0.1540!
CAP261) Full/length!gp120! 63! 197! 0.6295! /6! 0.8311!
) ! 413! 113! 0.0032! 36! 0.0078!
) ! 945! 69! 0.1456! /31! 0.0234!
CAP270) Full/length!gp120! 56! 88! 0.4090! /3! 0.5000!
) ! 147! 48! 0.0676! 15! 0.1563!
) ! 231! 45! 0.8069! /1! >!0.9999!
) ! 406! 109! 0.0041! 21! 0.0313!
) ! 595! 19! 0.8453! 0! >!0.9999!
) ! 903! 96! 0.0152! 31! 0.0234!
 
Significant differences in the number of PNLGs between tissue-types was found at 4 of the 
17 time points where samples from both tissues were available (Table 3.15), most of which 
(± 3) occurred within the later sampling time points among all participants. Generally, there 
were more PNLGs gained than lost during disease progression and tissue-specific differences 
became evident during later sampling points, when viruses were more diverse than 
populations present at earlier time points as expected. 
!
! !
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3.6.1 Clustering!of!PNLG!sites!on!phylogenetic!trees!
To gain an insight into the evolutionary relationship between PNLGs accumulation and 
disease progression, PNLG sites were mapped to Bayesian MCC trees (previously produced 
in section 3.2.3). While it was evident that there was an overall increase in the number of 
glycosylation sites among all participants over the sampling period, it was unclear if PNLG 
site accumulation occurred discretely or within genetically related sequences. To evaluate 
this, PNLG sites that appeared in an increasing number of sequences over time, were assessed 
for clustering on phylogenetic trees.  
 
Table 3.16 PNLG sites showing evidence of increasing frequency within gp120 subregions 
in blood plasma and CVL viruses over the course of infection. PNLGs indicated in red text 
were of particular interest as they showed a rise in occurrence in more than one participant 
during the sampling period, whereas PNLGs in black showed an increase in a single 
participant only.  
Participant)ID) HIV.1)env)region) PNLGs)relative)to)HXB2)) Total)PNLGs)
CAP177) C1! N130! 1!
) V1V2! N137,!N139,!N141,!N142,!N186! 5!
) C2! N234! 1!
) V4! N393! 1!
) C4! N442,!460! 2!
) C5! N674! 1!
CAP217) V1V2! N131,!N142,!N190! 3!
CAP261) V1V2! N141,!N187,!N190! 3!
) C3! N356! 1!
) V4! N386,!N408,!N413! 3!
CAP270) C1! N130! 1!
) V1V2! N135,!N186,!N187! 3!
) V4! N413! 1!
) C5! N637,!N674! 2!
 
From the total of 28 PNLGs that showed a clear rise in frequency over time, 16 were detected 
in more than one participant, 10 of which were located in the V1V2-loop. When PNLG sites 
where then mapped to Bayesian MCC trees, glycosylation sites appeared in monophyletic 
clades containing two or more sequences for all 16 PNLGs that were mapped (Figures 3.9a-
d), consistent with patterns of selection (Cherry et al., 2009).  
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!
 
Figure 3.9a Time-ordered Bayesian maximum clade credibility trees illustrating potential N-
linked glycosylation sites N141, N142, N186 and N460 in participant CAP177. Participant 
ID and the PNLG site that is mapped per tree are shown in the black box above each tree, 
with red branches indicating sequences that contained the PNLG site listed above. 
CAP177 - N141 CAP177 - N142 
CAP177 - N186 CAP177 - N460 
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!
Figure 3.9b Time-ordered Bayesian maximum clade credibility trees illustrating potential N-
linked glycosylation sites N674, N142, N190 and N141 in participants CAP177, CAP217 and 
CAP261 respectively. Participant IDs and the PNLG site that is mapped per tree are shown in 
the black box above each tree, with red branches indicating sequences that contained the 
PNLG site listed above.  
CAP177 - N674 CAP217 - N142 
CAP217 - N190 CAP261 - N141 
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!!
Figure 3.9c Time-ordered Bayesian maximum clade credibility trees illustrating potential N-
linked glycosylation sites N187, N190, N413 and N130 in participants CAP261 and CAP270. 
Participant IDs and the PNLG site that is mapped per tree are shown in the black box above 
each tree, with red branches indicating sequences that contained the PNLG site listed above. 
CAP261 - N187 CAP261 - N190 
CAP261 - N413 CAP270 - N130 
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!
Figure 3.9d Time-ordered Bayesian maximum clade credibility trees illustrating potential N-
linked glycosylation sites N186, N187, N413 and N674 in participant CAP270. Participant 
ID and the PNLG site that is mapped per tree are shown in the black box above each tree, 
with red branches indicating sequences that contained the PNLG site listed above. !
CAP270 - N186 CAP270 - N187 
CAP270 - N413 CAP270 - N674 
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3.7 Intrapatient!recombination!detection!
To identify potential recombinants, full-length gp120 env blood plasma and CVL sequences 
were analysed from all participants. Evidence of recombination was detected in three of the 
four participants analysed using RDP4, however since samples from the initial time of 
infection were not available for any of the participants, the transmission of recombinants at 
the point of infection could not be ruled out (Abrahams et al., 2009).  
 
A total of 17 unique, statistically significant recombination events (p-value < 0.05 after 
Bonferroni correction) were identified using RDP4 (Table 3.17), approximately 71% of 
which were identified in sequences from mid to late sampling points in participants CAP177 
(Figure 3.10a) and CAP261 (Figure 3.10b), whereas all recombinants detected in CAP270 
occurred during the last sampling point at 903 days post-infection (Figure 3.10c). Table 3.17 
shows an overview of unique recombination events detected in CAP177, CAP261 and 
CAP270. Although no recombination breakpoints were detected in viral populations from 
CAP217, recombination is believed to be present at an undetectable level in this participant.   
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Table 3.17 Summary of unique intrapatient recombination events detected among CAP177, CAP217 and CAP261 env sequences. RDP4 
methods with supporting p-values and recombination block graphs are shown. Striped regions within the recombination block graphs represent 
fragments of the gp120 sequence where recombination was predicted, while the absence of p-values signify recombination events that were not 
detected by the selected method.  
! Event!number! Recombination!block!pattern! Recombination!detection!analysis!p6value!
! ! ! RDP! GENECOV! BootScan! MaxChi! Chimaera! Siscan! 3Seq!
CA
P1
77
!
1! ! –! –! 4.014!x!10
A04! 1.599!x!10A02! 2.147!x!10A02! 6.185!x!10A07! 1.981!x!10A05!
2! ! 2.260!x!10
A02! 1.358!x!10A02! 2.240!x!10A03! –! –! –! 9.287!x!10A05!
3! ! –! –! 1.120!x!10
A02! 3.293!x!10A03! –! –! 9.119!x!10A02!
4! ! –! –! –! 1.083!x!10
A02! 9.366!x!10A04! 3.345!x!10A05! 1.750!x!10A05!
5! ! 1.506!x!10
A05! 2.582!x!10A06! 5.607!x!10A06! 3.881!x!10A03! 1.129!x!10A03! 5.133!x!10A05! 1.568!x!10A04!
6! ! 8.449!x!10
A03! 4.250!x!10A02! 1.626!x!10A02! 8.182!x!10A04! 2.622!x!10A03! 2.261!x!10A06! 2.182!x!10A02!
7! ! –! –! –! 3.751!x!10
A04! 5.892!x!10A04! 2.437!x!10A04! 2.254!x!10A06!
8! ! –! –! –! A! 4.402!x!10
A02! 5.722!x!10A04! 5.366!x!10A03!
CA
P2
61
!
1! ! 4.089!x!10
A03! 1.588!x!10A02! 4.475!x!10A03! 1.403!x!10A02! 3.447!x!10A02! 1.144!x!10A02! 1.119!x!10A04!
2! ! 1.540!x!10
A04! 2.038!x!10A03! 6.184!x!10A04! 3.625!x!10A07! 9.851!x!10A07! 6.988!x!10A10! 2.632!x!10A08!
3! ! 3.507!x!10
A03! –! 3.544!x!10A03! –! –! –! 1.671!x!10A02!
4! ! 2.554!x!10
A04! 3.699!x!10A05! 1.256!x!10A05! 1.775!x!10A05! 4.521!x!10A04! 1.858!x!10A06! 3.865!x!10A08!
5! ! 2.264!x!10
A02! –! 1.553!x!10A02! 3.281!x!10A05! 4.693!x!10A05! 3.045!x!10A04! 1.300!x!10A04!
6! ! –! 9.283!x!10
A03! 8.117!x!10A04! 2.797!x!10A01! –! 4.006!x!10A04! –!
7! ! –! –! –! 6.889!x!10
A04! 1.289!x!10A02! –! 9.173!x!10A03!
8! ! 4.637!x!10
A05! 7.656!x!10A03! 4.671!x!10A05! 8.297!x!10A05! 3.302!x!10A03! 1.266!x!10A07! –!
CA
P2
70
! 1! ! –! –! 3.644!x!10
A02! 9.973!x!10A01! –! 6.894!x!10A04! –!
! !!
! !!
!!
!!
! !!
!!
! !!
!!
!!
!!
!!
!!
!!
!!
!!
!!
!!
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Figure 3.10a Time-scaled Bayesian MCC tree for CAP177 indicating sequences in which 
recombination breakpoints were detected using RDP4. Recombination block graphs 
displayed to the right of taxon names indicate unique recombination events as listed in Table 
3.17. Branches are coloured according to the most probable state of their tissue origin where 
red represents viruses from the blood plasma and black indicates viruses from the cervix. 
Posterior probabilities > 90% are indicated by a filled circled and > 70% by an open circle at 
the nodes, with branch labels coloured according to the time points sampled. 
!!
Time!(days!post.infec2on)!
0.0500.01000.01500.02000.02500.0
6-blood-924days
4-blood-924days
114-cvl-378days
10-blood-1295days
21-cvl-378days
19-blood-1295days
12C-blood-28days
7-blood-924days
6-cvl-378days
7-cvl-28days
22-blood-1295days
5-blood-560days
26-blood-378days
29-cvl-28days
71-cvl-1295days
103-cvl-378days
21-blood-1295days
8-blood-1295days
H7-blood-196days
9-blood-1295days
124-cvl-1295days
136-cvl-1295days
142-cvl-378days
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A4-blood-14days
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4-cvl-378days
E7-blood-196days
38-cvl-28days
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32-blood-378days
2-blood-560days
12A-blood-28days
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11-blood-1295days
H8-blood-196days
24-blood-1295days
119-cvl-378days
148-cvl-1295days
A13-blood-14days
TB9-blood-14days
16-blood-1295days
112-cvl-1295days
8-blood-560days
150-cvl-378days
A10-blood-14days
73-cvl-1295days
7-blood-560days
H9-blood-196days
A11-blood-14days
63-cvl-378days
TB11-blood-14days
56-cvl-378days
1-blood-378days
132-cvl-28days
6-blood-1295days
1-cvl-28days
29-cvl-560days
D7-blood-196days
13-cvl-560days
B8-blood-196days
TB3-blood-14days
9-blood-560days
75-cvl-28days
12-blood-1295days
20-blood-1295days
A2-blood-14days
32-cvl-924days
113-cvl-1295days
A1-blood-14days
3-cvl-28days
6-cvl-1295days
83-cvl-1295days
5-blood-1295days
76-cvl-28days
G7-blood-196days
2-blood-924days
A3-blood-14days
A7-blood-196days
65-cvl-28days
7-blood-1295days
40-cvl-1295days
B13-blood-14days
117-cvl-1295days
11-blood-378days
12G-blood-28days
G8-blood-196days
146-cvl-378days
13-blood-378days
87-cvl-378days
F7-blood-196days
125-cvl-28days
134-cvl-28days
7D-blood-28days
A12-blood-14days
96-cvl-28days
11D-blood-28days
146-cvl-1295days
10D-blood-28days
23-blood-1295days
92-cvl-378days
46-blood-378days
TB8-blood-14days
49-cvl-28days
TB2-blood-14days
14-blood-1295days
8D-blood-28days
59-cvl-28days
1-blood-560days
44-blood-378days
12F-blood-28days
TB6-blood-14days
TB1-blood-14days
36-blood-378days
76-cvl-1295days
24-cvl-560days
B7-blood-196days
9A-blood-28days
132-cvl-378days
23-cvl-1295days
63-cvl-28days
17-cvl-28days
9G-blood-28days
7-blood-378days
117-cvl-378days
138-cvl-378days
!! !!!!
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!!!! !!!!
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Figure 3.10b Time-scaled Bayesian MCC tree for CAP261 indicating sequences in which 
recombination breakpoints were detected using RDP4. Recombination block graphs 
displayed to the right of taxon names indicate unique recombination events as listed in Table 
3.17. Branches are coloured according to the most probable state of their tissue origin where 
red represents viruses from the blood plasma and black indicates viruses from the cervix. 
Posterior probabilities > 90% are indicated by a filled circled and > 70% by an open circle at 
the nodes, with branch labels coloured according to the time points sampled. 
  
0.0500.01000.01500.02000.02500.03000.0
47-cvl-945days
49-blood-63days
18-blood-945days
98-blood-63days
41-blood-413days
2-cvl-945days
159-blood-63days
17-cvl-63days
11-cvl-413days
44-cvl-945days
70-cvl-63days
9-blood-945days
2-cvl-63days
29-cvl-413days
11-cvl-945days
20-blood-413days
49-cvl-413days
37-blood-413days
34-blood-413days
95-blood-63days
24-blood-413days
26-blood-63days
25-cvl-63days
4-blood-63days
31-cvl-945days
156-blood-63days
26-cvl-945days
93-cvl-63days
5-cvl-945days
38-cvl-63days
42-cvl-945days
59-cvl-63days
110-blood-63days
7-cvl-413days
59-cvl-945days
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11-cvl-63days
13-blood-945days
10-blood-945days
41-blood-63days
43-cvl-945days
31-blood-63days
36-blood-63days
88-cvl-63days
15-blood-413days
42-cvl-413days
120-blood-63days
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25-blood-945days
67-cvl-63days
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28-cvl-63days
23-blood-945days
52-cvl-413days
37-cvl-413days
13-blood-413days
87-blood-63days
53-cvl-63days
100-blood-63days
65-cvl-63days
19-blood-945days
26-blood-413days
30-cvl-413days
66-cvl-413days
45-blood-413days
16-blood-413days
1-cvl-63days
17-blood-945days
47-blood-63days
57-cvl-413days
5-cvl-413days
44-cvl-63days
41-cvl-63days
2-blood-63days
51-blood-63days
1-blood-63days
153-blood-63days
22-blood-945days
6-blood-945days
66-cvl-63days
50-blood-413days
Time%(days%post.infec2on)%
Posterior probability support!
>90% 
>70% 
Unlabeled  <70% 
Blood plasma 
CVL 
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Figure 3.10c Time-scaled Bayesian MCC tree for CAP270 indicating sequences in which 
recombination breakpoints were detected using RDP4. Recombination block graphs 
displayed to the right of taxon names indicate unique recombination events as listed in Table 
3.17. Branches are coloured according to the most probable state of their tissue origin where 
red represents viruses from the blood plasma and black indicates viruses from the cervix. 
Posterior probabilities > 90% are indicated by a filled circled and > 70% by an open circle at 
the nodes, with branch labels coloured according to the time points sampled. 
0.0250.0500.0750.01000.01250.0
73-cvl-56days
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6-cvl-231days
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42-blood-56days
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72-blood-406days
39-cvl-595days
95-cvl-406days
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47-cvl-406days
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56-cvl-56days
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3-blood-903days
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Figure 3.11 Summary of unique recombination events and recombinant sequences detected 
in participants CAP177 and CAP261. In CAP177, two unique recombination events were 
found in the majority of sequences, i.e. event 1 (47%) and event 5 (7%) whereas in CAP261, 
recombination events 1 and 2 were detected in the majority of sequences (40% and 11% 
respectively). There were also a few sequences that contained more than one recombination 
event in CAP177 (n = 8) and CAP261 (n = 2), however none of these recombinant sequences 
were unique to a particular tissue type or stage of infection.  
 
The first recombination event in CAP177 (event 1) was detected at 14 days and subsequently 
at 28, 196 and 378 days, after which sequences displaying this event were no longer, found 
(Figure 3.10a). In sequences sampled at 28 days two further unique recombination events 
were detected (events 2 and 3) followed by another two at 196 days (events 4 and 5), then a 
single new event at 378 days (event 6) and finally, two new events at 1295 days (events 7 and 
8).  
 
In CAP261, the first recombination event (event 1) was detected in sequences sampled at 63 
days after which it was no longer found. Three further unique recombination events then 
emerged at 413 days (events 2, 3 and 4) followed by another four at 945 days (events 5, 6, 7 
and 8) (Figure 3.10b). Whereas in CAP270, the first and only detectable recombination event 
was found at 903 days, which was the last time point sampled for this participant (Figure 
3.10c).  
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3.7.1 Tissue*specific.recombination.signatures.
When the total numbers of recombinants were tallied per tissue type and time point no tissue-
specific differences were evident. In CAP177, there were no CVL sequences available for 
comparison with blood plasma sequences at 14 and 196 days, whereas at 924 days only a 
single HIV-1 amplicon from the CVL was available compared to a total of four sequences 
from the blood plasma (Figure 3.12).  
 
Figure 3.12 Percentage of recombinant viruses detected in blood plasma and CVL sequences 
from CAP177 over the sampling period. Time points where no recombinant sequences were 
detected within blood plasma or CVL samples are indicated by whitespaces. 
 
The total number of recombinants appeared to fluctuate in CVL viral populations through 
time while the number of detectable recombinants in the blood plasma declined over the 
sampling period.  
!
Patterns of recombination were further evaluated by analysing data related to parental 
sequences, including the tissue of origin and time points at which each parental sequence was 
detected. The percentage of total recombinant sequences with major and minor parents from 
the same or an earlier time point increased from 0% at 14 days to 79% at 378 days in 
CAP177, while recombinants with at least one parent from a later time point decreased from 
100% at 14 days to 0% at 1295 days. No recombinants with a parent from a later time point 
could have been estimated at 1295 days as this was the last time point sampled in CAP177. 
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The number of recombinants with parents from the same tissue type also remained low (0 – 
3%) at all time points, except at 378 days (17%), while the number of recombinants with 
parents from different tissue types was much higher but fluctuated from 100% at 14 days to 
62% at 378 days, and finally to 8% at 1295 days. Nevertheless at all time points tested, there 
were more recombinants comprised of parents from different tissue types compared to those 
with parents from the same tissue type in this participant. One of the weaknesses of this 
approach however was that parents of recombinant sequences could have been unsampled at 
earlier time points, therefore if a major parent was found to be sampled after the time point 
when the recombinant sequence was detected for example, it is likely that the actual parent of 
the recombinant sequence could have been a relative of the predicted parental sequence, as 
estimated by RDP4. 
 
 
Figure 3.13 Percentage of recombinant viruses detected in blood plasma and CVL samples 
sequences from CAP261 over the sampling period. Although there were only sequences 
available from three time points for CAP261, the total number of recombinants fluctuated in 
frequency between 63 and 945 days in CVL sequences, whereas the number of recombinants 
in the blood plasma declined in frequency over the same period. Among the recombinant 
variants found in CAP261, 83% were comprised of a major and minor parent from the same 
tissue type whereas only 17% were made up of parents from different tissue types. A total of 
36% were recombinant variants comprised of parents from the same or an earlier time point, 
while 64% were variants with at least one parent from a later time point.  
0!
20!
40!
60!
80!
100!
63! 413! 945!
%
"R
ec
om
bi
na
nt
s"
Days"post1infec3on"
CAP261 
Blood!plasma! CVL!
 
 
 
 
! 108!
When recombinants were analysed per time point the number of recombinants with major 
and minor parents from the same or an earlier time point increased from an absence in all 
sequences at 63 days to a presence in all sequences at 945 days. Recombinants with at least 
one parent from a later time point decreased from 100% at 63 days to 0% at 945 days, 
however no recombinants with a parent from a later time point could have been estimated at 
945 days as this was the last time point sampled in CAP261. The total percentage of 
recombinants with parents from the same tissue type also decreased from 100% at 63 days, to 
37% at 945 days, whereas the number of recombinants with parents from different tissue 
types increased from 0% at 63 days to 25% at 413 days, and finally to 75% at 945 days.  
 
 
Figure 3.14 Percentage of recombinant viruses detected in blood plasma and CVL sequences 
from CAP270 over the sampling period. Time points where no recombinant sequences were 
detected within blood plasma or CVL samples are indicated by whitespaces.  
 
Despite the availability of sequences from six time points for CAP270, only five recombinant 
sequences were detected at 903 days, three in the blood plasma and two in the CVL. All 
detected recombinant viruses were inferred to have minor and major parents from different 
tissue types, and showed no evidence of tissue-specific recombination.  
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3.7.2 Relationship.between.glycosylation.and.recombination..
To test the hypothesis that the accumulation of potential N-linked glycosylation sites 
(PNLGs) along the env gene may be associated with recombination, all recombinant 
sequences were analysed for the location of recombination breakpoints. Although the 
detection of precise breakpoint positions are estimations only (Lamers et al., 2009), probable 
breakpoint positions from RDP4 were translated to amino acid base positions and compared 
to PNLG sites (predicted in section 3.6), across the gp120 region for each participant.  
 
Table 3.18 Average number of PNLG sites within HIV-1 env subregions before and after the 
occurrence of a recombination event in CAP177, CAP217 and CAP270. Only regions where 
recombination events were detected between matched samples are shown below. Regions 
where the average number of PNLGs increased after the occurrence of a recombination event 
is shown in red text, with regions where the average number of PNLGs decreased after the 
occurrence of a recombination event shown in blue text. Regions where no change in the 
average number of PNLGs occurred before or after a recombination event are indicated in 
black text.  
 
Participant"ID" HIV11"env"region" Average"number"of"PNLGs"
" ! Before!or!at!first!recombinant! After!or!at!last!recombinant!
CAP177" FullBlength!gp120! 23! 31!
" V1V2! 4! 8!
" V4! 3! 3!
" V5! 2! 1!
" C1! 1! 2!
" C2BC3! 8! 9!
" C4! 1! 3!
" C5! 4! 5!
CAP261" FullBlength!gp120! 29! 32!
" V1V2! 7! 8!
" V4! 3! 4!
" V5! 1! 1!
" C1! 1! 1!
" C2BC3! 10! 10!
" C4! 3! 2!
" C5! 5! 4!
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Participant"ID" HIV11"env"region" Average"number"of"PNLGs"
" ! Before!or!at!first!recombinant! After!or!at!last!recombinant!
CAP270" Full!length!gp120! 31! 30!
" C1! 1! 2!
" C5! 4! 4!
 
A distinct difference in the average number of PNLGs before and after the occurrence of a 
recombination event was observed in all participants where recombination was detected. In 
53% of the env subregions analysed, there was an increase in the number of PNLGs after the 
occurrence of a recombination event, whereas in only 21% there was a decrease in the 
number of PNLGs following recombination (Table 3.18). In 26% of the regions analysed, no 
change in PNLGs accumulation was observed before or after a recombination event.  
 
In CAP177, there was an increase in the number of PNLGs in all regions analysed except in 
the V3 and V5-loops (Table 3.18), however differences between PNLGs numbers before and 
after the occurrence of a recombination event were not statistically significant (Mann-
Whitney p-value > 0.5604). In CAP261, although there were env regions where the number 
of PNLGs increased, decreased or remained unchanged following a recombination event, 
overall there was a greater number of regions where there was an increase in the number of 
PNLGs after recombination (Mann-Whitney p-value > 0.9999). Unsurprisingly, regions 
where there was no change in the number of PNLGs were mostly limited to regions of low 
variability, i.e. conserved regions C1, C2, C3, C5 and the V4-loop (Table 3.18).  
 
In CAP270 all of the recombinant regions detected occurred in the conserved regions of the 
env gene (C1 and C5), and although a slight rise in the number of PNLGs was evident in 
sequences from this participant within the C1 region, bearing the signature of this 
recombination event the increase was not significant (Mann-Whitney p-value > 0.8248).  
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3.8 Codon*based.selection.analysis.
Selection analysis was performed using four different methods including the Single 
Likelihood Ancestor Counting (SLAC) method, the Fixed Effect Likelihood (FEL) method, 
the Mixed Effects Model of Evolution (MEME) and the Fast Unbiased Bayesian 
AppRoximation (FUBAR) method. Based on recommendations from other authors, only sites 
that were identified by at least three of these methods with significant statistical support (p < 
0.05 or Posterior probability > 0.9) were considered as credible evidence of positive or 
negative selection (Wlasiuk & Nachman, 2010; Castel et al., 2014).  
 
Table 3.19 Percentage of amino acid (aa) sites identified as being under positive or negative 
selection along the gp120 region in blood plasma and CVL sequences using FUBAR, FEL 
and SLAC methods. Sites under negative selection were not tested for by MEME and have 
therefore been excluded from the table below. The “(+)” symbol indicates the total 
percentage of sites identified as being under positive selection, with “(-)” indicating the 
percentage of sites under negative selection.   
Method" Participant"ID"
" CAP177! CAP217! CAP261! CAP270!
" (+)! (B)! (+)! (B)! (+)! (B)! (+)! (B)!
FUBAR" 48%! 52%! 60%! 40%! 54%! 46%! 37%! 63%!
FEL" 39%! 61%! 27%! 73%! 30%! 70%! 22%! 78%!
SLAC" 38%! 62%! 19%! 81%! 15%! 85%! 29%! 71%!
 
Selection analyses revealed between 40% (with FUBAR) and 85% (with SLAC) of 
negatively selected sites in CAP217 and CAP261 respectively, and between 15% (with 
SLAC) and 60% (with FUBAR) of positively selected sites in CAP261 and CAP217 (Table 
3.19). Overall, there was more evidence of sites under negative selection (65%) than positive 
selection (35%) among all participants, consistent with selection signatures observed by 
others (Bazykin et al., 2006; Frank, 2002). Nevertheless, strong evidence of positive selection 
was detected for a number of sites in each participant, by all four methods (Table 3.20).  
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Table 3.20 Codon-based sites along the translated gp120 env region identified as being under 
positive selection in each participant using SLAC, FEL, MEME and FUBAR methods. The 
“*” symbol indicates sites with significant statistical support for positive selection that 
coincided with a PNLG site on the translated env gene, with sites that were predicted by all 
four methods indicated in red text. 
Participant"ID"" Method"
" FUBAR! FEL! MEME! SLAC!
CAP177" 82,!139,!158,!281,!
294,!304,!306,!308,!
333,!342,!349*,!363,!
366,!367,!419,!424*,!
438,!453,!664,!687,!
756,!820,!823,!825,!
829,!876!
158,!281,!294,!304,!
306,!308,!333,!342,!
349*,!363,!366,!367,!
419,!424*,!438,!453,!
664,!687,!756,!820,!
823,!825,!829,!876!
82,!158,!281,!294,!
304,!306,!308,!333,!
342,!349*,!363,!366,!
367,!419,!424*,!438,!
453,!664,!687,!756,!
820,!823,!825,!829,!
876!
82,!158,!294,!306!
CAP217" 27,!129,!354,!472,!
474*,!509,!530,!800,!
833!!
27,!129,!354,!472,!
474*,!509,!530,!800,!
833!
27,!129,!354,!472,!
474*,!509,!530,!800,!
833!
27,!474*!
CAP261" 132,!189*,!359,!396,!
412*,!515,!655,!789,!
831!
132,!189*,!359,!396,!
412*,!515,!655,!789,!
831!
132,!189*,!359,!396,!
412*,!515,!655,!789,!
831!
189*,!359,!396,!
412*,!789!
CAP270" 129,!132,!154*,!180,!
182,!188,!293,!374,!
866!
129,!132,!180,!182,!
188,!293,!374,!866!
129,!132,!154*,!180,!
182,!188,!293,!374,!
866!
129,!132,!154*,!180,!
182,!188,!374,!866!
 
FUBAR, FEL and MEME results were mainly in agreement in their prediction of sites, 
whereas the SLAC method was more conservative. Evidence of positive selection was found 
in both conserved and variable regions along the gp120 env region in all participants. A total 
of 17 positively selected sites were detected by all four methods, three of which (aa 474 in 
CAP217, and aa sites189 and 412 in CAP261) were found to coincide with a previously 
predicted PNLG site. Overall, at least one site that was predicted to be under positive 
selection, coincided with a PNLG site in each participant (Table 3.20).  
 
To assess if there were any tissue-specific differences in selection patterns, blood plasma and 
CVL sequences were analysed separately per participant (Figure 3.15).  
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Figure 3.15 Number of sites identified as being under positive or negative selection in blood 
plasma and CVL sequences with significant statistical support by at least three different 
methods.  
 
In participants CAP261 and CAP270 almost identical selection signatures were seen in both 
tissues (i.e. between 93 and 98% equivalent), whereas in CAP177 and CAP217 noticeably 
larger differences were evident (Figure 3.15). In CAP177, 47% more sites were found to be 
under both positive and negative selection in sequences isolated from the blood plasma 
compared to the amount found in CVL sequences. In CAP217 there was a slightly smaller 
tissue-specific difference (38%), with more sites predicted in CVL sequences instead of 
blood plasma.   
!
3.9 Prediction.of.HIV*1.co*receptor.tropism.
Genotypic analysis of HIV-1 co-receptor tropism performed on the V3-loop region of all 
sequences obtained from the blood plasma and cervix showed that all except one sequence 
from CAP177 sampled at 378 days were CCR5-trophic. Upon closer inspection this sequence 
contained a deletion in the V3-loop, which resulted in a coding frame shift and an incorrect 
prediction, and was subsequently excluded from any further analyses. None of the 
participants experienced tropism changes between chronic and acute infection stages, despite 
this phenomenon having been previously associated with disease progression (Connor et al., 
1997; Burger & Hoover, 2008; Cecilia et al., 2000).  
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To further evaluate the role of the V3-loop in modulating gp120 structure, net charges were 
analysed. It has been reported that the V3-loops of CCR5-tropic viruses are usually less 
positively charged than CXCR4-tropic viruses and an increase in net charge has been linked 
to the conversion of CCR5-tropic viruses into CXCR4-tropic (Yokoyama et al., 2012; Speck 
et al., 1997; Fouchier et al., 1992; Kato et al., 1999). Positively charged amino acids at 
positions 11 and 25, increases in total net charge or decreases in the number of PNLGs in the 
V3-loop have also been associated with CXCR4 co-receptor usage (De Jong et al., 1992; 
Hoffman et al., 2002; Fouchier et al., 1995). 
 
On average, net charge analysis revealed a slightly higher V3-loop charge in viruses from the 
blood plasma compared to viruses from the cervix in all participants. From the total of 18 
time points where sequences were available from both tissue types among all participants, 7 
showed a higher V3-loop charge in viruses from the blood plasma, whereas an equal charge 
in both blood plasma and CVL viruses was seen at 9 time points, and 2 showed a higher 
charge in CVL viruses (Table 3.21).  
 
Table 3.21 Average V3-loop net charges of HIV-1 blood plasma and CVL env sequences. 
Time points at which the average V3-loop charge was higher in the blood plasma is indicated 
in red text, with higher charges in CVL sequences shown in blue.  
Participant"ID" Days"p.i." Average"V31loop"net"charge"
" ! Blood!plasma! CVL!
CAP177" 14! 4.00! –!
" 28! 4.00! 4.00!
" 196! 3.82! –!
" 378! 3.70! 3.68!
" 560! 4.25! 3.20!
" 924! 5.00! 5.00!
" 1295! 4.06! 4.06!
CAP217" 14! 6.00! –!
" 63! 6.00! 6.00!
" 420! 6.83! 6.40!
" 770! 6.00! 5.80!
" 1316! 3.84! 3.95!
CAP261" 63! 3.95! 3.84!
" 413! 3.91! 3.58!
" 945! 3.90! 3.90!
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Participant"ID" Days"p.i." Average"V31loop"net"charge"
" ! Blood!plasma! CVL!
CAP270" 56! 4.00! 4.00!
" 105! –! 4.00!
" 147! 4.00! 4.00!
" 231! 4.00! 4.00!
" 406! 4.00! 4.00!
" 595! 4.00! 4.00!
" 903! 3.80! 3.83!
 
Although there were sequences available from more time points in some participants than 
others, overall considerably higher V3-loop net charges were found in blood plasma 
sequences. No consistent tissue-specific patterns in V3-loop net charges could be inferred in 
each participant, however based on reports from literature, there is a more likely possibility of 
co-receptor switching in viruses present in the blood plasma compared to those present in the 
cervix further into disease progression, based on the higher positive V3-loop net charges 
within sequences from this tissue. 
!
3.10 Identification.of.APOBEC*induced.hypermutation..
No evidence for the presence of hypermutation was found in any of the sequences from the 
blood plasma or CVL in any participant (Fisher’s Exact test p > 0.05), however, a higher 
number of G to A mutations were detected in sequences from all participants and in both 
tissue types, with the exception of CVL sequences from participant CAP177 (Figure 3.16a). 
A larger number of A to G mutations were seen in CVL sequences from CAP177 at all time 
points where sequences from both tissues were available, throughout the sampling period. 
Interestingly, the opposite pattern was observed in blood plasma sequences from CAP177, 
where G to A mutations were consistently higher throughout the course of infection (Figure 
3.16a).  
 
In participants CAP217 and CAP270, both G to A and A to G mutation patterns were alike in 
both tissues (Figure 3.16a-b). Sequences from the blood plasma showed only a slight 
difference in the average numbers of G to A and A to G mutations in CAP261, whereas in 
CVL sequences, considerable differences between all sampled time points were detected 
(Figure 3.16b). Generally, hypermutation patterns remained consistent in all participants and 
in both blood plasma and CVL sequences, i.e. either more G to A mutations or more A to G 
mutations that persisted throughout the sampling period.     
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!
Figure 3.16a Column chart depicting hypermutation patterns within blood plasma and CVL sequences from participants CAP177 and CAP217 
over the course of infection. The average numbers of Guanine to Adenine (G to A) mutations are shown in black, with the average numbers of 
Adenine to Guanine (A to G) mutations shown in red. Time points where G to A or A to G mutations were not detected within blood plasma or 
CVL sequences are indicated by whitespaces.  
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!
Figure 3.16b Column chart depicting hypermutation patterns within blood plasma and CVL sequences from participants CAP261 and CAP270 
over the course of infection. The average numbers of Guanine to Adenine (G to A) mutations are shown in black, with the average numbers of 
Adenine to Guanine (A to G) mutations shown in red. Time points where G to A or A to G mutations were not detected within blood plasma or 
CVL sequences are indicated by whitespaces. 
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3.11 Length*variation*within*the*env*V2loop*regions*
V-loop lengths generally increased over the sampling period in all of the V-loop regions 
except in V3 and V5-loops in all participants’ sequences, irrespective of tissue type (Figure 
3.17). The greatest increases in length were observed in the V1V2-loops, which ranged from 
56 amino acid (aa) bases in CAP217 to 81 bases in CAP270, while the V4-loop ranged from 
18 aa bases in CAP177 to 35 bases in CAP261, and in the V5-loop from 9 aa bases in 
CAP270 to 17 bases in CAP217 (Table 3.22).  
 
Table 3.22 Summary of the minimum, maximum, median and mean V1V2, V4 and V5-loop 
lengths in blood plasma and CVL sequences among all participants. Values shown in the 
table below indicate loop length in amino acid bases.  
Participant)ID) Statistic) V1V2) V4) V5)
) ! Blood)
plasma)
CVL) Blood)
plasma!
CVL! Blood)
plasma!
CVL!
CAP177) Mean! 63! 64! 20! 21! 13! 13!
) Median! 60! 62! 20! 20! 13! 13!
) Maximum! 80! 75! 26! 29! 15! 15!
) Minimum! 57! 57! 18! 18! 11! 11!
CAP217) Mean! 71! 69! 23! 22! 14! 14!
) Median! 74! 67! 23! 23! 17! 15!
) Maximum! 78! 74! 23! 23! 17! 17!
) Minimum! 56! 59! 20! 20! 10! 10!
CAP261) Mean! 72! 71! 28! 28! 14! 13!
) Median! 73! 73! 28! 28! 14! 12!
) Maximum! 77! 77! 29! 35! 17! 17!
) Minimum! 65! 60! 28! 22! 10! 10!
CAP270) Mean! 77! 76! 23! 24! 12! 12!
) Median! 76! 76! 22! 22! 12! 12!
) Maximum! 81! 81! 28! 28! 12! 15!
) Minimum! 66! 66! 19! 19! 9! 10!
 
CAP177 and CAP261 displayed similar average V-loop lengths (CAP177 mean = 32, range = 
11-80; CAP261 mean = 38, range = 10-77 respectively) over the sampling period compared 
to participants CAP217 and CAP270 (CAP217 mean = 35, range = 10-78; CAP270 mean = 
37, range = 9-81 respectively). Nevertheless, significant tissue-specific differences between 
V-loop lengths were discovered at isolated timepoints in the V1V2 and V4-loops in 
sequences from CAP177, CAP217 and CAP261, but not CAP270 (Table 3.23).  
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Figure 3.17 Variable-loop length changes in the V1V2, V4 and V5-loop regions among all participants over the sampling period. The actual V-
loop lengths per sample are presented on the scatterplot, separated by tissue type for each V-loop region, where the V-loop length is shown on 
the y-axis in amino acid bases and the time in days post-infection on the x-axis. 
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Table 3.23 Statistical assessment of tissue-specific differences in V-loop lengths using 
the Mann-Whitney and Wilcoxin signed-ranked non-parametric tests. Tests where the 
standard deviation was equal to zero or where an “invalid floating point operation” error 
was received (i.e. where GraphPad was unable to fit the data using the selected model 
and options (Motulsky, 2003)), are indicated by the “–” symbol. P-values below 0.05 for 
both tests were considered as credible evidence of significant tissue-specific differences 
between V-loop lengths. 
Participant)ID) HIV.1)env)region) Days)p.i.) Mann.Whitney))U)test)
!
Wilcoxin)signed.rank))
)
) ! ! U!value! p-value! W!value! p-value!
CAP177) V1V2! 28! –! –! –! –!
) ! 378! 125! 0.3798! 15! 0.4922!
) ! 560! 29! 0.2250! 11! 0.1875!
) ! 1295! 183! 0.7191! -7! 0.7646!
) V4! 28! –! –! –! –!
) ! 378! 133! 0.0452! –! –!
) ! 560! –! –! –! –!
) ! 1295! 234! 0.0394! -69! 0.0295!
) V5! 28! –! –! –! –!
) ! 378! 123! 0.3671! 9! 0.3125!
) ! 560! –! –! –! –!
) ! 1295! 172! 0.9845! -13! 0.3828!
CAP217) V1V2! 63! 255! 0.0763! 32! 0.0547!
) ! 420! 21! 0.3061! -4! 0.5000!
) ! 770! 24! 0.1114! -9! 0.3125!
) ! 1316! 289! 0.0001! 99! 0.0006!
) V4! 63! –! –! –! –!
) ! 420! –! –! –! –!
) ! 770! –! –! –! –!
) ! 1316! 204! 0.2616! 22! 0.3652!
) V5! 63! –! –! –! –!
) ! 420! –! –! –! –!
) ! 770! –! –! –! –!
) ! 1316! 181! 0.5634! -4! 0.5000!
CAP261) V1V2! 63! 200! 0.3098! 5! 0.3750!
) ! 413! 104! 0.0187! 40! 0.0117!
) ! 945! 65! 0.2040! -9! 0.3125!
) V4! 63! –! –! –! –!
) ! 413! –! –! –! –!
) ! 945! 55! 0.6960! -4! 0.6250!
) V5! 63! 189! 0.7090! 0! >!0.9999!
) ! 413! 84! 0.2710! 16! 0.3125!
) ! 945! 53! 0.8213! 0! >!0.9999!
!
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Participant)ID) HIV.1)env)region) Days)p.i.) Mann.Whitney))U)test)
!
Wilcoxin)signed.rank))
)
) ! ! U!value! p-value! W!value! p-value!
CAP270) V1V2! 56! –! –! –! –!
) ! 147! –! –! –! –!
) ! 231! –! –! –! –!
) ! 406! 70! 0.8331! 7! 0.5625!
) ! 595! 20! 0.7235! 4! 0.6250!
) ! 903! 68! 0.6247! 7! 0.4375!
) V4! 56! 87! 0.3827! –! –!
) ! 147! 43! 0.1058! -6! 0.2500!
) ! 231! 31! 0.1063! 0! >!0.9999!
) ! 406! –! –! –! –!
) ! 595! 19! 0.8028! -1! >!0.9999!
) ! 903! 71! 0.1864! 3! 0.5000!
) V5! 56! –! –! –! –!
) ! 147! –! –! –! –!
) ! 231! –! –! –! –!
) ! 406! –! –! –! –!
) ! 595! –! –! –! –!
) ! 903! 60! 0.9720! -13! 0.2969!
 
Significant differences in V-loop lengths between blood plasma and CVL sequences were 
only observed at three isolated time points (i.e. 3 of the 51 paired samples tested) among all 
participants. None of the estimated significant differences coincided with early stages of 
infection, and two of the three tests that were significant for tissue-specific differences in V-
loop lengths occurred within the V1V2-loops (Table 3.23), a region that is known to be highly 
variable. Generally however, although V-loops gradually increased in base length over the 
course of infection in all participants (Figure 3.17), changes were mostly similar in both blood 
plasma and CVL viruses (Table 3.23). 
!
3.11.1 Relationship/between/V3loop/expansion/and/PNLGs/accumulation/
In CAP177 both the number of PNLGs in the V1V2-loops and the lengths of these loops 
increased over time, ranging from 5 PNLGs and an average length of 57 amino acid bases at 
28 days, to 15 PNLGs and 74 bases in length at 1295 days, while V4-loop lengths increased 
moderately from 3 to 5 PNLGs between 14 and 1295 days (Figure 3.17).  
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A similar pattern was observed in CAP261, with increases in both the number of PNLGs and 
base length of the V1V2 and V4-loops over time, ranging from 8 to 11 PNLGs and an average 
length of 72 to 75 amino acid bases between 63 and 945 days in the V1V2-loop, and from 6 to 
9 PNLGs and 22 to 35 bases between 63 and 945 days in the V4-loop (Figure 3.17). 
 
In CAP217 and CAP270 all detectable PNLG site gains or losses occurred in the V1V2-loops 
in the former participant while almost half (47%) occurred in the latter. Overall there was an 
increase in V1V2-loop lengths ranging from 76 amino acid bases at 56 days to 81 bases at 903 
days in CAP270. In CAP217 V1V2-loop lengths ranged from 71 amino acid bases at 63 days 
to 70 bases at 1316 days. Similarly in CAP270, increases in the length of the V4-loops ranged 
from an average of 27 amino acid bases at 56 days to 22 bases at 903 days, corresponding 
with PNLGs losses in this region at positions N400 and N407, both of which appeared to 
decline from being present in 82 and 100% of sequences at 56 days to 0 and 42% respectively 
at 903 days.  
 
Table 3.24 Comparison of significant tissue-specific differences in the number of PNLG sites 
and V-loop lengths using the Mann-Whitney non-parametric test. Time points where 
significant differences in both the number of PNLG sites and V-loop lengths between blood 
plasma and CVL sequences were estimated are shown in red text.  
Participant)ID) HIV.1)env)region) Days)p.i.) Mann.Whitney)p.values)
) ) ) PNLGs)) V.loop)lengths))
CAP177) V1V2! 28! –! –!
) ! 378! 0.1170! 0.3798!
) ! 560! 0.0191! 0.2250!
) ! 1295! 0.0078! 0.7191!
) V4! 28! –! –!
) ! 378! 0.4606! 0.0452!
) ! 560! 0.0244! –!
) ! 1295! 0.0002! 0.0394!
) V5! 28! –! –!
) ! 378! 0.5340! 0.3671!
) ! 560! –! –!
) ! 1295! 0.1503! 0.9845!
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Participant)ID) HIV.1)env)region) Days)p.i.) Mann.Whitney)p.values)
) ) ) PNLGs)) V.loop)lengths))
CAP217) V1V2! 63! 0.0515! 0.0763!
) ! 420! 0.7621! 0.3061!
) ! 770! –! 0.1114!
) ! 1316! 0.0600! 0.0001!
) V4! 63! –! –!
) ! 420! –! –!
) ! 770! –! –!
) ! 1316! –! 0.2616!
) V5! 63! –! –!
) ! 420! –! –!
) ! 770! 0.0578! –!
) ! 1316! –! 0.5634!
CAP261) V1V2! 63! 0.6646! 0.3098!
) ! 413! 0.0216! 0.0187!
) ! 945! 0.!7071! 0.2040!
) V4! 63! 0.2058! –!
) ! 413! 0.1771! –!
) ! 945! 0.8146! 0.6960!
) V5! 63! –! 0.7090!
) ! 413! 0.8590! 0.2710!
) ! 945! –! 0.8213!
CAP270) V1V2! 56! –! –!
) ! 147! 0.9443! –!
) ! 231! –! –!
) ! 406! 0.4203! 0.8331!
) ! 595! 0.9294! 0.7235!
) ! 903! 0.9281! 0.6247!
) V4! 56! 0.4096! 0.3827!
) ! 147! 0.8577! 0.1058!
) ! 231! 0.4256! 0.1063!
) ! 406! –! –!
) ! 595! –! 0.8028!
) ! 903! 0.4020! 0.1864!
) V5! 56! –! –!
) ! 147! –! –!
) ! 231! –! –!
) ! 406! –! –!
) ! 595! –! –!
) ! 903! 0.6981! 0.9720!
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Significant tissue-specific differences in both PNLGs numbers and V-loop lengths were only 
evident in two participants at isolated time points ((Table 3.24) and in different V-loop 
regions (i.e. within the V4-loop in CAP177 sequences and V1V2-loop in CAP261 sequences), 
however there was no evidence of similar differences in 96% of the paired samples tested, 
suggesting a relatively similar pattern in PNLGs accumulation and V-loop length variation in 
viruses from both tissue types. 
 
3.11.2 Relationship/between/V3loop/length/variation/and/recombination/
To test the hypothesis that recombination may be associated with V-loop length variation, 
average V-loop lengths were compared between sequences taken before and after the 
occurrence of a recombination event in all participants that exhibited evidence of 
recombination (section 3.7). 
 
Table 3.25 Average V-loop lengths before and after the first and last occurrence of a 
recombination event in participants CAP177, CAP217 and CAP270. Regions where the V-
loop length increased after the occurrence of a recombination event is shown in red text, with 
regions where the average number of PNLGs decreased after the occurrence of a 
recombination event shown in blue text. Regions where no changes in V-loop lengths were 
found before or after a recombination event occurred are indicated in black text.!
Participant)ID) V.loop)region) Average)loop)length)(amino)acid)bases))
) ! Before!or!at!first!recombinant! After!or!at!last!recombinant!
CAP177) V1V2! 57! 73!
) V3! 34! 34!
) V4! 20! 21!
) V5! 13! 13!
CAP261) V1V2! 72! 75!
) V3! 34! 34!
) V4! 28! 29!
) V5! 16! 10!
CAP270) V1V2! 76! 76!
) V3! 34! 34!
) V4! 27! 22!
) V5! 12! 12!
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V-loop lengths were found to have increased in the V1V2- and V4-loops within viruses from 
participants CAP177 and CAP261, the two participants that harboured the most recombinant 
viral populations (Table 3.17), whereas no such increase was noted in CAP270. V3- and V5-
loop lengths remained consistent among all participants despite the presence of 
recombination, with the exception of the V5-loop in CAP261 sequences, where an average 
decrease in length was discovered. Generally however, the occurrence of a recombination 
event could not conclusively be linked to V-loop length expansion, but could potentially be 
associated with multi-variant infections.  
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Chapter(4!Discussion!
 
Defining the characteristics of HIV compartmentalization and evolution in specific tissue 
types may offer important clues to our understanding of transmission dynamics and disease 
persistence (Heath et al., 2009; Santoro & Perno, 2013), yet despite its importance in the 
control of HIV infection, only a few studies have characterized HIV evolution in the female 
genital tract over long-term infection. Many studies that have investigated tissue-specific viral 
compartmentalization and its role in disease persistence have reported conflicting results 
(Philpott et al., 2005; Kemal et al., 2003; Bull et al., 2013; Zhu et al., 1996; Diem et al., 
2008). From those that have reported the existence of distinct viral populations within the 
female genital tract, compartmentalization patterns were defined mainly on visual inspection 
of phylogenetic trees, while other studies focused on env subregions or reported evidence for 
compartmentalization at isolated time points during the course of infection.  
Furthermore, some studies did not employ measures to avoid the misrepresentation of 
compartmentalization patterns caused by monotypic and low diversity sequences, or account 
for the number of transmitted viral variants, or the presence of recombination. In contrast, 
studies that did account for test biases and employed both tree and distance-based methods 
found no persistent tissue-specific compartmentalization, although despite the lack of 
consistent structure over long-term infection, reports of “transient”, “partial”, and 
“subcompartmentalization” patterns were described. This study therefore sought to investigate 
HIV evolution between the female genital tract and blood plasma in a treatment naïve cohort 
over acute and chronic infection, using recommended methods for compartmentalization 
detection (Zárate et al., 2007).  
Given the lower quantities of viruses present in the genital tract, it was hypothesized that 
compartmentalization of HIV viruses could exist within the genital tract. HIV-1 subtype C 
sequences were subsequently amplified, cloned and sequenced from CVL and blood plasma 
samples obtained from four treatment naïve women using single genome amplification 
methods that minimized template resampling and PCR recombination.  
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Contaminated samples, such as CVL samples containing any trace of blood were also omitted 
from further analysis to eliminate the presence of potential variants from the blood plasma, 
similar to guidelines followed by Imamichi et al. (2011).  
To accurately detect viral compartmentalization, confounding factors such as the presence of 
single or multiple HIV-1 variants within a single participant, had to be identified and to do 
this, information on the shape and arrangement of phylogenetic trees, the estimated time to 
the most recent common ancestor (tMRCA), Poisson distributions, pairwise genetic distances 
and results from statistical tests were analysed. Differences in V-loop length variation, 
potential N-linked glycosylation site accumulation, recombination patterns and clinical 
indicators were also investigated to assess differences between viral populations from the 
blood plasma and cervical compartments within each participant as well as between inferred 
single and multiple-variant infected participants. To this end, the number of transmitted viral 
variants was first examined, as it greatly affects the elucidation of almost all other 
downstream analyses performed in this study.  
 
4.1 Estimating/the/number/of/transmitted/viral/variants/
Of the four participants studied here, two (CAP270 and CAP217) were likely infected by a 
single viral variant and two (CAP177 and CAP261) by multiple HIV variants. As a result, 
estimates of pairwise genetic distances and the number of detectable recombination events 
were significantly lower in the former participants compared to the latter, consistent with 
previous studies (Novitsky et al., 2011; Carvajal-Rodríguez et al., 2008; Aulicino et al., 2011; 
Lemey et al., 2007; Lukashov & Goudsmit, 1997). TMRCA estimates for participants 
CAP177 and CAP261 also exceeded the known time of infection substantially, compared to 
estimates for CAP217 and CAP270, characteristic of infection by more than one viral variant 
(Keele et al., 2008; Abrahams et al., 2009). Strong evidence for the presence of multiple 
variants in CAP177 and CAP261 was also discovered in phylogenetic analyses, where 
multiple lineages were visible on cross-sectional maximum likelihood and longitudinal 
Bayesian MCC trees, similar to phylogenetic structure observed by others (Novitsky et al., 
2011; Abrahams et al., 2009). 
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Although CAP177 and CAP261 are considered to be examples of multi-variant infections, the 
question of whether these women were initially infected by multiple HIV variants at the onset 
of transmission or were superinfected later on, remains unclear. Since sequences from only 
the blood plasma were available at 14 days post-infection for CAP177, the presence of a 
highly divergent minor variant in the CVL, that was not present in the blood plasma at 28 
days could also be explained by the transmission of a second viral variant in the period 
separating these two sampling points, suggesting superinfection in this participant (Van der 
Kuyl & Cornelissen, 2007). However, given that only four clones were sequenced from the 
blood plasma at 14 days in CAP177 during acute infection when the viral load was high, it is 
more plausible that the sample size was simply too small to reliably detect viral variants that 
accounted for less than 30% of the population at this time-point. In principle, the same 
reasoning could be applied to the other participant, CAP261, which has been described as 
likely involving a multi-variant transmission, since the first viruses to be successfully 
amplified from both the blood plasma and CVL were from samples collected at 63 days post-
infection, i.e. two months after the initial transmission event. 
 
In both CAP177 and CAP261 despite the presence of multiple variants, not all lineages 
persisted to subsequent sampling time points, possibly due to a selective advantage as it has 
been reported that some viral variants with greater competitive ability or superior fitness 
actually displace viruses from the original infection (Kiwelu et al., 2013; Templeton et al., 
2009; Van der Kuyl & Cornelissen, 2007).  
 
4.2 Study/population/and/clinical/indicators/
Blood plasma viral loads during chronic and acute infection is known to be a strong predictor 
of viral loads within the female genital tract (Kovacs et al., 2001; Lavreys et al., 2006) and 
accordingly, the four women from whom it was possible to amplify CVL viruses had among 
the highest blood plasma viral loads from the 18 originally analysed. Only five of the original 
18 women in the CAPRISA cohort were sampled within 30 days of infection, however 
amplification of env genes was not possible from many samples taken and the only participant 
for whom it was possible to amplify viruses from all time points sampled was CAP270.  
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HIV infection is normally characterized by an acute phase during which viral loads are high, 
followed by a decrease as host immunity develops eventually leading to the chronic phase of 
infection, which can last several years (depending on the progressor type), until the onset of 
AIDS. Among the participants studied here, all exhibited typical signs of disease progression. 
Viral loads increased during the acute phase and remained steady in participants CAP177, 
CAP261 and CAP217, whereas in CAP270 disease progression was substantially faster.  
 
Despite the rise in viral loads, CD4 counts remained stable in CAP261, indicative of patterns 
observed in “HIV-1 controllers” or long-term non-progressors, which has also previously 
been observed within multiple-variant infected patient groups (Lamine et al., 2007; Casado et 
al., 2007; Van der Kuyl & Cornelissen, 2007). Viral load control was also evident in CAP217 
and CAP177 to a lesser degree, where despite slight fluctuations in viral loads, CD4 cell 
counts appeared to decline at a slow rate, while viral loads appeared to remain relatively 
stable over the sampling period in both participants. In CAP270 however, the only participant 
in whom viral loads were exponentially higher than CD4 cell counts, CD4 cell counts 
declined rapidly as viral loads grew. This participant was later classified as a rapid progressor 
and was subsequently placed on ARVs following the sampling period analysed here. 
Alternatively in CAP177, the only participant in whom a significant correlation between viral 
genetic diversity and viral load was detected (Table 3.12), it is likely that this result was 
confounded by time since early infections are associated with high viral loads and a largely 
homologous founder population followed by a period of strong immune response, which 
results in a viral load decrease and selection of immune escape variants associated with an 
increase in diversity (van Deutekom et al., 2013; Troyer et al., 2005). 
 
In all four women there was also consistent evidence of coinfection with single or multiple 
STIs, which has previously been associated with an increase in inflammation and leukocytes 
in the genital tract, factors that have been reported to significantly increase HIV shedding 
(Johnson & Lewis, 2008; Anderson & Cu-Uvin, 2008). Overall there was a high prevalence 
of HSV type 2 and B. vaginosis coinfection among all participants, with other STIs arising 
along the sampling period that did not appear to be associated with HIV progression, since 
CAP270 (i.e. the participant that progressed to AIDS faster than all other participants 
analysed), only tested positive for two STIs throughout the entire sampling period.  
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The implications of HIV coinfection has previously been studied by others and is reported to 
alter the course of both HIV and STI disease progression (Funnye & Akhtar, 2003), while 
complicating therapeutic efforts (Griemberg et al., 2006).  
 
Furthermore, some researchers have investigated if the presence of STIs actually facilitates 
the transmission or acquisition of HIV, which has been reported to be possible in the case of 
Syphilis coinfection as explained by Funnye and Akhtar (2003). Other STIs, capable of 
causing genital ulcers have also been associated with an increased risk of HIV transmission, 
including HSV-2 (Funnye & Akhtar, 2003; Galvin & Cohen, 2004) which is estimated to 
increase the chance of HIV acquisition by approximately 3-fold in men and women, and up to 
6-fold in high-risk individuals (Sheth et al., 2008). Shockingly, in sub-Saharan Africa HSV-2 
coinfection is estimated to be present in approximately half of all HIV infections (Wald, 
2004). This not only complicates HIV disease progression, but also reduces HIV-specific 
immune responses (Sheth et al., 2008) thereby limiting natural host responses against HIV. 
Among the participants studied here however, the number of STIs appeared to be associated 
with the number of transmitted variants, as participants CAP177 and CAP261, both of whom 
were inferred to be infected by more than one viral variant, consistently tested positive for 
more STIs than participants CAP217 and CAP270 throughout the sampling period.  
 
This could potentially be explained by the hypothesis described by Haaland et al. (2009), who 
suggests that the presence of some STIs, that occur before HIV is acquired, creates 
inflammatory genital conditions which substantially increases the risk of becoming infected 
by multiple HIV variants within a single transmission event. It may be possible, based on this 
hypothesis that CAP177 and CAP261 could have been infected with STIs before HIV, 
although this could equally have been possible with participants CAP217 and CAP270 too.  
 
4.3 Phylogenetic/evaluation/of/viral/compartmentalization//
Tree-based methods for compartmentalization detection are known to be sensitive to 
topological uncertainty and the presence of recombination, and therefore place much weight 
on phylogenetic segregation achieved via poorly supported short interior branches (Zárate et 
al., 2007; Rousseau et al., 2007; Posada & Crandall, 2002).  
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There was little evidence for the latter effect here as all participants demonstrated well 
supported (posterior support >70% or >90) phylogenetic structure on longitudinal Bayesian 
MCC trees, where monophyletic compartmentalization patterns among all participants was 
largely driven by diverse sequences from the final sampling time points, during chronic 
infection.  
 
Visual examination of longitudinal trees showed the presence of blood plasma and CVL 
samples intermingled between clades in cross-sectional and longitudinal trees among all 
participants, suggesting that viruses were readily mixing between anatomical compartments, 
consistent with recent findings by Bull et al. (2013). Similar branching topologies and 
clustering patterns were also evident on Bayesian MCC trees, between single and multi-
variant HIV infected participants. In all participants, clades that were monophyletic by tissue 
type comprised mostly of sequences from the same time point and can be explained by either 
rapid turnover of population genetic diversity through time, transient bursts of viral 
replication (Bull et al., 2013; Marchant et al., 2006; Ostrowski et al., 1998) or a short HIV life 
span, since the half-life of infected cells is estimated to be around 1.6 days (Heeregrave et al., 
2009). 
Although cross-sectional studies are inherently limited, particularly in the estimation of 
temporal dynamics (Sturdevant et al., 2012), when data sets were analysed individually per 
time point a clear indication of multiple lineages was visible at 28 days in CAP177 and 63 
days in CAP261, supporting the conclusion that these participants were infected by more than 
one viral variant. Furthermore, phylogenetic structure among these participants was consistent 
with those observed in other multi-variant infections (Kearney et al., 2009). These findings 
are in contrast to a study by Moore et al. (2012), in which data sets “with evidence of dual 
infection” were claimed to be excluded, however CAP177 was included among the study 
participants analysed, despite the vast evidence of multiple variants in this participant, 
presented here. Alternatively, in participants CAP217 and CAP270 outgrowth of a single viral 
variant was evident on both cross-sectional and longitudinal phylogenetic trees.  
Nevertheless, tissue-specific viral compartmentalization was not evident during long-term 
infection, regardless of population homogeneity or the number of transmitted variants in any 
of the participants studied. 
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4.4 Statistical/evaluation/of/compartmentalization/and/population/
migration/
Despite at least three quarters of statistical tree-based tests for compartmentalization 
suggesting significant evidence for the existence of distinct viral populations in the cervix and 
blood plasma, in three of the four participants (CAP177, CAP217, CAP270), tissue-specific 
lineages did not evolve and persist over time in any of these participants, consistent with 
previous studies (Bull et al., 2013; Kemal et al., 2003). Transient bursts of viral replication, 
visible on Bayesian MCC trees, are known to bias the results of these tests through the 
production of numerous monotypic and low diversity sequences (Bull et al., 2009). While the 
exclusion of identical sequences from the longitudinal datasets removed almost all statistical 
evidence of populations being structured by tissue type in CAP270, tissue specific population 
structure was retained in CAP177 and CAP217 in 2/3 and 1/3 of tree-based tests respectively.  
 
Results from cross-sectional analyses revealed three different compartmentalization patterns 
among the four participants. An example of the first pattern was demonstrated by CAP177 
whereby statistically significant evidence for compartmentalization was detected at all 
sampling time points including sequences collected in the acute and chronic stages of 
infection. An example of the second pattern was seen in CAP270, where statistical evidence 
for compartmentalization was only transiently observed at particular, but not successive time 
points during the chronic stage of infection, while the third pattern, evident in CAP261 and 
CAP217 exhibited statistical evidence for compartmentalization during the later stages of 
chronic infection. Although the removal of monotypic sequences led to a reduction in the 
number of significant results in CAP177 using tree-based tests at 28, 328 and 560 days post-
infection, all evidence supporting the existence of compartmentalization was absent at the 
final sampling point (1295 days) in this participant. There was no effect on results from cross-
sectional analyses following the removal of monotypic sequences in CAP217 and CAP270 
where, in the later time points, significant evidence of compartmentalization remained 
detectable at 1316 and 406 days, respectively.  
When both monotypic sequences and low diversity tissue-specific sequences were removed 
from CAP177 and CAP217 datasets, evidence for significant compartmentalization was only 
detectable at 28 days in CAP177.  
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In distance-based compartmentalization testing, both FST and Snn statistics estimated fewer 
statistically significant results to support compartmentalized structure between blood plasma 
and cervical populations, than tree-based tests. After analysis of gp120 regions including and 
excluding monotypic and low diversity sequences, the Snn test predicted strong significance 
for the presence of compartmentalization in CAP177, whereas no such structure was found in 
all other participants. As expected however, after the removal of monotypic and low diversity 
sequences, almost no evidence of compartmentalization remained, except at 378 days in 
CAP177. The detection of significant structure with FST and Snn tests however, may be due in 
part to the small viral population sizes analysed per participant (i.e. limited effective 
population size) (Gantt et al., 2010) or the lesser power of distance-based tests (Zárate et al., 
2007). 
 
The flow of viral populations between anatomical compartments was then analysed to 
determine if viruses were trafficking between the blood plasma and cervix, and to assess the 
rate at which this movement was occurring using a structured coalescent model. Analyses 
revealed substantial mixing of viruses between the blood plasma and cervical compartments 
in all participants during chronic and acute infection stages, indicating “an equilibrium of 
viral quasiespecies between the two compartments”, (Imamichi et al., 2011). An almost equal 
rate of viral movement was estimated between the blood plasma and cervical compartments in 
CAP261, while in CAP270 and CAP177 four times the amount of viruses were predicted to 
migrate from the cervix to the blood plasma compared to movement in the opposite direction. 
Unlike all other participants however, there was a higher rate of viral movement from the 
blood plasma to the cervix in CAP217. After the exclusion of monotypic sequences, bi-
directional movement was again observed in all participants with an almost equal rate of 
migration in CAP177, CAP261 and CAP270, whereas in CAP217 more viruses were 
estimated to migrate from the cervix to the blood plasma. When sequences were analysed per 
time point, there was no consensus on migration direction and migratory patterns fluctuated 
between acute and chronic infection.  
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In summary, exchange of viruses between the blood plasma and cervical tissues was evident 
in all participants both longitudinally and cross-sectionally, suggesting a continual mixing of 
populations throughout the infection period. 
 
4.5 Intrapatient/viral/diversity//
The extensive genetic variability of HIV is the product of various mechanisms including host 
factor immune pressures, mutations that occur through the process of reverse transcription, 
rapid turnover rates, recombination between replicating viruses and drug resistant mutations, 
among other pressures (Luft et al., 2011; Santoro & Perno, 2013). Not only do these 
mechanisms lead to extensive variability within the HIV genome, but they also contribute to 
the creation of millions of variants within a single individual, directly affecting response to 
therapy, disease progression and viral transmission (Santoro & Perno, 2013).  
 
In intrapatient diversity analysis, genetic distances increased over the course of infection in all 
participants, consistent with previously published data on variability within the env gp120 
region (Rossenkhan et al., 2012). Viral diversification was more pronounced in participants 
CAP177 and CAP261 when compared to CAP217 and CAP270, regardless of tissue origin, 
suggesting an association between diversity and the number of transmitted viral variants 
(Sagar et al., 2003). Although patterns of increased viral diversity were similar in blood 
plasma and CVL viruses, they appeared to diverge more distinctly within the acute stage of 
infection in all participants, in a linear manner, similar to observations by Shankarappa et al. 
(1999). This linear pattern in diversity was more pronounced in CAP217 and CAP270, 
possibly due to the presence of a single founder variant in these participants, although the 
number of sampled time points where sequences from both tissues were available per 
participant likely played a role in this observation.  
 
In a study that looked at HIV diversity over a much longer time frame than that studied here 
(between 6 and 9 years), three distinct phases of diversity were reported, the first of which is 
consistent with results reported here, i.e. phase one – corresponding to a linear increase in 
diversity at a rate of about 1% per year (Shankarappa et al., 1999).  
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In this study, the greatest increases in diversity were found in CAP270, CAP177 and CAP261 
all of whom harboured populations that evolved at rates of 1.29%, 1.27% and 1.20% per year 
respectively, whereas populations in CAP217 diversified at approximately 0.73% per year. 
This can be associated with the rate of disease progression in these participants, since 
CAP270 (i.e. the participant with the highest diversification rate) was later classified as a 
rapid progressor, while CAP177 and CAP261 were inferred to have been infected by multiple 
viral variants (reported to progress to AIDS faster than those infected by single founder 
viruses) and finally CAP217, who was inferred to be infected by a single viral variant 
(Novitsky et al., 2011; Van der Kuyl & Cornelissen, 2007), possessed the lowest rate of 
evolution per year, as expected.  
 
4.6 Accumulation/of/potential/N3linked/glycosylation/sites/
Examination of glycosylation accumulation patterns revealed substantial changes in the 
frequency of PNLGs within env subregions over the sampling period. PNGLs had a tendency 
to emerge midway or at later time points as the infection progressed however these changes 
were not specifically associated with viruses from the cervix or blood plasma. PNLG site 
changes in the V1V2, V4 and V5-loops among viruses from CAP270, CAP261 and CAP217 
could potentially have been driven in response to neutralizing antibodies, however env 
antibody binding sites in these individuals presently remain unmapped. In CAP177, it is 
known that the emergence of a PNLG site at amino acid site 332 and associated loss of a 
PNLGs at amino acid site 334 one year post-infection allowed viruses to escape the 
neutralizing effect of autologous monoclonal antibodies targeting an epitope at site 332 (Gray 
et al., 2011; Moore et al., 2012).  
!
No tissue-specific differences in PNLGs accumulation was evident in any participant and 
viruses appeared to accumulate PNLG sites discretely with time, although when PNLGs data 
was analysed per time point, significant differences in PNLGs numbers between blood plasma 
and CVL viruses was found in 5 out of the 51 paired samples tested (i.e. per V-loop region 
and sample time point). Nevertheless, these differences did not correspond to acute or chronic 
stages of infection and were not consistent between single and multiple variant infections.  
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In the analysis of PNLG site accumulation and its association with viral evolution, PNLGs 
that appeared in an increasing number of viruses over time were mapped to longitudinal 
Bayesian MCC trees in search of PNLG sites that occurred locally to a small subset of closely 
related branches/viruses. In doing so, several sites that appeared to accumulate in an 
increasing number of closely related viruses from both blood plasma and CVL sequences 
were found, i.e. N130, N186, N141, N142 and N190. Five of these six PNLGs appeared 
predominantly during the mid to later stages of infection pointing towards the evolution of 
fitter viruses, while three of the five PNLGs were found to be within the V1V2-loop region, 
an area of the env gene that has previously been associated with host immune escape (Van 
Gils et al., 2011).  
!
4.7 Intrapatient/recombination/
In intrapatient recombination analysis, evidence of env gp120 quasispecies in three of the four 
participants (CAP177, CAP261 and CAP270) was found. In CAP177 and CAP261 
continuous recombination was evident throughout the entire infection period, however no 
evidence of recombination was found in CAP217 with only a single recombination event 
detected in CAP270 at the latest time point sampled (903 days). It was possible that 
recombinants were not detected in CAP270 due to “low levels of replication, or substitution 
with non-recombinant viruses due to lower fitness” as suggested by Kiwelu et al. (2013). 
 
The average incidence of recombination was higher in multi-variant infected participants 
(present in 57.64% of all sequences) than single-variant (present in 3.89% of all sequences) 
infections within the same env region. These findings are consistent with other studies in 
participants infected with HIV-1 subtype C viruses (Kiwelu et al., 2013; Novitsky et al., 
2011). The relatively high rate of recombination in multi-variant HIV infections has 
previously been attributed to the virus’s ability to combine the functionality of the reverse 
transcriptase enzyme between RNA templates in each variant during the transcription stage of 
replication, making it easier to accumulate recombinants this way (Kiwelu et al., 2012; 
Coffin, 1979; Kiwelu et al., 2013). Nevertheless, intrapatient recombination does not require 
coinfection to produce recombinants, because as the infection progresses “intrahost 
diversification produces a pool of quasispecies that can be used as distinct templates” for 
recombination (Kiwelu et al., 2013).  
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When recombination breakpoints were analysed, the distribution of breakpoints across the 
gp120 region was consistent with results reported by Kiwelu et al. (2013) and Lamers et al. 
(2009). Although there were similar recombination patterns in participants CAP177 and 
CAP261, all identified recombinants were unique and none of the participants shared 
estimated recombination breakpoints, suggesting ongoing recombination within populations 
in the blood plasma and cervix. Analysis of the number of HIV-1 recombinants over chronic 
and acute infection indicated that the proportion of detectable recombinants decreased from 
an average presence of 92% to 25% in combined blood plasma and CVL sequences among all 
participants where recombination was detected, while the number of unique recombination 
events increased from approximately 0.67 events at the earliest time points sampled to 2.67 
events at the last time points sampled in all participants.  
 
When changes in V-loop lengths were compared to recombination patterns, differences 
between single and multiple variant infections were noted, particularly in sequence length 
increases within the V1V2-loops of multi-variant infected participants CAP177 and CAP261. 
Transmission of more than one HIV variant has previously been linked to faster disease 
progression, which may explain this difference (Novitsky et al., 2011). Minor increases in 
sequence lengths were also observed in the V4 and V5-loops in these participants, however 
the presence of five recombinant sequences in CAP270 did not affect any sequence length 
changes in any of the V-loop regions. Similarly when comparing the average number of 
PNLGs present in the same env subregions before and after the occurrence of a recombination 
event, there were considerable differences between single and multiple variant infections. 
Recombinant regions were spread across multiple subregions in blood plasma and CVL 
sequences isolated from participants CAP177 and CAP261, where increases in PNLGs 
numbers were found in almost all variable loops (excluding the V5-loop). Non-significant 
increases in PNLGs were also present in the conserved regions of all participants, specifically 
in the C1 and C5 regions of CAP270 sequences, i.e. the regions in which the single 
recombination event was detected in this participant.  
!
! /
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4.8 Codon3based/selection//
Molecular and purifying selection are caused by a range of pressures acting on a viral variant 
including those induced by the host itself, and are both responsible for selectively applying 
evolutionary forces that preserve certain amino acid residues while allowing nucleotide 
sequence variation to persist in other parts of a sequence (Castel et al., 2014). In selection 
analyses, both blood plasma and CVL viruses were found to be subject to positive and 
negative selection pressures along the gp120 env region using at least three different methods. 
Although more evidence of negative than positive selection was discovered among all 
participants, significant evidence of positive selection was found for a total of 17 amino acid 
sites using FUBAR, MEME, FEL and SLAC methods. The FUBAR method provided results 
on sites that were under diversifying selection, i.e. sites that occurred locally to a small subset 
of viruses on phylogenetic trees. In tissue-specific selection analysis, to test the hypothesis 
that viruses in the cervix were under different selective pressures than those sampled from the 
blood plasma, sequences were separated and analysed individually by tissue type per 
participant.  
Viruses from CAP261 and CAP270 showed a similar number of sites under positive/negative 
selection, while viruses from CAP177 and CAP217 showed very different numbers of sites 
under selection between tissue types. This may have been partly due to the sample sizes 
acquired from each participant or to the adaptation of viral populations to their host 
environment and the result of evolutionary pressures exerted on them by the host immune 
system as suggested by Castel et al. (2014). Although there is little information concerning 
the exact role of selective pressures on PNLGs accumulation, the number of amino acid sites 
identified as being under positive selection was compared to PNLG sites along the translated 
gp120 env gene in search of potential overlaps between the two. Interestingly, six sites 
identified with significant evidence of positive selection coincided with previously identified 
PNLG sites at positions N349 & N424 in CAP177, N474 in CAP217, N189 & N412 in 
CAP261 and N154 in CAP270.  
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More PNLG sites were found to be under positive selection in multi variant infected 
participants CAP177 and CAP261 than single variant infected participants CAP217 and 
CAP270, suggesting a possible selective advantage in viral populations within multi variant 
infections. In studies that investigated adaptive and selective mutations, it was found that 
slower disease progression was actually linked to a larger number of positively selected sites 
and faster env adaptation rates (Lemey et al., 2007), consistent with patterns found in CAP177 
and CAP261, both of whom have previously been identified as long term non-progressors.  
!
4.9 Co3receptor/tropism//
Although several studies have previously reported that the V3-loop (i.e. the primary 
determinant for co-receptor usage) is a highly variable region (Fernandez et al., 1995; 
Almond et al., 2010), V3-loops remained consistent in both blood plasma and CVL viruses 
from all participants, which may be due to the absence of antiretrovirals in this cohort, based 
on a 2011 study in which Waters et al. demonstrated the influence of ARVs on co-receptor 
usage, by suppressing planned treatment and retesting co-receptor tropism, wherein 2 of the 
37 participants showed evidence of co-receptor switching.  
Detection of CCR5 and CXCR4-tropic viruses is usually expected where HIV recombination 
has been observed according to Mild et al. (2007) however in this data set no CXCR4-topic 
viruses were evident despite the presence of recombination in three of the four participants. 
Many authors have also hypothesized that a shift in co-receptor tropism from CCR5 to 
CXCR4 usage tends to occur within the later stages of infection (Mild et al., 2007; Lusso, 
2006; Cecilia et al., 2000), however this was not the case in any of the participants analysed 
here either.   
Net charge analyses revealed an overall higher possibility of co-receptor switching from 
CCR5 to CXCR4-tropic viruses in the blood plasma further into disease progression, based on 
the higher net charges observed in viruses from this tissue type at 6 of the 8 time points where 
differences were noted. Tissue-specific differences in net charge could not be attributed to V-
loop length variation or PNLGs distribution however, as these traits remained constant in the 
V3-loop in both blood plasma and CVL viruses throughout the course of infection in all 
participants.  
  
 
 
 
 
!
!
!
140!
The change in co-receptor usage is also dependent on the presence of recombination and the 
number of transmitted viral variants, hence viral populations in participants CAP177 and 
CAP261 are more likely to exhibit shifts in co-receptor usage as the infection progresses, 
since these participants have both been inferred to be infected by multiple viral variants and 
have demonstrated extensive evidence of recombination in both blood plasma and CVL 
viruses.  
!
4.10 Hypermutation/signatures/
To determine if viruses from each tissue type were differentiated by characteristics associated 
with hypermutation, gp120 blood plasma and CVL sequences were analysed for G-to-A and 
A-to-G mutations, resulting in no statistically significant evidence of hypermutation in any of 
the isolated sequences (p > 0.05). Despite this finding more G-to-A mutations were observed 
in both blood plasma and CVL viruses with the exception of viruses isolated from the CVL in 
participant CAP177. Conflicting hypermutation patterns were evident in viruses from the 
blood plasma and CVL in CAP177, suggesting the possibility of differential selection 
pressures in each anatomical compartment within this participant. However, despite the larger 
number of G-to-A mutations among all participants (excl. CAP177 CVL viruses), no 
significant evidence of a host immune response in the form of APOBEC3-induced 
hypermutation was found. A study by Armitage et al. (2012) describes this as a “discrete all 
or nothing phenomenon” stating that not all G-to-A mutations result in a lethal effect on the 
virus and in simulated studies “sub-lethal” activity has been shown to occur, resulting in 
increased genetic diversities as opposed to virus inactivation.  
!
4.11 Length/variation/within/the/env$V3loop/regions/
After systematic examination of length variation within the V-loop regions, V1V2, V4 and 
V5-loops displayed length expansions in addition to an increase in PNLGs accumulation 
during disease progression among all participants, most predominantly in the V1V2-loops, a 
region that is widely known to be important in inducing neutralizing antibody response 
(Gorny et al., 1994; Scanlan et al., 2002; Thali et al., 1993; Xiang et al., 2002; Mild et al., 
2007). Minimal length variation was found in the V5-loop while no changes occurred in the 
V3-loops of both blood plasma and CVL viruses from all participants, consistent with 
findings by Novitsky et al. (2009) and Coetzer et al. (2007).  
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V1V2, V4 and V5 loop lengths increased gradually over the course of infection in all 
participants, a trend that has previously been associated with the accumulation of PNLGs and 
induction of neutralizing antibodies, where transmitted viruses with shorter loops capable of 
containing fewer PNLGs slowly increase in length to confer viral fitness, although this is yet 
to be confirmed experimentally (Novitsky et al., 2009). When tissue-specific differences were 
analysed per env subregion, significant differences in loop lengths and the number of PNLGs 
between blood plasma and CVL viruses were found at isolated time points in participants 
CAP177, CAP217 and CAP261, once again mainly in the V1V2-loops during mid to late 
infection stages, similar to findings by Curlin et al. (2010). Despite this finding however, no 
significant tissue-specific differences between PNLGs numbers and loop lengths were evident 
in the majority (86%) of the paired samples tested.  
/
4.12 Study/limitations/
One of the key limitations affecting this study was during the amplification of CVL-derived 
viruses, where there was a presence of microscopic blood contamination in CVL samples. 
Almost three quarters of acute and chronic infection samples contained microscopic blood 
and were subsequently excluded from further analysis, leading to a smaller sample size from 
this tissue compared to the number of samples obtained from the blood plasma. Other 
drawbacks included the total number of sequences that were eventually amplifiable in 
addition to the long follow up periods between sampling points in some of the participants 
studied here, which played an important role in the outcome of statistical test results and other 
downstream analyses. More specifically in participants CAP261 and CAP270, there was a 
lack of samples from the first 50 days post infection, which was a major limitation in the 
analysis and comparison of viral sequences between the chronic and acute infection stages. 
Comparisons between genomic and clinical data also potentially contained a few drawbacks. 
Firstly, all clinical testing was performed outside of this study and the same individual may 
not have conducted laboratory testing of all samples obtained from each participant over the 
3.6-year sampling period. Consistency of clinical measurements may therefore be difficult to 
assume, however international guidelines were followed in the processing of all samples and 
therefore any slight inconsistencies that may exist are regarded as negligible.  
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Conclusions!
!
This study is one of a few that reports on the evolution of HIV-1 in treatment naïve female 
participants over acute and chronic infection stages in which both single and multiple subtype 
C variant infections were surveyed within a subtype C dominated region. Given all of the 
findings presented here, the presence of recombinant strains, viral diversity, PNLG sites, 
selection signatures and other confounding factors, pose major challenges to treatment 
strategies and the design of a suitable HIV vaccine. Nevertheless, this study has demonstrated 
that over long-term HIV infection viral populations are not compartmentalized by tissue type, 
despite the presence of statistical support at isolated time points. From the four participants 
analysed here, CAP270 and CAP217 showed evidence of infection with a single viral variant 
whereas, CAP177 and CAP261 indicated infection by more than one variant. As a result, 
genetic diversity, selection signatures and the number of detectable recombination events in 
viral populations were significantly lower in the former participants compared to the latter.  
 
Genetic diversity increased over the course of infection in all four participants, while CD4 cell 
counts declined and viral loads grew steadily. Although there was a jump in viral loads in 
CAP270, there was no other evidence to suggest that this participant was superinfected since 
the tMRCA was quite accurately reconstructed to the known time post infection and the 
Poisson distribution suggested infection by a single variant. Despite these results however, 
samples from the first 50 days were not available for CAP270, therefore we cannot 
definitively say whether this or any other participant studied here was superinfected.  
 
No consistent evidence for the existence of separate populations in the cervix and blood 
plasma was found in any of the participants using phylogenetic and statistical measures. 
Significant test results were attributed to the presence of monotypic or low diversity 
sequences, and test sensitivity, wherein tree-based tests have been reported to be more reliable 
than distance-based tests (Zárate et al., 2007). Furthermore, sequences generally clustered 
together by time point on Bayesian maximum clade credibility (MCC) trees in longitudinal 
phylogenetic analyses. Clades that were monophyletic by tissue type comprised mostly of low 
diversity or monotypic sequences from the same time point, consistent with rapidly 
replicating viral populations.  
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Viral sequences from the cervix and blood plasma did not exhibit significant tissue-specific 
differences in recombination, co-receptor usage, V-loop length variation, codon-based 
selection or PNLGs accumulation patterns, although notable differences in these traits were 
observed between multiple and single-variant infected participants. Furthermore, although this 
project would have benefited significantly from an expansion of the study population, it is 
important to note that only three published longitudinal studies containing cervical and 
plasma derived sequences exist to date, with the largest data set consisting of 14 women. 
Ultimately however, while this study provides a new contribution on the subject of HIV 
compartmentalization in female seroconvertors, the presence of compartmentalized viral 
populations in a minority of women cannot be ruled out, since only four women were 
analysed.  
! !
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Appendices!
Appendix/I/–/Python/script/to/predict/PNLG/sites/
!
#!!/usr/bin/env!python!
import!sys!
import!re!
f=open("CAP177-string.txt")!
HXB2="MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAK
AYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPL
CVSLKCTDLK--NDTNTNSS-----------SGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDND------
TTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLL
LNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIG-
KIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLF
NSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGN--
--SNNESE----
IFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAAS
MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLIC
TTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWN
WFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDR
DRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGR-------
RGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQGLERILL--
---------*"!
temp2=[]!
def!findtriplet(seqsnip):!
!!!!triplet=""!
!!!!for!i!in!seqsnip:!
!!!!!!!!if!i!!=!"-"!and!len(triplet)!=4:!
!!!!!!!!!!!!triplet+=i!
!!!!return!triplet!
!!!!triplet=""!
def!sequon(triplet):!
!!!!temp=[]!
!!!!for!i!in!triplet:!
!!!!!!!!temp.append(i)!
!!!!if!(temp[2]=="S")!and!(temp[1]!="P")!and!(temp[1]!="W")!and!(temp[1]!="D")!and!
(temp[1]!="E")!and!(temp[1]!="L")!and!(temp[3]!="P"):!
!!!!!!!!return!"yes"!
!!!!elif!(temp[2]=="T")!and!(temp[1]!="P")!and!(temp[3]!="P"):!
!!!!!!!!return!"yes"!
!!!!else:!
!!!!!!!!return!"no"!
!!!!temp=[]!
def!indexing(allpos):!
!!!!hxb2pos=""!
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!!!!for!i!in!allpos:!
!!!!!!!!count!=!HXB2[:i].count("-")!
!!!!!!!!hxb2pos+=","+str((int(i)-count))!
!!!!!!!!#print!"alignment!pos:!",i,"!HXB2!pos:!",int(i)-count!
!!!!return!hxb2pos!
for!line!in!f:!
!!!!if!">"!in!line:!
!!!!!!!!temp2.append(line[:-1])!
!!!!else:!
!!!!!!!!sequence=line[:-1]!
!!!!!!!!for!index!in!range(len(sequence)):!
!!!!!!!!!!!!if(sequence[index]=='N'):!
seqsnip=sequence[index]+sequence[index+1]+sequence[index+2]+sequence[index+3]+sequ
ence[index+4]+sequence[index+5]+sequence[index+6]+sequence[index+7]+sequence[index+
8]+sequence[index+9]+sequence[index+10]+sequence[index+11]+sequence[index+12]+sequ
ence[index+13]+sequence[index+14]+sequence[index+15]+sequence[index+16]+sequence[i
ndex+17]+sequence[index+18]+sequence[index+19]+sequence[index+20]+sequence[index+
21]+sequence[index+22]+sequence[index+23]+sequence[index+24]+sequence[index+25]!
!!!!!!!!!!!!!!!!triplet=findtriplet(seqsnip)!
!!!!!!!!!!!!!!!!if!sequon(triplet)!==!"yes":!
!!!!!!!!!!!!!!!!!!!!temp2.append(index+1)!
allpos=[]!
for!i!in!temp2:!
!!!!if!(">"!not!in!str(i))!and!(i!not!in!allpos):!
!!!!!!!!allpos.append(i)!
allpos.sort()!
tmp4=""!
tmp3="Alignment!pos:,"!
tmp4+="HXB2!pos:"+indexing(allpos)!
for!i!in!allpos:!
!!!!tmp3+=str(i)+","!
print!tmp3+",Total"!
print!tmp4!
all=""!
for!i!in!temp2:!
!!!!if!">"!in!str(i):!
!!!!!!!!all+="|"+str(i)!
!!!!else:!
!!!!!!!!all+=","+str(i)!
def!check(tmp):!
!!!!tmp2=""!
!!!!count=0!
!!!!for!i!in!allpos:!
!!!!!!!!if!str(i)!in!tmp:!
!!!!!!!!!!!!tmp2+=",N"!
!!!!!!!!!!!!count+=1!
!!!!!!!!else:!
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!!!!!!!!!!!!tmp2+=",!"!
!!!!print!tmp[0],tmp2+",",",!",count!
for!i!in!all.split("|"):!
!!!!tmp=i.split(",")!
!!!!check(tmp)!
f.close()!
!
/
!
! /
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Appendix/II/–/Python/script/to/count/V3loop/aa/base/length/
!
#!/usr/bin/python!
name=''!
!
def!count(line):!
!!!!c=0!
!!!!for!i!in!line:!
!!!!!!!!if!i!!=!""!and!i!!=!"-":!
!!!!!!!!!!!!c+=1!
!!!!return(c-1)!
!
f=open('V1V2.txt')!
for!line!in!f:!
!!!!if!">"!in!line:!
!!!!!!!!name=line[:-1]!
!!!!else:!
!!!!!!!!print!name,"=",count(line)!
f.close()!
!
!
! /
 
 
 
 
!
!
!
187!
Appendix/III/–/Supplementary/Figures/
!
!
 
Figure 3.4a Cross-sectional maximum likelihood tree for HIV sequences from CAP177 at 28 
days post-infection constructed under GTR + G substitution model using PHYML. Branches 
are coloured by tissue type where red = blood plasma and black = CVL, with bootstrap 
support greater than 90% indicated by a filled circle and greater than 70% by an open circle at 
the nodes. 
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Figure 3.4b Cross-sectional maximum likelihood tree for HIV sequences from CAP261 at 63 
days post-infection constructed under GTR + G substitution model using PHYML. Branches 
are coloured by compartment where red = blood plasma and black = CVL, with bootstrap 
support greater than 90% indicated by a filled circle and greater than 70% by an open circle at 
the nodes. 
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Figure 3.4c Cross-sectional maximum likelihood tree for HIV sequences from CAP217 at 63 
days post-infection constructed under GTR + G substitution model using PHYML. Branches 
are coloured by compartment where red = blood plasma and black = CVL, with bootstrap 
support greater than 90% indicated by a filled circle and greater than 70% by an open circle at 
the nodes. 
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Figure 3.4d Cross-sectional maximum likelihood tree for HIV alignments from CAP270 at 
56 days post-infection under GTR + G nucleotide substitution model predicted using 
PHYML. Branches are coloured by compartment where red = blood plasma and black = CVL, 
with bootstrap support greater than 90% indicated by a filled circle and greater than 70% by 
an open circle at the nodes 
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